Physical aspects of selective internal radiation therapy for hepatic cancer. by Ho, King Wah Stephen. & Chinese University of Hong Kong Graduate School. Division of Surgical Sciences.
PHYSICAL ASPECTS OF SELECTIVE INTERNAL 
RADIATION THERAPY FOR HEPATIC CANCER 
.^-- “ ' ' ^ ^ ^ ^ ' " * - < w ^ 
.、‘:、.;:?s^ "• \ ^ 
• 、 - \ . A 
••，.• H«^ :•. \ 
] . \ -:\ 
\ by . 厂！ 
\ • • -.• 
I --.….„ • 玄 
I HO King Wah Stephen / 
‘ ^ :•:' •. / 
I • - ' y 






A thesis submitted as part of the requirement for the 
degree of Doctor of Philosophy 
Department of Surgery 
Surgical Sciences Division 
Graduate School 
The Chinese University of Hong Kong 
May, 1996 
U u 
j ( f ^ ^ 
f^^^Mi^^^^^ 
fe[u _ • p) 
\^•"“m^“一惑 
| k _ S Y S ^ J ^ / 
^ ' ^ ^ ^ y 
TABLE OF CONTENTS 
Page 
Title Page 1 
Table of Contents 2 
Summary 3 
Glossary of abbreviations used in the thesis 10 
List ofFigures 12 
List of Tables 20 
Acknowledgments 24 
Chapter 1 Hepatic Cancer - Review of the Medical Literature 25 
Chapter2 Selective Internal Radiation Therapy - Review of 47 
the Medical Literature 
Chapter 3 The Background In Physics 76 
Chapter 4 Hypothesis and Testing the Hypothesis 88 
Chapter 5 Parameters Required in the Partition Model 98 
Chapter 6 Prediction of Radiation Dose and Verification of the 143 
Partition Model 
Chapter 7 Clinical Evaluation of the Partition Model 181 




Hepatocellular carcinoma (HCC) and colorectal liver metastases usually 
present late and only about 10% or below is resectable. Recurrence in the 
first two years after curative surgery is up to 60%. Various treatment 
modalities such as systemic and regional chemotherapy have not been 
proved to improve survival in inoperable hepatic cancer through randomised 
trials. 
Radiation can kill hepatic cancer if the dose is sufficiently high. However, 
external radiation therapy for hepatic cancer has been regarded as ineffective 
because the dose of radiation delivered to the liver is limited by tolerance of 
the normal liver The tumouricidal dose required is at least 120 Gy but dose 
above 30 Gy for whole liver irradiation may result in radiation hepatitis. 
Selective internal radiation (SIR) therapy by intraarterial infusion of yttrium-90 
(90y) microspheres, making use of the preferential arterial blood flow to 
tumours, is a possible way of delivering a high dose to the tumours while 
minimizing the radiation damage to the non-tumourous liver. Yttrium-90 with 
beta radiation of high energy and deep penetration is the isotope of choice for 
treating large tumours. However the efficacy of the treatment depends on the 
actual tumour-to-normal (T/N) ratio of radioactivity uptake. Extrahepatic 
shunting of radioactivity to the lungs or gastroduodenum does not only cause 
radiation pneumonitis or gastroduodenitis but also a reduction in the tumour 
dose. 
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Direct detection of the distribution of 卯丫 microspheres and hence the 
measurement of radiation doses to tumour and normal liver is impossible 
without open surgery because 卯丫 only emits beta radiation that is completely 
attenuated by the abdominal wall. Radiation dose referred to the entire liver, 
without distinction between tumour and non-tumourous liver, has been 
estimated by assuming a uniform distribution of the microspheres throughout 
the whole liver. 
Simulation using technetium-99m macroaggregated albumin (®®^Tc-MAA) 
which has an average size similar to that of the ®°Y microspheres permits 
prediction of T/N ratio and degree of extrahepatic shunting. 
A partition model for estimating the fractions of activity uptake by the lungs, 
tumour and non-tumourous liver was formulated. The percentage of lung 
shunting and T/N ratio from ®®^Tc-MAA simulation and the masses of the 
tumour and non-tumourous liver from CT slices need to be determined. 
Extending the preliminary study on lung shunting, the degrees of 
arteriovenous shunting of radioactivity to the lungs in 377 patients with HCC 
were found to be between < 1% and 75.4% and a smaller range (< 1% to 
23.9%) was found in 25 patients with colorectal liver metastases. The 
percentages of lung shunting increased with the vascularity of the tumour 
assessed by hepatic angiography (HAG). The difference between any two 
vascularity grades was statistically significant (p < 0.05, Wilcoxon rank test) in 
HCC. There were significant correlations between the percentages of lung 
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shunting and tumour size in HCC (linear regression : r = 0.359, p < 0.0001) 
and colorectal liver metastases on excluding one outlier (linear regression : r 
=0.686, p < 0.0001). Increases in mean lung shunting with increase tumour 
size up to 15 cm was observed in HCC. Changes in degree of shunting 
associated with the disease status observed further supported our preliminary 
postulation of a neoplastic nature of the blood vessels responsible for the 
shunts. 
In another extended study, the T/N ratios in 377 HCC patients were found to 
vary between 0.2 and 26.5 and in 25 patients with colorectal liver metastases 
between 2.3 and 7.2. The T/N ratios did not correlate with tumour size for the 
whole group but significantly lower T/N ratios were found to associate with 
HCC tumour > 20 cm due to the presence of central necrosis in these big 
tumours. Higher vascularity grades assessed by HAG were found to 
associate with bigger tumour size in HCC but not in colorectal liver 
metastases. Tumours with vascularity grade 1 had significantly lower T/N 
ratio but vascularity grade assessed on planar two dimensional images of 
HAG correlated poorly with T/N ratios from ®®^Tc-MAA simulation in general 
because tumours with large necrotic centres may appear highly vascular on 
the periphery. Thus SIR therapy should be given to patients with high T/N 
ratios but not to tumours that only appear vascular on HAG. 
The radiation doses to the lungs, tumour and non-tumourous liver could then 
be estimated by assuming the relative distribution of ®°Y microspheres in 
subsequent treatment was identical to that of ®®^Tc-MAA. The estimated 
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radiation doses to the tumours and the non-tumourous livers in 14 patients 
with HCC and 3 patients with colorectal liver metastases were verified by the 
dose values measured by intra-operative beta-probe and liquid scintillation 
counting of biopsies. Good correlation existed between the dose values 
determined by the three different methods. T/N ratios determined from 
Bremsstrahlung scans performed before the patients were discharged home 
also correlated well with T/N ratios from pre-treatment Tc-MAA scans. With 
this partition model, the activity of ®°Y microspheres required to deliver a 
certain radiation dose to the tumour can be predicted and the radiation doses 
to the tumour, the non-tumourous liver, and the lungs can be estimated. 
The validity of the radiation doses estimated by the partition model was 
further evaluated in clinical settings. The lung doses in 90 patients who 
received SIR therapy were estimated by the model. Sixty-eight patients 
received a single and 22 patients received multiple (up to 5) SIR treatments. 
Two patients developed radiation pneumonitis. One out of 3 patients who 
received an estimated dose > 30 Gy in a single treatment and one out of 2 
patient who received an estimated cumulative dose > 50 Gy developed 
radiation pneumonitis. These results suggested that 30 Gy from a single 
treatment and 50 Gy accumulated from multiple treatments may probably be 
the tolerance limits of the lungs. 
Based on these values, the risk of complication in 5 patients with lung 
shunting > 20% was predicted. Their estimated lung dose were all over 30 
Gy from a single treatment. Three out of these 5 patients showed evidence 
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of complication despite partial hepatic embolization using lvalon particles was 
attempted to reduce the lung shunting. 
The radiation doses to the tumours and non-tumourous livers in 71 HCC 
patients treated through percutaneous routes (Port-A-Catheters or hepatic 
angiographic catheters) were also estimated by the partition model. Fifty-six 
received a single and the other 15 received repeated treatments for residual 
or recurrent tumours. The maximum doses to the tumour and non-tumourous 
liver were 748 Gy and 136 Gy respectively from a single treatment. There 
was no radiological complete remission. The number of patients who 
achieved partial remission was significantly greater when the estimated 
tumour dose was > 300 Gy. Thus there is a close correlation between the 
response rate and the radiation dose estimated by the partition model. 
Cumulative dose to the tumour and the non-tumourous liver reached 1,580 
Gy and 324 Gy respectively from multiple treatments. The treatments were 
well tolerated. The maximum tolerance of the non-tumourous liver is not yet 
known as there was no incidence of radiation hepatitis, but it is definitely 
much higher than the 30 Gy for whole liver irradiation by external beam. 
Likewise, despite the histological documentation of complete remission in a 
patient who received 426 Gy to his tumours from two treatments, and in 
another patient who received 189 Gy to his tumour from a single treatment, 
the radiation doses required for complete eradication of tumours remained 
uncertain. Patients who received much higher tumour doses still showed 
persistent residual disease. Analysis of the distribution of radioactivity, which 
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is actually heterogeneous, revealed necrotic areas with T/N ratios < 2 
although the overall T/N ratio is higher. These areas which received sub-
optimal dose remained as residual disease. New lesions which grew from 
microscopic seedlings spared by the initial treatment accounted for the 
recurrence that needed repeated treatment. 
SIR therapy succeeded in converting inoperable tumours in 4 patients to 
become operable. The median survival of 71 patient after SIR therapy was 
9.4 months which is longer than that of 2 months for inoperable HCC in areas 
of high incidence. This improvement in survival needs to be proved by the 
randomised trial which is now in progress. There is no statistically significant 
difference between the median survivals of recurrent and non-recurrent HCC 
(log-rank test : p = 0.941). This suggests that SIR therapy may be a useful 
treatment option even for HCC patients with post-operative recurrence. The 
median survival of 36 patients who received > 300 Gy of radiation, as 
estimated by the partition model, to their tumours is 11.0 months. Although 
this appeared to be better than the 6.8 months in 35 patients who had the 
estimated tumour dose < 300 Gy but the difference is not statistically 
significant (log-rank test: p = 0.3502). The difference needs to be proved by 
increasing the number of patients. 
The present clinical evaluation of the validity of the radiation doses estimated 
by the partition model based on complication and response rates has some 
weaknesses. Firstly the criteria for the diagnosis of radiation pneumonitis and 
radiation hepatitis are never clearly defined. Subclinical complication might 
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have occured in some of the patients. Secondly, the limiting or optimal doses 
were deduced from the results of only a small number of patients and should 
therefore be regarded as preliminary. These weaknesses have to be 
addressed in a suitable animal model. 
With a better understanding of the physics involved SIR therapy has become 
a safe and repeatable treatment. Simulation using ®®^Tc-MAA and the 
partition model derived in this study permit a better insight into the distribution 
of radioactivity in the tumour, the non-tumourous liver and adjacent organs, 
as well as the radiation doses they are expected to received. Thus patients 
who are at risk of developing radiation complications can be excluded and the 
optimal activity of 卯丫 microspheres can be pre-determined. Also repeated 
treatments for residual or recurrent diseases can be given in a well-controlled 
mannerwhen the estimated radiation doses to the various regions are known. 
Applying the ®®^Tc-MAA simulation and the partition model on 71 patients with 
HCC，6 to 90.2% of their tumours were estimated to have received less than 
120 Gy in a single SIR therapy because of the heterogeneous distribution of 
activity within the tumours. Thus the radiation doses estimated by the 
partition model explain why residual disease was common after a single 
treatment and emphasize the need for repeated treatments. 
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®®^ Tc Technetium-99m 
AFP Alphafetoprotein 
ANSTO Australian Nuclear Science and Technology Organization 
Bq Becquerel 
CEA Carcinoembryonic Antigen 
CR Complete Remission 
CT Computerised Tomography 




HAG Hepatic Angiography 
HBV Hepatitis B virus 
HBgAg Hepatitis B Surface Antigen 
HCC Hepatocellular Carcinoma 
ICRP International Commission for Radiation Protection 
ILP Interstitial Laser Photoagulation 
KeV Kilo-electron-volt 
Lp-TAE Lipiodol-Transarterial Embolization 
MeV Mega-electron-volt 
MIRD Medical Internal Radiation Dose 
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MRI Magnetic Resonance Imaging 
mSv Milli Sevet 
mCi Milli-Curie 
NA Not Available 
32p Phosphorus-32 
PAI Percutaneous Alcohol Injection 
PEI Percutaneous Ethanol Injection 
PET Positron Emission Tomography 
PD Progressive Disease 
PR Partial Remission 
RLFT Renal and liver function test 
ROI Region of Interest 
RT Radiotherapy 
SD Static Disease 
SIR Selective Internal Radiation 
SPECT Single Photon Emission Computerised Tomography 
99mTc-MAA Technetium-99m-Macroaggregated Albumin 
TLD Thermoluminescence Dosemeter 
T/N ratio Tumour to Non-tumour ratio or Tumour-to-Normal ratio 
USG Ultrasonogram 
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1丄 THE DISEASE 
I 
Hepatic cancer here mainly refers to hepatocellular carcinoma (HCC or 
malignant hepatoma) and liver metastasis from colorectal cancer. 
Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is one of the most common cancer in the 
world and accounts for 10% of all cancer cases and over 90% of all hepatic 
malignancies (1-3). In Asia, the incidence of HCC is about 10 - 20 per 
100,000 population in contrast to that of 1 - 3 per 100,000 population in 
Australia, Europe and North America (4,5). HCC affects predominantly males 
(male to female ratio between 4 to 7 in 1). In Asian countries, the incidence 
per 100,000 population for Taiwan is 150 (6) and for Singapore is 28.1 (7). In 
Hong Kong the incidence rates per 100,000 population for men and women 
are 40 and 10 respectively. HCC is the second most common cancer among 
males and the seventh among females in Hong Kong (8). HCC in developed 
country occurs mainly in elderlies with long history of alcoholic cirrhosis. On 
the contrary, in developing countries of Africa and Asia the tumours occur in 
patients of a younger age group and correlate strongly with chronic hepatitis 
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B viral infection except in Japan (4). In Japan, hepatitis C virus infection is 
emerging as the predominant cause of cirrhosis and HCC :- evidence of past 
hepatitis C virus infection has been found in 51% of patient with HCC (9) and 
hepatitis B virus in 26% only (10). The relative risk of developing HCC in 
patients with hepatitis C cirrhosis is 52.3 (9). Both hepatitis B and C virus 
may interact in the hepatocellular carcinogenesis (11). The relative risk of 
hepatitis B carriers developing HCC is 4.8 in China (12) and 21.3 in Hong 
Kong (13). Over 80% of the HCC arise from a cirrhotic background (1,14-16 
)• 
Liver metastases from colorectal cancer 
In colorectal cancer the liver constitutes the primary site of metastatic 
disease. At the time of diagnosis, 10 - 25% of colorectal cancer have hepatic 
metastasis (17-21). Liver metastases, either isolated or associated with other 
secondary locations have been found in 19.4% of 1105 patients with 
colorectal cancer diagnosed in Melbourne between 1981 and 1982 (22). 
Synchronous liver metastases were found in 14.6% in 1986 colorectal cancer 
diagnosed in the Dijon area betwe6n 1976 and 1984 (23,24). The incidence 
of liver metastases is slightly higher for colon cancer (20.5% in Melbourne 
series; 15.4% in Dijon series) than for rectal cancer (17.8% and 13.5% 
respectively for the two series). 
Another 20% to 30% of patients with colorectal cancer will develop metastatic 
lesions subsequent to resection of their primary tumours. Ultimately, at least 
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50% of the patients will die secondary to metastatic disease and for many, 
their survival will be determined to a large extent by the progressive 
involvement of the liver (25,26). Between 1976 and 1984，the cumulative 
incidence rate for liver metastases were 6% at 1 year, 17% at 3 years and 
20.2% at 5 years follow up in the Dijon area (23,24). The incidence of liver 
metastases rose rapidly during the first 3 years following the diagnosis of the 
primary tumour with 88.8% of metastases being detected within this period. 
Metastases were uncommon thereafter (23). Cumulative incidence rates at 5 
years were higher for rectal cancer (22.2%) and left-slde colonic cancer 
t 
(21.1%) than for right-side colonic cancer (13.1%) but the difference did not 
reach statistical significance. For colonic cancer the risk of developing liver 
metastases increased with the depth of tumour infiltration through the wall of 
the viscera (p < 0.01). In rectal cancer, the risk was similar for tumours 
invading the muscular and serous layers. Tumour spread to adjacent viscera 
was associated with an increased risk of metachronous liver metastases (p < 
0.01) for colonic cancer but not for rectal malignancies. Lymph node status 
highly correlated with the incidence of metachronous liver metastases (p < 
0.001). The incidence of liver metastases was slightly higher for rectal cancer 
as compared to colonic primary when lymph nodes were invaded. When 
more than two lymph nodes showed tumour infiltration the incidence of liver 
metastases at 5-year follow-up was 61% and 43% respectively for rectal and 
colonic cancer. The incidence rates dropped to 14% and 13% respectively in 
patients with negative node. Colorectal tumours less than 3 cm diameter 
were associated with lower incidence of liver metastases (p < 0.001) than 
largertumours. 
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1.2 TREATMENT OPTIONS 
The treatment options for HCC and liver metastases from colorectal cancer 
can be divided into two main groups : surgical and non-surgical. The more 
important treatments are 




(B) Non-surgical treatment included 
Systemic chemotherapy 
Arterial embolization 
Intraarterial chemotherapy (土 embolization or±lipiodolization) 
Radiation therapy (external or internal) 
lntratumour injection of alcohol 
Immunotherapy 
All these modalities, except internal radiation therapy and immunotherapy, 
will be reviewed in subsequent sections. The two remaining modalities of 
treatment will be discussed in details in chapter 2. 
1-3 HEPATIC RESECTION 
Liver resection for HCC is one of the two surgical tmatments that offers the 
best chance of cure (27). Liver resection is limited by the presence of 
28 
cirrhosis in the majority patients because the liver reserve might not be 
sufficient and hepatic failure results. The operative mortality is therefore 
significantly worse than in patients without cirrhosis (28). 
Liver resection is suitable for only about 10-15% of the patients because the 
tumour at presentation is already too large，it has already metastasized 
and/or the liver function has irreversibly been impaired (29). Even in 
countries like Japan where extensive screening is practiced and small 
tumours are more often being picked up, less than 20% of 7320 cases 
reported by the Liver Cancer Study Group of Japan underwent an attempt of 
resection (30). 
Some recent results of hepatic resection for HCC are shown in Table 1.1. 
With the exception of the report by Nagasue et al (31)，the 3-year survival is 
between 16and 39%. 
Hepatic resection has been referred to as a curative treatment based on 
reports of prolong survival after resection (27) but it has never been proven 
that hepatic resection improves the survival of the surgically treated group as 



































































































































































































































































































































































































































































































































































































































































The Table shows that in more than half the patients undergoing resection with 
curative intent, the tumour recurs within the first two years and majority of 
these patients will become candidates for non-surgical management (47). 
I Early detection of colorectal liver metastases has become possible through 
fii . 
1 。 
1 repeated measurements of serum tumour markers such as carcinoembryonic 
t 
••}； 
I antigen (CEA) and various imaging modalities including ultrasound scan, 
I 
1 computerized tomographic (CT) scan and magnetic resonance imaging 
(MRI). With improvement of surgical techniques，extensive liver resections 
are limited only by the need to preserve adequate liver function 
(corresponding to 15 - 20% of the total undiseased liver volume) and vital 
vascular and biliary structures. However, liver resection，which remains the 
i 
only curative treatment modality for colorectal liver metastases is only 
;i 
feasible in 5 - 10% of patients (48)。The operative mortality varies between 
0% and 10%. Operative morbidity varies between 13% and 27%. The 5-year 
survival rate range from 16% to 45% (Table 1.2). Recurrence occurred in 
two-thirds of patients in the French survey (24) with 50% of patients having 
intrahepatic involvement, it has been postulated that surgical resection may 









































































































































































































































































































































































































































































































































































































1.4 ORTHOTOPIC LIVER TRANSPLANTATION 
Theoretically orthotopic liver transplantation is superior to hepatic resection 
for HCC because all intrahepatic tumours, both macroscopic and microscopic 
(below the limit of clinical and radiological detection), as well as the cirrhosis 
which is regarded as the underlying aetiological disease are removed. 
However, such radical surgery has been complicated by high recurrence rate 
(72,73) which has been attributed partly to immunosuppression post 
transplantation, leading to accelerated growth of pre-existing extrahepatic 
micrometastases, 
The rate of recurrence has been shown to be influenced by tumour size, the 
number of tumours present, histological type and differentiation, and the 
presence of gross vascular or lymph node involvement (72,74). 
McPeake et al (75) has shown that recurrence of tumour did not occur in 
patients with single dominant lesion of less than 4.0 cm. In patients with 
lesions between 4.0 and 8.0 cm the recurrence rate was 40%. The 
recurrence rate was 78% in patients with tumours of greater than 8.0 cm or 
those with multifocal tumours. These accord with the finding of 7% 
recurrence in patients with small single tumours of less than 5.0 cm and 63% 
recurrence in those with large tumours by lwatsuki et al (74). 
Best result is obtained with small ‘incidental， tumours and the long-term 
survival of patients with symptomatic tumours is poor (76). The procedure has 
now been virtually abandoned except for very small tumours (77). 
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1.5 CRYOTHERAPY 
This involve the application of a cooling agent to the tumour with the intention 
of inducing tumour necrosis. Cooper first reported the destruction of primary 
and secondary tumours using freezing probes in 1963 (78). Improvements in 
probe design and imaging technology make it possible to treat superficial and 
deeply seated lesions within the liver with real time intraoperative ultrasound 
monitoring. 
Zhou et al reported on 27 patient with HCC treated by cryotherapy alone (79). 
Patients were treated at laparotomy using 3-5 cm diameter hollow plate probe 
with circulating liquid nitrogen. There was no procedure-related complication. 
The survival rates were 33%, 23% and 4% at 1-year, 2-year and 5-year 
respectively. There was a good correlation between the extent of the frozen 
area seen at the end of the treatment and the final extent of the necrotic zone 
produced. 
Ravikuma et al treated 10 patients with multiple deep-seated metastatic 
lesions within the liver using liquid nitrogen under intraoperative ultrasound 
guidance (80). The evolving and final area of frozen tissue can be seen 
sonographically in real time as the ice ball generated around the cryoprobe. 
Charnley et al reported another study on cryosurgery for metastastic liver 
diseases (81). Seven patients with a total of 39 metastases with a size range 
of 0.5 to 6.5 cm were treated under ultrasound guidance. Tumour necrosis 
and regression in size were seen 6 weeks in all the lesions treated. Steele et 
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al (82) reported 18 of 25 patients treated by cryotherapy were alive with a 
mean survival time of 20 months and 7 had no sign of recurrence. 
Several factors operate when a cryogenic stimulus is applied to biological 
|
tissue leading to irreversible cell damage. These include cellular dehydration 
and denaturing of structural and functional proteins. Induction of an 
immunological response to residual viable tumour has been demonstrated in 
animal model (83) as a result of liberation of tumour-specific antigens that 
provoke a host immune reaction. 
Technological advancement has made cryotherapy a feasible and safe 
technique for treating hepatic tumours. All parts of the liver can be accessed 
and lesion < 2 cm can be detected with intraoperative ultrasound. The main 
disadvantage is that the patient has to undergo laparotomy with its associated 
morbidity and the operation time may become unacceptably long when 
1 several lesions have to be treated. 
• 
1.6 SYSTEMIC CHEMOTHERAPY 
Almost all the cytotoxic agents used in oncological practice have been 
evaluated on HCC but none has been shown as a single agent or in 
i combination with other agents, to improve survival or to achieve consistent 
response rate of greater than 20%. 
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Early trials concentrated on 5-fluorouracil (5-FU) but the accumulated 
response rate in over 100 patients in published trials was less than 5% with 
most trials showing no response whatsoever (84). 
Results with cisplatin, a drug which has had a major impact on several areas 
of oncology, has been disappointing in HCC。There was no response in 14 
patients in the first study (85) and response rates of 5% (1/20) and 6% (2/35) 
were recorded in two more recent studies (86,87). 
The most widely used agent has been Adriamycin (doxorubicin) although 
other anthracyclines such as epirubicin and mitoxantrone have a similar 
degree of activity. In a recent review of several published trials involving over 
600 patients, the objective response rate was 19% with a median survival of 4 
months (88). 
The poor response has been partly attributed to the innate inefficacy of 
available drugs compounded by the consistent expression of P-glycoprotein 
(89,90) acting as an efflux pump preventing intracellular accumulation of 
several different drugs thus resulting in drug resistance. The other possible 
reason suggested is that we may often be treating more than one clones of 
malignant cells. It has been documented that different tumour nodules within 
a liver may be of different clonal origin and therefore conceivably have 
different chemosensitivity (91). New clones may also develop during the 
course of chemotherapy. 
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The role of chemotherapy in the management of colorectal liver metastases 
has become more important from the results of recent studies. 5-Fluorouracil 
{5-FU) is the most effective therapeutic agent in colorectal liver metastases 
(92,93). An objective response rate was obtained in 5 - 15% of patients (94). 
Response rates between 8 and 85% have been reported in the literature and 
are notably poorer in large series (94,95). However the impact on survival is 
minimal and non-significant (95). 5-FU has also been used as an adjuvant 
therapy post-resection. Although it is not a randomised prospective trial, five-
year survival was significantly improved (33% versus 29%, p < 0.05) in 155 
patients receiving adjuvant chemotherapy, particularly those with fewer than 
3 liver metastases (55,96). In another report, involving 666 patients who 
received adjuvant chemotherapy and 1101 who received no further 
treatment, there was no significant difference in the long term survival 
between these two groups (24). 
1.7 ARTERIAL EMBOLIZATION 
The liver has a dual blood supply with 75% of parenchymal blood flow coming 
from the portal vein and 25% from the hepatic artery. Anatomy studies 
demonstrated that malignant liver tumours, both primary and metastatic， 
derive most of their blood supply from the hepatic artery (97)，although there 
is good evidence that the peripheral parts of hepatic tumours, particularly 
those that are not encapsulated, may still receive part of their blood supply • 
•:'i } 
j from the portal vein (98). 
j 
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• One of the first methods to take advantage of the differential blood supply 
between tumours and normal liver was ligation of the hepatic artery. This 
procedure suffers from several disadvantages including the need for 
•: j 
: laparotomy, the technical difficulty of accessing the artery in patients with 
•i 
^ 





： Intraarterial embolization using agents such as Gelfoam introduced through 
i hepatic angiographic catheter overcomes the problems with ligation，allows 
i • 
I more peripheral embolization of the arteries and allows repeated treatments 
i j 
I (99). This technique have been used as palliative treatments, either alone or 
1 
\ in combination with other treatment，for example, chemoembolization (100). 
.1 .i 
Response rates of 50 to 60% have been reported on HCC with some 
increase in short-term survival (101,102). The efficacy of embolization is 
limited by the liver's ability to develop collateral blood supply when the hepatic 
( 
artery is occluded For this reason, benefits from hepatic artery embolization 
tend to be transient. 
With the increasing use of chemoembolization, simple intraarterial 
embolization on its own is now used less in HCC although its value in 
controlling severe pain has been recognised and it is still used for slow 
growing metastatic hormone-secreting hepatic tumours where symptomatic 
control for several years can be achieved (103). In colorectal liver 
metastases, the relief of pain by hepatic arterial ligation only lasts for 2 
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months in two-third of patients (104,105) and there is no improvement in 
survival. The combination of intraarterial embolization with chemotherapeutic 
|
drugs or other agents makes it difficult to define which of the individual part of 









I 1,8 INTRAARTERIAL CHEMOTHERAPY (土 Embolization 土 Lipiodolization) 
I The technique of intraarterial hepatic chemotherapy was first described in the 
early 1950s (106,107). There are anatomical, pharmacological, and 
尹 
I toxicological rationale for treating hepatic tumours with intraarterial hepatic 
chemotherapy (108). The blood supply of hepatic tumours derived mainly 
？ 
^ from the hepatic arterial bed，therefore more drug given through the hepatic 
artery than drug given either systemically or into the portal circulation should 
^ 
reach the tumour (109-111). It has been documented that the mean tumour 
level of FUDR (5-fluorodeoxyuridine) may be more than tenfold higher 
following intraarterial injection compare to portal vein injection (111). Using 
drugs with short plasma half lives that can efficiently be extracted by the liver 




I concentration of drug for longer duration may increase the tumour regression 
j 
rate (112). Slow infusion of the drugs with decreasing hepatic arterial blood 
.i 
1 
I flow at the same time may further enhance the cytotoxic effect on the tumour 
j 
(113). Concomitant injection of inertparticulate matter such as biodegradable 
1 
] 
starch microspheres or the use of Gelfoam embolization may not only 
decrease the blood flow but also infarct the tumour (99,114,115). 
This technique wHI have no advantage if the tumour is maximally sensitive at 
drug levels which are achieved by systemic administration, or if the tumour is 
totally insensitive. It may lead to significant increase in efficacy if the drug 
has a modest systemic activity (116). One major factor limiting the use of 
intraarterial chemotherapy is the lack of effective drugs to treat HCC or liver 
metastases from colorectal cancer. 
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] 
I • < 
I Lipiodol, an oily based contrast medium with 38% by weight of iodine was 
5 
I initially used for lymphography. When injected into the hepatic artery at the 
'! 
1 
\ time of angiography, sequential CT scanning shows that it is cleared from 
j 
I normal hepatic tissues but accumulates in malignant tumours, probably due 
::J 
..i 
i to the ‘leaky，character of neovascular tissue, coupled with the lack of 
"i • 
lymphatic clearance from tumour tissue. Patterns of Lipiodol accumulation in 
•j 
I liver tumour tissue vary with respect to the tumour type. Diffuse 
,:.j 
•� 
； homogeneous uptake is seen in HCC which is usually hypervascular. 
'i 
j Peripheral uptake with a central defect usually appears in colorectal liver 
'1 j 
metastases which commonly exhibit a rim of dilated peritumoural sinusoids 
around a relatively avascular centre. These observations support the theory 
that Lipiodol retention in the initial phase is due to microvascular entrapment. 
I Study on the long term fate of Lipiodol has demonstrated both cellular uptake 
1 
and membrane adhesion of lipid droplets by tumour cells (117). In early days 
it was used as a diagnostic aid for detecting small tumours (118-120). 
Several groups from Japan and the Far East have suggested that Lipiodol 
might be an ideal vehicle for targeting cytotoxic drugs because, after mixing 
with a therapeutic agent, it leads to an increased concentration of drug in the 
tumour, and decrease systemic toxicity and increase clinical efficacy might be 
anticipated. It was also postulated that Lipiodol itself might also act as an 
embolic agent (121-125). 
Lipiodol chemoembolization has been considered as an effective treatment 
for HCC on the basis of reports of a decrease in tumour size in non-
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randomized trials (121-125). However, improved survival by case-control 
study has not been clearly demonstrated. 
Comparison of chemoembolization using doxorubicin and Gelfoam powder 
with conservative management in a randomized trial suggested the treatment 
i 
has no significant improvement in survival (126). A multicentre study on 
randomised trial of lipiodol chemoembolization using 70 mg of cisplatin with 
fj 
Gelfoam versus conservative treatment for non-resectable HCC concluded 
that Lipiodol chemoembolization reduced tumour growth, often caused acute 
liver failure, and did not significantly improve survival (127). 
Reports on chemoembolization for colorectal liver metastases are sparse. 
Patients entered usually had failed systemic or intraarterial chemotherapy. At 
the University of Pennsylvania, 20 patients were treated with cisplatin, 
doxorubicin, mitomycin, iodized oil and polyvinyl alcohol particles (128). The 
biological partial response rate was 100% with a mean decrease in CEA level 
of 74%. Actuarial survival rate at 1 year from diagnosis and from first 
chemoembolization were 100% and 67% respectively. Another 52 patients 
treated with the same drug but using bovine collagen as the embolic agent 
showed 78% biological partial response and 34% of morphologic partial 
response (129). Median actuarial survival from the time of embolization was 
11 months. Biological and morphologic response rates of 100% and 71% 
respectively were documented in 11 patients treated by the same protocol at 
another centre (130). A multicentre phase II trial of the protocol involving 
several hundred patients has been completed but not yet reported. The 
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I response rates in these patients are promising but a phase 丨丨丨 trial is needed 
1 to determine if a survival benefit exists. 
I . i 1 
i 
1 
1.9 EXTERNAL RADIOTHERAPY 
Conventional external radiotherapy (ERT) for HCC with doses of 20 to 30 Gy 
, 
from linear accelerators or Colbalt sources as a single modality has been 
considered as treatment of no benefit, and it is ineffective even just for 
palliation (131 -134). This is particularly true for doses < 20 Gy (135). 
！ 
The success of ERT for HCC is limited by two factors. 
I 
』 1. The relatively low radiosensitivity of HCC. HCC has long been 
j regarded as radioresistant (136). It has been observed that HCC has 
.| . .¾ 
I radiosensitivity which ranges from fairly sensitive to highly resistant. 
•i . 
i , 
There was one patient who had his disease controlled for more than 
17 years after receiving less than 20 Gy. On the contrary progressive 
！ disease was seen in a patient given more than 70 Gy. 
i 
2. The relatively low whole organ tolerance of the liver to radiation. The 
liver has been considered as a radiosensitive organ, A patient who 
developed radiation hepatitis after receiving 35 Gy for liver metastasis 
in a series of 36 cases of whole liver irradiation was reported by Philip 
et al (137). 
lngold et al (138) observed a correlation between the incidence of radiation 
hepatitis and total dose to the liver. One of eight patients who received doses 
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I . 
of 30.0 - 34.5 Gy developed radiation hepatitis while five of nine patients who 
>. 
1 received total doses of 35.0 - 39.5 Gy developed radiation hepatitis. Two 
i 
y ？ 
i patients with mild asymptomatic reversible radiation hepatitis developed after 
j 
; 25 - 30 Gy were reported by Kraut et al (139). These observations suggested 
: j 
i that whole liver irradiation tolerance is at 30 Gy when the radiation is 
a 





Although HCC has been considered too virulent a disease for this modest 
radiation dose of 30 Gy to be potentially tumouricidal except perhaps in only a 
small minority of patients, various investigators have reported the 
effectiveness of radiation therapy in HCC (135,141-145). Partial remission 
.] 
was observed in 35% in one series of 17 patients (146) and the response of 
extrahepatic metastases of HCC has been found to be even better than the 
j • 
primary lesion towards ERT by Chen et a! (147). 
I 
Similar to HCC, ERT is of little value for colorectal liver metastases except for I i 
the purposes of pain relief. The dose required to cause tumour reduction 
1 




1 1.10 INTRATUMOUR INJECTION OFALCOHOL 
] 
I In mid 1980's, Shinagawa et al (149) and Fujimoto et al (150) independently 
reported their attempts of ultrasound guided percutaneous alcohol injection in 
i the treatment of intrahepatic tumours, 
i 
t . i ^ 
In two series reported by Livraghi et al a total of 37 lesions < 4.5 cm diameter 
i 
I 
j in 28 patients were treated by percutaneous alcohol injection under 
I 
sonographic control (151,152)。 These lesions included 33 HCC and 4 
metastatic liver tumours. The number of injection per lesion varied from 3 to 
24 depending on the initial diameter and the response. There was no 
procedure-related complications. In the first 11 patients, all lesions < 3 cm in 
diameter became negative on fine needle biopsy and volume reduction of up 
to 100% was seen on follow-up ultrasound scan. However, lesions > 3 cm in 
diameter remained positive for malignant cells and showed no evidence of 
regression. In the next 17 patients all lesions were smaller and negative on 
biopsy. Eight of 12 lesions < 2 cm disappeared on ultrasound follow up. 
Similar results was obtained by Shina et al in 14 patients with HCC < 5 cm in 
diameter (153). Intraperitoneal bleeding in one patient 2 days post injection 
which settled on conservative treatment was the only complication observed. 
With one or more steel coils implanted before treatment to serve as land 
marks and using a needle with multiple side holes in order to delineate the 
margin of a lesion after multiple alcohol injection, Sheu et al treated 6 patients 
with solitary HCC < 3 cm in diameter (154). The tumours in four patients 
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disappeared completely on angiography and biopsy was negative in five 
patients. 
All these results suggest that percutaneous alcohol injection is an effective 
palliation and in some cases a form of curative treatment for small hepatic 
tumours. However the optimum volume and frequency of injection have not 
1 been determined. The average volume of alcohol administered per lesion 




The advantages of the treatment included low costs, ease of handling and 
ready availability of ethano!. A survival rate of 92% at first year has been 
•1 
j reported in 12 patients treated with alcohol alone (151,152) which compares 、 
favourably with the results of hepatic resection for HCC of < 5 cm in diameter. 
I 
This suggests that ethanol injection has the potential to cure and achieve 
) 
•) 
results that are better than resection in terms of mortality and morbidity in 
selected patients, particularly those with small, solitary tumours. 
Percutaneous alcohol injection has been found to be relatively ineffective in 












SELECTIVE INTERNAL RADIATION THERAPY 
FOR HEPATIC CANCER 
Review of the medical literature 
Z1 INTRODUCTION 
Cancer therapy aims at arresting or at least slowing down the growth and 
spread of the tumour while limiting the damage to normal tissue. 
The poor efficacy of external radiotherapy in treating hepatic cancer has 
stimulated active search for new methods which can deliver a high radiation 
dose selectively to the tumourwhile sparing the normal liver parenchyma. 
Internal radiation therapy makes use of unsealed radioactive substance 
getting into the tumour and irradiate the cancer cells from inside. There are 
two main types of internal radiation therapy basing on the nature of the carrier 
of the radioisotopes :-
1. Radio-labelled monoclonal antibodies against an antigen produced by 
the tumour. 
2. Intraarterial targeting therapy using radio-labelled colloid, Lipiodol or 
microspheres. 
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Both methods require the carrier to bind specifically to the tumour or have the 
main bulk of the carrier being transported to the tumour and stays there for a 
sufficient duration of time to deliver the scheduled doses of radiation. 
2.2 INTERNAL RADIATION WITH RADIO-LABELLED IMMUNOGLOBULINS 
The isolation of tumour-associated antigens, carcinoembryonic antigens 
(CEA) by Gold and Freedman in 1965 led to enthusiasm in exploring targeted 
radionuclides (1). Clinical trials in which radio-labelled polyclonal antibodies 
were used for the treatment of patients were pioneered by Order et al (2,3). 
A major advance in this field has been the ability to produce monoclonal 
antibodies using the hybridization technique of Kohler and Milstein in 1975 
(4). 
With the development of various monoclonal antibodies raised against 
antigens such as ferritin, alphafetoprotein (AFP) and CEA, which have some 
degree of specificity for HCC or colorectal liver metastases, a therapeutic 
dose of radiation can be delivered to the tumour specifically by antibody-
antigen interaction even though the appropriate antibodies labelled by iodine-
131 (i3i|) or yttrium-90 (卯丫)，are administered through a systemic route. A 
partial remission rate of 41% and a complete remission rate of 7% in HCC 
were achieved after ^^^l-antiferritin treatment (5). The radiation dose 
delivered was in the order of 10 to 12 Gy. Median survival was up to 5 
months for patients with raised AFP levels and 10 months for AFP negative 
patients. The treatment was, however, preceded by whole liver irradiation 
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with external beam and radiosensitisers (doxorubicin and 5-FU) were added 
in the later phase of the trial. Hence the '^^l-antiferritin appears to served as 
a ‘boost，to the tumour and the combination has made it difficult to delineate 
the specific cytotoxic role of the radio-labelled antibodies. The treatment was 
compared with systemic chemotherapy in a randomised trial. Comparable 
response rates and survival duration were achieved (6). Even those who 
failed systemic chemotherapy still showed response to ^^^l-antiferritin 
treatment. 
However despite the essentially unlimited supply of monoclonal antibodies， 
the therapeutic application of them has evolved slowly for a number of 
reasons (7,8). Due to the heterogeneity of tumour cells, not all cells in a 
tumour express a particular antigen。 The amount of injected murine 
immunoglobulin actually localized in tumour tissue has been found to be 
small (< 0.01 % per gram of tumour tissue). The vascularity of tumours also 
varies considerably，and therefore the degree of penetration of antibody into 
large, often necrotic, tumours has been irregular. Also considerable amount 
of the radio-labelled antibodies might stay in the peripheral circulation thus 
causing bone marrow toxicity. This resulted mainly in thrombocytopenia and 
leucopenia. These toxicities tend to accumulate after repeated treatments. 
Host reaction towards the antibody might lead to development of anti-
antibodies prohibiting further treatment. Although cyclosporin A might be 
used to suppress this anti-antibodies production (9,10) there are pros and 
cons for administering such immuno-suppression agent on patients bearing 
malignant tumours. 
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2.3 INTERNAL RADIATION THERAPY WITH ''P-COLLOlD 
Radioactive gold was given intravenously to prevent hepatic metastases by 
Alfonso et al in 1978 (11). Radioactive phosphous-32 (即）chromic 
phosphate colloid with a particle size of 0.5 - 1.5 ^im has been the most 
commonly used agent for treating and preventing hepatic metastases (12) 
until the other two agents, lodine-131 i3i|-Upiodol and yttrium-90 卯丫 
microspheres, came into predominance. 
The distribution of ^^P-colloid has been well established (13-16) with nearly all 
the injected radioactivity concentrated in the liver. Less than 2% was found in 
the blood which could deliver only 0.06 Gy of radiation to the bone marrow 
even if all the activities were incorporated into the marrow. During 
recirculation majority of the isotope in the form of colloid was taken up by the 
spleen and liver, which further reduced the bone marrow uptake. 
Eight patients with locally extensive colorectal cancer were treated with 
colloidal 32p chromic phosphate via the superior mesenteric artery following 
resection to prevent development of hepatic metastases by Mantravadi et al 
(17). Minimal amount of activity was found in the right arterial blood and urine 
and the treatment was well tolerated. A cumulative dose of 33.75 Gy was 
delivered to the liver which is approximately equal to the suggested tolerance 
of human liver to whole liver irradiation using external beam (18,19) and is 
above the minimally effective dose for preventing liver metastasis (11). 
However, the role of the agent in preventing hepatic metastases has not been 
evaluated on long-term follow-up. 
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As the uptake of ^^P-colloid by the liver is due to phagocytosis by 
recticuloendothelial (RE) cells, it is useful as an adjuvant therapy for occult 
metastatic deposits embedded in the normal liver to be irradiated by the 
radiolabelled colloid in their vicinity. Hepatic tumour does not contain RE 
cells are often deprived of the ability of phagocytosis, and the tumour does 
not uptake the agent. The radiation from the ^^P-colloid localised in the 
normal liver tissue may not be sufficiently high to cause any response if the 
tumour is large. Thus ^^P-colloid is not useful for targeting visible tumours, 
particularly large ones. 
2A INTRAARTERIAL INFUSION OF RADIOISOTOPES 
Selective Internal Radiation (SIR) therapy by intraarterial infusion of 
radioisotopes for hepatic cancer makes use of the dual blood supply to the 
liver. Hepatic tumours usually derive their blood supply almost exclusively 
from the hepatic artery while the normal part of the liver obtain 80% of its 
blood flow from the portal vein and only 20% from the hepatic artery. 
Radioactive substances (e.g.卯丫 microspheres) infused through the hepatic 
artery mainly enter the tumour which receives a much higher radiation dose 
compared to the normal liver parenchyma. The ratio of the radiation dose 
received by the tumour to that received by the normal liver is called the 
tumour-to-normal ratio (T/N). The higher the T/N, the more effective is the 
treatment. 
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2.4.1 Internal RaHmtinn Therapy with Intraarterial ^^l-Lipiodol 
Lipiodol, an oily based contrast with 38% by weight of iodine is selected as 
the carrier of radioactivity into hepatic tumours, mainly HCC's for a number of 
reasons :-
1. with the experience of using Lipiodol to detect HCC in diagnostic 
radiology, it is known that Lipiodol accumulates selectively in malignant 
tumours and is retained there for long periods (20-23) whereas it is 
cleared from norma! hepatic tissue with a half-life of 4 to 6 days. The 
targeting of HCC is therefore further enhanced by the increased 
residence time of i3i|-Lipiodol in the tumour. 
2. Lipiodol can readily be converted to radioactive i3i|-Upiodol by 
replacing a small fraction of the iodine component (^^ l^)of Lipiodol with 
i3i| through a simple ‘atom-atom exchange，reaction. 
3. Lipiodol is radiopaque so that the flow of ^^^l-Lipiodol injected through 
the hepatic artery can be monitored closely under fluoroscopy. 
In an animal model i3i|-Lipiodol has been shown to have a significantly longer 
effective half-life in tumour than in normal tissue which is consistent with 
prolonged residence of non-radioactive Lipiodol as observed in diagnostic 
radiology (24). The dose of i3i|-Upiodol resulted in almost complete necrosis 
of the tumour in the animal. 
Targeting HCC in a patient with a test d6se of 37 MBq (1mCi) ^^^l-Lipiodol 
intraarterially was first reported in 1986 (25). Sequential gamma imaging of 
organs including the liver, lung, stomach and thyroid over 8 days after 
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injection demonstrated that the i3i|_Upiodol concentrated in the tumour 
resulting in a high tumour-to-normal (T/N) ratio with negligible amount of 
radioactivity in other organs. 
Kobayashi et al (26) first applied the treatment on 7 patients with HCC. 
knowing that ^^ 1^ ions resulting from biodegradation of i3i|-Lipiodol would enter 
the thyroid and might result in hypothyroidism, the thyroid was blocked with 
Lugol iodine solution before the treatment. The activity of ^^^l-Lipiodol used 
was between 281 and 592 MBq. Decrease in tumour size from 36 - 78% was 
observed in all patients and AFP level dropped in 6 cases. One patient with 
severe cirrhosis died of hepatorenal failure after 2 months. Histology showed 
no viable cell in the largest tumour of this patient and several areas of 
necrotic cancers cells were observed in the small lesion. No severe 
complication or other adverse reaction were encountered. 
Another 47 patients with HCC were given 74 - 4440 MBq i3i|_Lipiodol for both 
imaging and therapy purposes (27). The treatment was found to be effective 
in eliminating ascites, improving symptoms and shrinking the tumour when 
high doses were administered. ^^^l-Lipiodol was found to be most effective in 
solitary, well-encapsulated tumours. The highest T/N ratio obtained was 
approximately 20 : 1. 
Two subsequent reports focused mainly on the biodistribution and in vivo 
kinetics of i3ihUpiodol after intrahepatic infusion in patients with hepatic 
cancer (28,29). In 4 patients with HCC and one with cholangiocarcinoma, 
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i3i|-Upiodol appeared to result in oil embolization to the tumour and the 
adjacent hepatic tissue followed by secondary embolization to the lungs and 
finally the radioactivity was mainly excreted into urine (28). The effective half 
life of i3i|-Lipiodol in vascular tumours was 5.7 土 1.2 days which was longer 
than that of 3.7 土 0.6 days for the normal liver compartment. The T/N ratios 
in 3 patients were estimated to be 7.5 - 21 to 1. The activity in the lung 
increased gradually from 30 minutes to a steady state but was always lower 
than that in the normal liver. The activity in the organs other than the liver 
and the lungs was negligible from gamma scintigraphy. 
The other biodistribution study included 47 patients with HCC, 14 patients 
with hepatic metastases and 10 patients with normal livers (29). Similar to 
the observations in the previous study (28) the ^^^l-Lipiodol was found to 
concentrate mainly in the liver and lung with consistently higher activity in the 
liver. Distribution of ^^^l-Lipiodo! was homogeneous in normal livers and 
heterogeneous in cirrhotic livers. T/N ratio was 4.3 土 3.6 for HCC and 2.4 土 
0.7 for hepatic metastases. Clearance from tumour was slower than from 
normal liver. The biodistribution did not change in patients who had a second 
injection, indicating that there is probably no saturation phenomenon. 
The dosimetric aspects of i3i|-Lipiodol in the treatment of HCC was 
investigated in details by Madsen et al on 4 patients (30). The effective half-
life of i3i|-Lipiodol in normal liver tissue was about 4 days while the clearance 
from the tumour was 20 - 25% longer. Activity in the lungs initially increased 
and then cleared with a 5-days effective half-life. All these parameters 
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concord with those from other studies on biodistribution (28,29). Based on 
these parameters, the estimated radiation dose is 31 cGy to the normal liver， 
22 cGy to the lungs and 239 cGy to a tumour 4 cm in diameter for every mCi 
of i3i|_Lipiodol administered. These of course vary between patients because 
the half-lives and T/N ratios might be different. 
i3i|-Lipiodol with activity between 900 and 2,400 MBq was used to treat 15 
patients with HCC and 8 patients with hepatic metastases by Bretagne et al 
(31). Five of the HCC patients were treated more than once. The maximum 
number of treatment was three. The treatment was tolerated very well with 
analgesic effect in two patients with painful HCC. For HCC, AFP levels 
dropped rapidly in 11 of the 12 patient with raised pre-treatment levels. The 
average reduction in tumour size was 50% (17 - 92%) in 9 cases. Six of the 
15 patients were alive after 5 - 12 months follow-up. No objective response 
was noted in the group of patients with hepatic metastases apart from 
analgesic effect in 3. 
A large series of 60 patients with HCC treated by intraarterial ^^^l-Lipiodol was ^ 
reported by Yoo et al (32). In 15 patients, small HCC less than 5 cm in 
diameter were treated with single or multiple injection of ^^^l-Lipiodol with an 
8-week interval between treatment, aiming to delivered a total protracted 
radiation dose of 120 Gy to the tumour. Response rate was 80% for tumour < 
5 cm and was 60% for tumour between 5 to 8 cm. For larger tumours, ®^^ l-
Lipiodol combined with chemotherapy emulsion, lvalon embolization or 
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hepatic artery ligation were used. The response rate was 50% for tumours 
between 8 and 10 cm and was 21.9% for tumours greater than 10 cm. 
There was another pilot study of treating 10 patients with HCC (lung 
metastases in 2) using i3i| Lipiodol (3(3)。The number of patients receiving 
one, two, three and four treatments were 2，5，1 and 2 respectively. The total 
activity given was between 444 and 6,220 MBq. T/N ratio up to 25 : 1 was 
observed. The tumour dose of a single treatment was 90 - 260 Gy. The 
response rate was about 70% with reduction in AFP levels and tumour size. 
The median survival was 9 months (range 2 - 17 months). However, the 
documentation of lung shunting between 15 - 67% is alarming although no 
radiation pneumonitis was reported. Based on the activity of ^^^l-Lipiodol 
infused, the radiation dose to the lungs in some of the patients might have 
been much higher than the generally accepted limit of 20 Gy (34). 
Ablation of recurrent HCC in an 65 year old female using i3i|-Upiodol was 
reported by Novell et al (35). Two months after treatment with a dose of 475 
MBq, two tumour nodules with initial sizes of 4.3 and 9.3 cm decreased to 1.7 
and 4.0 cm respectively. These residual tumours were found to be totally 
necrotic after resection. The patient remained well after 9 months with no 
evidence of residual tumour despite of a persistently elevated AFP level. 
In 1991，Yoo et al (36) reported another series of 24 patients with nodular 
HCC which ranged from 2.5 to 8.0 cm in size. The activity of ^^^l-Lipiodol 
used was 555 to 2,220 MBq. The percentages of tumour reduction were 
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88.9%, 65.5% and 25.0% respectively for tumours less than 4 cm in 
diameter, between 4.1 to 6.0 cm and larger than 5.1 cm. These results 
suggested that ^^^l-Lipiodol is more effective in small tumours. 
Encouraged by the results in treating HCC, Hind et al treated 11 patients with 
colorectal liver metastases with 2 MBq contained in 3 ml of ^^^l-Lipiodol 
delivered during hepatic angiography. This was followed by laparotomy (37). 
Gamma counting of biopsies from the normal liver and metastases showed 
that large metastases (> 10 cm) had low T/N ratios and the smaller ones had 
values between 1.1 and 2.5 at 24 hours and between 1.5 and 63 at 3 - 9 
days. SPECT imaging in 3 patients confirmed selective retention of Lipiodol 
in small lesions but no activity was detected in large tumours (> 15 cm) 10 
days after injection. The results of the study suggested i3i|-Upiodol to be 
effective in only small colorectal liver metastases. 
After confirming the selective accumulation of isipLipiodol in the hepatic 
tumours of rabbits with extended residence time and remarkable anti-tumour 
effect, Yumoto and his associates treated 9 patients with HCC with 131卜 
Lipiodol and compared the results of treatment with combination therapy of 
Lipiodol-transarterial embolization (Lp-TAE) in 18 patients (38). Serum AFP 
levels dropped rapidly in eight of the 9 patients with raised pre-treatment 
levels after receiving isi^Lipiodol treatment. The average decrease in tumour 
size was 50% in eight patients in this group. The survival of patients treated 
by i3i|-Lipiodol was better than those treated by Lp-TAE. 
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Results of a French multicentre phase II trial on 50 patients with unresectable 
HCC was reported in the same year (39). The study confirmed that ’㊀’卜 
Lipiodol treatment was well tolerated, treatment results were highly 
reproducible between institutions with an objective response rate of 40%. 
The need of a randomised controlled trial was thus advocated. 
A subsequent study on treating 26 patients with inoperable HCC was carried 
out in our Hospital (Prince of Wales) (40). A single treatment using 1.11 -
2.22 GBq i3i|-Upjodol was given to 23 patients. The remaining three patients 
received 2.22 - 4.44 GBq given in three fractions at 4 days intervals, the 
objective response rate was 52% and the median survival was 6 months for 
the 26 patients. 
Portal vein thrombosis is a contraindication for chemo-embolization. 
Intraarterial injection of ^^^l-Lipiodol was considered feasible by the French 
group of investigators as the hepatic arterial blood flow was not occluded by 
the i3ihLipjodol infused。A randomised controlled trial of 27 HCC patients 
with portal vein thrombosis using i3i|-Upiodol versus medical supportive 
treatment was reported (41). The number of patients receiving one, two, 
three, four and five injections of ^^^l-Lipiodol were 5, 4，3，1 and 1 respectively. 
The estimated cumulated radiation doses ranged from 10 to 100 Gy. The 
survival of the 14 patients in the treated group was significantly better than 
the 13 patients in the control group. Portal vein tumourous thrombi have 
been found to be arterially vascularized (42) and i3i|_upjodol has been 
detected in these thrombi following intra-arterial injection of the agent and 
58 
biodistribution study showed that i3i|-Upiodol was retained within the tumour 
thrombi (43). Thus i3ihLipiodol might have also acted on the tumour thrombi 
in the portal vein. 
The most recent work on i3i|-Lipjodol was an comparison between epirubicin-
Lipiodol chemotherapy and ^^^l-Lipiodol radiotherapy in treating inoperable 
HCC (44). The last 28 patients in the study were within a prospective 
randomised trial. The cumulative radiation dose to the tumour, non-tumour 
liver parenchyma and lungs were 34.7 士 32.4 Gy, 3.3 士 1.5 Gy and 4.4 土 2.3 
Gy respectively. The results showed comparable survival benefit at 6 and 12 
months with either treatment modality in patients with Okuda stage I and II 
HCC with reference to historic controls (45). 
In summary, the works on i3i|-Lipiodol reviewed above suggest that: 
1. The preferential uptake of i3i|_Lipiodol by HCC relative to the non-
tumourous liver parenchyma is more significant than colorectal liver 
metastases. This probably explains the lack of objective response in 
colorectal liver metastases (31) except in small lesions (37) and that 
most of the studies have been focused on HCC. 
I 2. Even in HCC, the smaller the tumour size, the more effective is the 
j intraarterial isipLipiodol treatment. This might be attributed to two 
factors:-
i.; 
(i) A higher percentage of large tumours has necrotic centres 
»‘ 
y which take up radiopharmaceuticals poorly. 
， 
(ii) The activity of i3i|-Upiodol used was insufficient to deliver the 
required tumouricidal radiation dose to large tumours. 
The tumouricidal radiation dose for HCC has been estimated to be 120 Gy or 
above (32). The activity of i3i|-Upiodol required to deliver 120 Gy to a 10 cm 
tumour has been estimated to be 58.82 mCi for the tumour alone. This 
means that over 100 mCi (3,700 MBq) of i3ihLipiodol need to be infused. A 
lot of problems including excessive radiation hazard to hospital personnel and 
long isolation period for patients are encountered in handling such high 
activity of i3i|-Lipiodol which has a highly penetrating gamma component in 
the radiation it emits. As a result lower activities which were feasible and 
convenient were usually used. For example, in the study by Madsen et al 
(30)，a restriction on the total activity not exceeding 25 mCi was imposed 
disregarding the tumour size。 Thus the actual radiation dose received by 
large tumours could be sub-optimal in many of these studies. 
These limitations in ^^^l-Lipiodol have been inferred in the early works using 
this agent (25,33). Two alternative radioisotopes with higher beta energy and 
without gamma emission, ^^P and 卯丫 have been suggested to be better 
choices of radiolabels for Lipiodol. However, the technique of labeling 
Lipiodol with 卯丫 was not available until recently (46,47) and the labeling of 
Lipiodol with ®^ P has not yet been successful. The biodistribution of the ®°Y-
labelled preparation has just been evaluated in hepatoma of rats and has not 
been put into clinical application. 
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2.4.2 lntf^rnal Radiatinn Therapy with lntmarterial Yttrium-90 Microspheres 
(a) RwiGW of wnrlcs hy others in the literature 
The treatment of inoperable primary pancreatic and liver cancer with 
intraarterial yttrium-90 (卯丫）microspheres was pioneered in the 1960's 
(48,49). Gamma emitting ytterbium-169 (^Yb) was added to the 
microspheres to aid in detecting the distribution of microspheres in the 
abdominal cavity in this first study (48) •卯丫 microspheres with activity 
between 20 and 150 mCi produced some beneficial effects in 4 
patients with primary liver cancer. 
The other study on inoperable liver cancer, mostly colorectal 
metastases, reported from the same centre included 37 patients 
treated with ®°Y microspheres alone and 59 patients treated by a 
combination of chemotherapy (methotrexate and 5-FU) and 卯丫 
microspheres (49). The objective response rate was 32% and the 
average survival was 4.6 months for the first group of patients while 
those for the second group of patients were 47% and 5.6 months. 
Grady described in details the calculation of radiation doses from 卯丫 
microspheres assuming a uniform distribution of the microspheres in 
the liver (50). The use of gamma ray (X-ray in the words of Grady) 
emitting albumin with size similar to that of the ®°Y resin microspheres 
to assess the distribution pattern of 卯丫 was proposed. There was 
objective reduction in the sizes of both the liver and tumour in 17 of 25 
patients. It was recognised that avascular tumours performed poorly 
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while vascular tumours responded well. Adrenalin was tried as the 
possible vasoconstrictor to increase the uptake of the radioisotope by 
the tumour relative to the normal liver parenchyma. It is worthwhile to 
note that there was a patient who developed radiation hepatitis after 
receiving a total of 6,000 rads from two separate treatments of 50 mCi 
each. This served as the first clue to the tolerance limit of the liver to 
this form of internal radiation therapy although the differential radiation 
doses to the normal liver and the tumour cannot be delineated. 
Mantravadi et al (51) treated 14 patients with liver metastases and one 
patient with primary hepatoma using intraarterial 卯丫 microspheres. 
The localization and distribution of the radiopharmaceutical were 
assessed by Bremsstrahlung scans and extrahepatic radioactivity was 
found in only one patient, A patient developed pancytopenia which 
resulted from free 卯丫 leached from the microspheres. Factors 
determining the success of the treatment were vascularity of the 
metastases，absence of extrahepatic disease, and good performance 
status before treatment. 
Ariel and Padula reported a series of 25 patients with colorectal liver 
metastases treated by 100 mCi of ®°Y microspheres and 5-FU (52). 
The average survival was 26 months ( 9 to 60 months). With the 
【（ 
identification of arteriovenous shunting of microspheres to the lungs in 
I 
j a patient with liver metastasis from thyroid cancer among 100 patients 
being treated, as a precaution, either a tracer dose of 卯丫 microspheres 
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or radiolabelled albumin microspheres were used to scan the lungs 
1 before administering the therapeutic dose. N ^ 
i? 
-j 
I Fifteen patients with vascular liver metastases were treated with 50 to 
1 
70 mCi 卯丫 microspheres by Blanchard (53). Size reduction of more 
‘ than 50% was found in the tumours of 8 patients at 6 weeks. 
,.1 
I Symptoms of radiation gastritis caused by microspheres refluxed into 
1 
i 0 
i the gastroduodenum were documented in three of the five patients in 
I 
3 
whom the catheter tip was not advanced beyond the gastroduodenal 
artery. 
A new type of glass microspheres with the 卯丫 incorporated into the 
^ 
matrix of glass emerged by the end of 1980's. The main advantage of 
I 
1 
the new product is the complete absence of free 卯丫 leaching which 
j 
has caused bone marrow suppression (50,51). 
•i 
i 
i • I 
I This type of safer microspheres was evaluated on 12 patients with 
colorectal liver metastases, one carcinoid, one islet cell tumour and 
one hepatoma (54). Technetium-99m labelled macroaggregated 
albumin (®®^Tc-MAA) scans were used to assess the percentage of 
radioactivity shunted to the lungs and gastrointestinal tract in order to 
avoid pulmonary fibrosis or gastroduodenitis with subsequent 
treatment using 卯丫 microspheres (50,53). Three levels of radiation 
doses : 5,000 cGy, 7,500 cGy and 10,000 cGy were used but the 
difference in response rate was not clearly documented. With the 
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careful pre-treatment assessment using ®®^Tc-MAA, no pulmonary 
complication occurred and no myelosuppression was observed with 
the glass microspheres. However, late gastroduodenal ulceration was 
still documented in 3 patients with histories of chronic alcohol abuse. 
In one patient glass microspheres were found in a biopsy specimen 
from the prepyloric area and gastroduodenal shunting of microspheres 
was not predicted by both the ®®^Tc-MAA and Bremsstrahlung scan. 
This discrepancy has been attributed to the difference in density of 
99mTc-MAA particles and the 卯丫 glass microspheres. The heavier 
glass microspheres have greater chance of getting into the 
gastroduodenal artery. 
Blanchard treated another 15 patients with liver metastases and one 
patient with hepatoma using plastic microspheres (55). Twenty 
？ additional patients were screened but were excluded from the 
r [ 
treatment because their tumours were found to be avascular on 
k •^ 
hepatic angiography. Reduction in tumour volume was detected in 7 
S patients 5 of which had a decrease of more than 50%. Despite the use 
of 99mTc-MAA scans in pre-treatment assessment, gastritis and/or ‘ • 
gastric ulceration still occurred in 6 patients and in 3 patients, the 
h 
cause was due to 卯丫 microspheres in the gastric circulation. The 
mean survival was 62 weeks compared to 30 weeks in the untreated 





Pure beta radiation from 卯丫 cannot penetrate soft tissue thicker than 
11 mm, making direct measurement of the distribution of the 
microspheres within the abdomen and the corresponding radiation 
doses to the hepatic tumour and the normal liver parenchyma 
impossible outside the body. Therefore in all the studies reviewed 
I above, the distribution of the microspheres throughout the entire liver 
1 was assumed to be uniform and radiation dose was always referred to 1 I 
the whole liver without distinction between the non-tumourous liver 
compartment and the tumour. Gray et al (56-60) pioneered 
intraoperative administration of 卯丫 microspheres with direct 
measurement of radiation counts from the liver and tumour surfaces 
； using a small beta-probe during laparotomy. The intraoperative ii k 
dosimetry was further verified by liquid scintillation counting of liver 




i ( )• 
I 
The technique was initially established by infusing 卯丫 microspheres 
into the normal livers of 10 sheep (56). A linear relationship was found ^ :j 




determined from liquid scintillation counting of liver biopsies. This 
intraoperative dosimetry was further assessed on a patient with 
hepatic metastases. With this technique, the radiation dose to the 
normal liver compartment can be closely monitored as ®°Y 
microspheres are being infused until the tolerance limit of the normal 
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liver is reached. In this way, maximum radiation dose can be delivered 
to the tumour and put it under good control. 
The technique was then applied on 9 patients with hepatic cancer (57). 
The mean tumour to normal ratio as determined from liquid scintillation 
counting of biopsy samples was 6 with a range of 0.4 to 45. It was 
found that similar activity of 卯丫 microspheres resulted in markedly 
different radiation doses to the tumours and normal liver. The liver 
size and tumour burden were considered to be the factors determining 
these doses. Angiotensin 丨1，a vasoconstrictor that contracts normal 
but not neoplastic blood vessels，was used to enhance the preferential 
I 
flow of microspheres to the tumour. Radiation doses as determined by 
l| 
liquid scintillation counting of 17 biopsies from these patients were 
I 
correlated with the corresponding counts of the beta-probe during 
j 




Treatment of 10 patients with colorectal liver metastases using activity 
i 
I of 卯丫 microspheres between 755 and 2,511 MBq was carried out at 
j 
\ 
laparotomy (59). The radiation doses to the normal liver were between 
i _ 
i 
j 16.8 and 138.9 Gy which correlated poorly with the total radioactivity 
administered. CEA level dropped in all 9 patients with elevated pre-
1 
j 1 treatment levels. The actual effect of radiation dose of 38.48 to 73.94 i 
Gy to the normal liver was examined in details through monitoring of 
liver function and histological changes in liver biopsies (60). Results 
indicated that human liver could tolerate radiation doses above the 
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t i f 
whole liver irradiation limit of 30 Gy (18) when delivered by ®°Y 
microspheres embedded in the liver parenchyma as a number of 
discrete point sources. 
I Detailed mapping of the distribution of microspheres in thin slices of 2 
i tissue samples 1 cm® in volume from the normal liver of a patient who 
j received 75 Gy was performed (61). The radiation dose at any point in 
I the sample was calculated using the depth dose relation by Russell et 
al (62). It was shown that one third of the normal liver received less 
than 33.7% of the dose predicted by assuming a homogeneous 
distribution of 卯丫. This explains the much higher tolerance of the 
i 
I normal liver towards this form of radiotherapy. 
»1 
1 j 
The treatment results of 29 patients with inoperable liver metastases 
1 j 
by the intraoperative technique was reported in 1992 (63). After 
I treatment, CEA level dropped in all 26 patients with elevated pre-
treatment levels and the mean decrease was 70%. Among these 88% 
'\ 
showed more than 50% fall in CEA levels. More than 50% decrease 
j j 








j Treatment using 卯丫 microspheres reviewed above mainly involved 
patients with hepatic metastases with only a single case of HCC being 
included in some of the series. 
.1 I 




I A pilot trial of treating 7 patients with HCC was reported in 1989 (64). 
i Gamma imaging using ®®^Tc-MAA was used to assess the degree of 
I shunting to the lungs and stomach immediately before the 
I administration of ®°Y microspheres. Patients with significant 
i ,{ 
] extrahepatic shunting were excluded. T/N ratio from ®®^Tc-MAA scan 
i 
1 varied from 1.0 to 10.0. The radiation dose was estimated to be 5,000 
.1 
•I 
I to 10,000 cGy for the normal liver and up to 32,000 cGy for the tumour, 
.i 
I Treatment with low doses had no effect and the tumour progressed. 
I 
•！ 
• ^  
J Static disease or reduction in tumour size were seen in patients who 
j 
I 
I received higher doses. The treatment was well tolerated and was safe 
•1 ] 
j 
i to hospital personnel in terms of radiation exposure. 
:,j 
j 
With the experience from the pilot trial, the radiation dose to the liver 
was escalated in another 10 patients with HCC (65) from 50 Gy to 100 
Gy. All patients had static disease after treatment and the median 
survival was 18 weeks. Radiation-induced duodenal ulcer that 
required surgical management was documented in one patient. From 
i the data presented there seemed to be no correlation between the 
I level of radiation doses and survival and this is probably why the paper 
did not discuss on this aspect. 
By assuming a uniform distribution of ®°Y microspheres within the 
whole liver a total calculated liver dose up to 150 Gy was used to treat 
j 
7 patients with colorectal liver metastases (66). No toxicity was 
I observed with such high radiation doses. The disease was static in 6 
1 
I 
I patients and their median survival was 11 months. 
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The tolerance of liver to radiation doses was studied in rabbits before 
18 patients with HCC were treated in a clinical study (67). The doses 
to the livers of the experimental rabbits were 114.1 - 845.2 Gy. The 
upper value is much higher than that recorded by Wollner et al in dogs 
(68) but the rabbits tolerated the dose well. The 18 patients were 
treated with 2,442 - 5,550 MBq of ®°Y microspheres resulting in a mean 
dose of 30.33 Gy to the liver and 88 Gy to the tumour. As 4 patients 
died of massive upper gastrointestinal bleeding 1 - 2 months after 
treatment, severe hepatic arterioportal shunt was suggested as an 
additional contraindication for intraarterial ®°Y treatment because ®°Y 
microspheres infused through the hepatic artery might cause an 
increase in portal hypertension. 
A study on intraarterial 卯丫 therapy on 23 patients with hepatic 
^ metastases focused on the changes in the non-tumourous hepatic 
parenchyma on serial CT images taken after the treatment (69). 
I Eleven patients showed no change。 Irregular low-attenuation 
geographic areas were evident in the other 12 patients. The changes 
were graded as mild, moderate or severe. Mild to moderate changes 
occurred in 9 of the 12 patients and the abnormality was either focal or 
asymmetric. Severe diffuse parenchymal changes were seen in all 
hepatic segments of 3 patients who received the highest dose of 
15,000 cGy. The changes were most pronounced at 8 weeks after 
therapy and were partially or completely reversible at 16 - 24 weeks. 
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All patients had minimum or no change in liver function and there was 
no clinical sign of radiation-induced liver injury. 
A more recent work using 卯丫 microspheres was the study on 23 
patients with liver metastases and one patient with HCC (71) which 
I was mainly designed to test the tolerance of the liver to radiation 
I 
delivered by glass 卯丫 microspheres. Whole-liver dose estimated by 
• assuming uniform distribution of microspheres throughout the liver was 
escalated from 50 Gy to 150 Gy in a stepwise manner。 No 
complication related to the radioactive microsphere was documented. 
Responses based on CT images at 16 weeks post treatment included 
partial response in 5 patients, minimal response in 4 patients, stable 
•-1 
I disease in 7 patients and progressive disease in the remaining 8 




216 and 228 weeks after treatment. I 
•! 
(b) Works carried out at our centre 
) 
j SIR therapy using 卯丫 microspheres was started in November 1990 at 
i 
Prince of Wales Hospital. The 卯丫 microspheres were infused during 
'； 




measurements of both the percentage of lung shunting and tumour-to-
j .:! 
normal ratio (T/N) utilizing technetium-99m labelled macroaggregated 
albumin (®®^Tc-MAA) were included as the pre-treatment 
i 
1 investigations. 1 1 f 
I 70 
i 
The percentages of lung shunting in 125 patients with HCC were 
measured (71). The percentages varied highly (range : < 1% to 
67.2%) with a median of 8.1%. There was no correlation between the 
percentages and the tumour size (linear regression, r = 0.0863). The 
ipercentages of lung shunting in 68 patients with HCC having vascularity grades 3 and 4，based on the appearance on hepatic 
I 
J angiography (HAG), were significantly higher than that in 49 patients 
with lowervascularity grades (0,1 and 2). 
1 
No significant change in the percentage of lung shunting was observed 
with and without the vasoconstrictor angiotensin iL A neoplastic nature 
1 
] of the blood vessel responsible for the shunting of radioactivity to the 
lungs was suggested as angiotensin II is known to constrict normal 
1 “ 
blood vessels but not malignant ones. This was further supported by 
;| the decrease of lung shunting from 28.5% to less than 1% in a patient 
• i 
after resection of his major tumour. 
;i -
The T/N ratios in 51 patients with HCC measured by using ®®^Tc-MAA 
scans ranged from 0.9 to 11.1 with a median of 3.7. There was no 
correlation between the tumour vascularity grading on HAG and T/N 
ratio from ®®^Tc-MAA scans. It was suggested that a tumour with a 
hypervascular periphery but a large necrotic centre may appear highly 
vascular on the two-dimensional planar HAG images. Thus the 
vascularity grade may not accurately reflect the T/N ratio. 
71 
A phase I and II study on 18 patients with inoperable HCC was carried 
out between November 1990 and May 1993 (73). Patients received 2 
to 7 GBq of 卯丫 microspheres through the hepatic artery during 
laparotomy. The different radiation doses received by the tumour and 
normal liver were obtained from the count-rates recorded by a small 
beta probe. Another independent set of dose data was derived from 
liquid scintillation counting of the biopsies taken at the completion of 
the infusion of 卯丫. There was no complete response in the 16 patients 
without extrahepatic disease. Partial response was documented in 7 
of 9 patients (subgroup A) who received a tumouricidal dose (> 120 
Gy) to all their tumour nodules compared to one of eight patients 
(subgroup B) who received < 120 Gy to at least one of the tumour 
nodules. (Fisher's test, p = 0.005)。The median survivals of the two 
subgroups were also found to be dose related, being 60.0 weeks 
(subgroup A) and 26.2 weeks (subgroup B) respectively and the 
difference is statistically significant (p = 0.005). 
To evaluate how accurate the T/N ratios determined from ®®^Tc-MAA 
can predict the relative distribution of ®°Y microspheres in the tumour 
and normal liver during subsequent SIR therapy, these T/N ratios were 
correlated separately with the T/N ratios derived from the radiation 
doses measured with a beta probe intra-operatively and with those 
calculated on the radiation doses from liquid scintillation of biopsy 
specimens (74). The correlations were good (linear regression : r = 
0.82 and 0.96 respectively). Thus a T/N ratio from ®®^Tc-MAA of > 2 
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has been adopted as an entry criteria to SIR therapy (73) to ensure a 
tumouridcidal dose (> 120 Gy) is being delivered to the tumour if the 
non-tumourous but often cirrhotic liver receive a radiation dose of 
below 70 Gy, which is believed to be the upper safety limit. 
(C) Problems associated with early works 
Early internal radiation therapy using intraarterial yttrium-90 
microspheres encountered three major problems : 
1. leaching of ®°Y from the microspheres causing bone marrow 
toxicity, 
2. arteriovenous shunting of 卯丫 microspheres to the lungs, 
3. reflux of ^Y microspheres into the gastroduodenum resulting in 
gastritis. 
The first problem disappeared when the new generation of ®°Y 
microspheres (both glass and resin type) with practically no leaching of 
activity emerged. 
Pre-treatment assessment of the degree of arteriovenous shunting to 
the lungs using ®®^Tc-MAA excluded patients at risk of developing 
radiation pneumonitis. 
The ®®^Tc-MAA perfusion scan also helps to identify patients with 
significant extrahepatic spread of radioactivity to the gastroduodenal 
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region. Dissection and cannulation of the gastroduodenal artery at 
laparotomy before infusion of 卯丫 microspheres pioneered by Gray et al 
(56-60,70) seemed to be a practical way of reducing radiation 
gastroduodenitis. 
(d) A major problem left to be solved 
The aim of internal radiation therapy is to deliver the highest possible 
radiation dose to the tumour so that the tumour is eradicated or at least 
is under good control. On the other hand the radiation dose to the 
non-tumourous liver should be as low as possible to preserve 
adequate liverfunction. 
Attempts were made to escalate the radiation dose to test the 
maximum tolerance of the liver. Experiments on animals have been 
very successful (67,68) because the dose distribution in their tumour 
and liver can be analysed in great details on killing the animals. 
In human, direct measurement outside the body of the radiation doses 
to the tumour and the normal liver is impossible because the pure beta 
radiation of 卯丫 is attenuated by 11 mm soft tissue.卯丫 does not have 
gamma emission for scintigraphic imaging of its distribution as in the 
case of i3i|-Lipiodol. Therefore all dose estimations in most studies 
were based on an assumption that the radioactivity was distributed 
uniformly through the entire liver, without distinction between the 
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tumour and the normal liver (50-55, 64-67, 70) except with the 
intraoperative approach of Burton et al (56-58). Without delineating 
the actual radiation doses to tumour and the normal liver, it is 
impossible to document the maximum tolerance of the normal liver as 
well as the dose-related response of the tumour. 
The intraoperative approach of Burton et al (56-58) allowed the actual 
radiation doses to the tumour and normal liver to be obtained through 
either beta-probe measurement or liquid scintillation counting of 
biopsies containing ®°Y microspheres. However, these measurements 
are impossible without the patient undergoing a laparotomy which 
carries definite risks of morbidity and mortality. Also associated 
medical illnesses such as diabetes and hypertension that preclude a 
patient from laparotomy will also deprive him of the opportunity to 
receive SIR therapy for his hepatic cancer. Furthermore, another 
laparotomy may be required when there is residual or recurrent 
disease to be treated and repeated laparotomy is not always feasible. 
An implanted arterial Port-A-Cathether helps to solve the problem of 
repeated laparotomy but the patency of the port must be maintained 
with extreme care. Thus a method by which the radiation doses to the 
tumour and the normal liver can be measured or at least be estimated 
without the need of a laparotomy is required. 
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CHAPTER 3 
THE BACKGROUND IN PHYSICS 
Targeted therapy for treating cancer is similar to the principles of using 
missiles in wars. Essentially the treatment consists of a warhead (the 
cytotoxic agent) and a rocket (the carrier). For selective internal radiation 
(SIR) therapy, the warhead is a suitable radioisotope and the carriers 
commonly used are Lipiodol and resin or glass microspheres. There are a 
number of physical aspects to be considered in the design of an effective and 





3,1 CHOICE OF RADIOISOTOPES 
There are controversies as to whether ^^1-Lipiodol or 卯丫 microspheres is 
] 
i better for treating hepatic cancer (1,2). There are a number of characteristics 
of the therapeutic radiopharmaceutical which need to be considered : 
i ‘ 
1. type of radiation 
2. energy characteristics of radiation 
3. penetrating depth of the radiation in soft tissue (cytotoxic range) 
4. physical half life of the radioisotope 
5. therapeutic effects and logistical problems 
) 6. biodistribution and rate of clearance of the radiopharmaceutical 
7. cost and availability 
76 
I 8. ease of synthesis or conjugation to suitable carriers 
I 
i 
f In fact some of these characteristics are inter-related. For example, the j；'； 
fe, fe 
^ cytotoxic range is determined by the type of radiation and their energy 
” 
characteristics, a,p or y radiation is known to have different penetration 
:j 
j power. Typical ranges of these three different kinds of radiation in air and 
# j 
.‘ I ：••：•! ., 
soft tissue are illustrated in Table 3.1. As can be seen y-radiation with the 
I . 
I highest penetration power can penetrate through human body while the 
3 :11 
1 common range of p-radiation in soft tissue is in the order of a few mm. 
； I 
:••I 
i Therefore the distribution of i3i|_Lipjodol within the body can be readily 
:d 
I.[ 
j detected outside the body making use of the y-radiation whereas the p_ 
‘ 
[； radiation (maximum range in soft tissue = 11 mm) from 卯丫 microspheres is 
fully attenuated by the body. 
•[ 
. 1 , 
Table 3.1 Ranges of different types of radiation in air and soft tissue 
m ! • ^ • ^ ^ — ^ • ^ ^ ^ ^ ^ ^ • ^ ^ ^ • ^ ^ — ^ — ^ ! " " • ^ " " ^ " • ^ " — " " • " — • ^ — — " — y ^ ^ ^ " — ^ ^ ^ ^ ^ " " " ^ ^ ^ ^ ^ ^ ^ — " " 
Type of radiation Range in air Range in soft t issue 
• 
i 
“ ^ 0.03 m 0.04 mm 
“ ^ 3lr i 5 mm 
Y very large Through the body 
« f ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ i ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M i i ^ M M i i ^ J M i ^ * * ^ " ^ ™ ^ * * ^ ^ ™ " ^ ^ ^ ^ ^ ^ " ^ ^ ^ " ' ^ ^ ^ ^ ^ ^ " ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ " ^ ^ ^ ^ ^ ^ ^ " " ' " " ™ " " ^ " ' ^ ^ ^ ^ " ^ " " ' * ^ ^ ^ ^ ^ ^ ^ ^ ^ " ^ ^ ^ " 
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A comparison of the first four characteristics of the three most commonly 
used radioisotopes ^® l^,卯丫 and 印 js shown on Table 3.2. The p-radiation of 
90丫 has the greatest range and therefore irradiates a greater volume of tissue 
and thus exhibit a 'field effect， (Figure 3.1) which may compensate for 
irregular distribution of the isotope within the tumour tissue. The cytotoxic 
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(b) For radiation with long range, produced a Tield effect，so that the doses experienced at A 
and B are closer. 
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• 
Figure 3.2 Cytotoxic and mean ranges of Y90 
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While 90丫 with p-radiation and having higher energy and deeper penetration 
than that of ®^^ l is the radioisotope of choice for large tumours, it is less ideal 
to be used on small tumours. As illustrated in Figure 3.3, the ®°Y 
microspheres in a small tumour may deposit excessive radiation to the 
• 





Cumulative radiation dose to the tumour and adjacent tissue are determined 
i by the energies of the radiation, the physical half life and the biological fate 




丨 be inferred by another term called the dose rate (dose delivered per unit 
： ] 
ri time). Isotopes with higher energy and shorter effective half life I £ 
(incorporating both the physical and biological half lives) will have a higher 
i' 
丨 
dose rate. In normal liver，^^^l-Lipiodol has been found to have an effective 
half life of about 4 days (3) as it is being actively degradated and excreted in 
biological fluids, mainly urine. On the other hand,卯丫 microspheres are 
retained within the body indefinitely. Figure 3.4 illustrates the dose rate 
curves (considering only p-radiation) of ''P,卯丫 and ' ' ' I with ' 'P colloid and 卯丫 
microspheres decay at their physical half lives and ^^^l-Lipiodo! with an 
effective half life of 4 days. The areas under the dose rate curves are 
proportional to the doses delivered over a defined period of time while the 
slopes of the curves reflect the dose rate. 
The physical half lives and types of radiation also determine the potential 
radiation hazard to other people and hospital staff. Isotopes with a longer half 




























































































































































































































































































































































































































































































































































































































































































































































procedures is required. However this usually only applies to isotopes with 
gamma emission. For isotopes with pure beta radiation the requirement for 
radiation protection is much alleviated as majority of the radiation can be 
attenuated by the patient's body。 
i . 
！ The data in Table 3.2 suggest yttrium-90 is the isotope of choice for treating 
large hepatic tumours because it has the shortest half life，the highest p 
I energy, the greatest cytotoxic range and mean penetration. The lack of 
I gamma emission is an advantage as well as a disadvantage. As mentioned 
I above, the requirement for radiation protection is alleviated. However the 
•'i 
i:j 
distribution of ®°Y cannot be directly detected outside the body using gamma 
scintigraphy as in the case of ®^^ l. 
In our center, as the majority of hepatic tumours are large and non-resectable 
||: 
I： at presentation,卯丫 is chosen as the isotope for these tumours while ^^ 1^-
!i 
Upiodol js reserved in an adjuvant setting after curative resection of HCC. 
The present study is focused on selective internal radiation (SIR) therapy 
using 卯丫 microspheres. 
3.2 CHOICE OF THE CARRIER 
Two types of 卯丫 microspheres are used nowadays for SIR therapy for hepatic 
I cancer. The first is glass microspheres with a density of about 3.3 g/ml and 
the second is resin based microspheres which have a density of 1.6 g/ml. 
The resin based type was selected and used in the present study because 
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the glass type was considered to be too heavy. It has been suggested that 
the heavier glass microspheres have a greater chance of getting into the 
gastroduodenal artery thus causing gastroduodenal ulceration (4) despite 
pre-treatment scan using ®°^Tc-MAA demonstrated no extrahepatic shunt. 
The density of the resin based microspheres is similar to that of ®®^Tc-MAA so 
that the arterial distribution of them are more close to each other. 
3A DOSIMETRY 
As has been stressed, the aim of SIR therapy for hepatic cancer is to deliver 
the highest possible radiation dose to the tumour while keeping the radiation 
dose to the normal liver below the tolerance limit. However in all previous 
studies (4-12) except those carried out by the group at Perth (13-16) and at 
；' our centre (17)，the radiation doses received by the tumour and the normal 
liver were taken as identical by assuming a uniform distribution of 卯丫 
microspheres throughout the entire liver. Thus it has been impossible to 
document the actual radiation doses received by the tumour and normal liver. 
I The intraoperative approach of Burton et al (13-15) allowed measurement of 
the respective doses to the tumour and normal liver but a laparotomy is 
required for each treatment. 
More importantly is that the effect of radiotherapy is non-reversible. Burton et 
I al (13-15) infused the 卯丫 microspheres in aliquots and measured the 
radiation doses, particularly that to the normal liver，before further amount of 
activity was given. However, it is desirable to be able to predict the radiation 
doses resulting from a certain activity of ®°Y microspheres in a particular 
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patient. An optimal amount of 卯丫 microspheres could then be planned and 
be administered. 




HYPOTHESIS AND TESTING THE HYPOTHESIS 
4.1 HYPOTHESIS 
A partition model can be formulated so that the radiation doses to the tumour 
and the non-tumourous parts of the liver, and the radiation doses to the 
extrahepatic organs (mainly to the lungs and gastroduodenum) in a patient 
who received a known activity of 卯丫 microspheres for this hepatic cancer can 
be estimated. 
4.2 TESTING THE HYPOTHESIS 
The hypothesis is tested by applying the partition model in clinical settings 
with known activities of ^Y microspheres being given to patients with 
inoperable liver cancer. With the help of ®®^Tc-MAA scans, the degrees of 
extrahepatic shunting and the T/N ratio can be calculated. If the masses of 
the tumour and non-tumourous compartment of the liver are also determined 
with the use of spiral CT scan, then the partition model may permit :-
1. prediction of radiation dose to the lungs 
2. prediction of radiation doses to the tumour and to the non-tumourous 
parts of the liver 
88 
The partition model can be verified by : 
1. intra-operative dosimetry and liquid scintillation counts of biopsies to 
correlate with the estimation of radiation doses to the tumour and non-
tumourous compartments of the liver 
2. correlation between T/N ratios determined from Bremsstrahlung scans 
performed after treatment with 卯丫 microspheres and those from the 
99mTc-MAA simulation 
The validity of the radiation doses estimated by the partition model can be 
further evaluated in clinical settings by : 
1 • the incidence of radiation pneumonitis in relation to the radiation doses 
to the lung as predicted by the partition model 
2. higher response rate associated higher radiation doses to the tumour 
？' -
j as predicted by the partition model 
3. better survival rate associated with higher radiation doses to the 
tumour as predicted by the partition model 
4. the persistence of residual tumour after a single treatment of SIR 
therapy because the radiation dose to part of the tumour is below the 
tumouricidal level as predicted by the partition mode! 
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4.3.1 The concept of partition mod&l 
Arteriovenous shunting to the lungs is well known in HCC (1) and colorectal 
liver metastases (2). Various degrees of lung shunting have also been 
demonstrated by ®®^Tc-MAA gamma scintigraphy (3-5). 
Reflux of 90丫 microspheres infused through the hepatic artery into the 
gastroduodenum resulting in gastroduodenitis have also been reported in 
previous trials (6,7). 
Thus an activity of 卯丫 microspheres when infused into the liver through the 
hepatic artery may be partitioned between 4 main compartments : the lungs, 
the gastroduodenum, the tumour and the non-tumourous liver. 
By superselective catheterization of the hepatic artery, the tip of the catheter 
was placed distal to the right gastric artery in all our patients. By careful and 
slow infusion of the 卯丫 microspheres，the amount of activity refluxed into the 
gastroduodenum was neglegible。 The 3 important compartments of activity 
uptakes are illustrated in figure 4.1. Practically the sum of the activity uptakes 
in lungs (⑷，tumour(^^) and non-tumourous liver ( ^ ^ ) e q u a l s to the total 
activity { A ) of ®°Y microspheres administered. That is 
A = AL + A r + 儿 
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Figure 4.1 Schematic diagram illustrating the partition model 
A ^ ^ 
_ • 
i V l N 
ML,Mx ,Mv = mass of lungs, tumour and and non-tumourous liver. 
AL ,Aj .Av = activity uptake in lungs, tumour and non-tumourous liver. 
91 
4.3.2 Method for calculation of radiation dn^ fmm ^Y 
The radiation dose was calculated by following the principle laid down by the 
Medical Internal Radiation Dose (MIRD) Committee (8,9). The basis for 
determining the dosage administered to tissue is to calculate the energy 
absorbed by the tissue due to the presence of the isotope. The unit of 
absorbed dose is Gy which is defined as the dose corresponding to the 
absorption of 10,000 ergs of energy by 1 g of the tissue of interest. 
The calculation of absorbed dose due to beta emitter is relatively simple 
providing the following two criteria are satisfied. 
1. The isotope is uniformly distributed in the region or organ of interest. 
2. The region or organ in which one wishes to determine the beta dose 
has dimensions which are large compared to the range of beta 
particles in the tissue. 
The first condition is self evident otherwise the exact number of microspheres 
and the exact location of each microspheres must be known before the 
radiation dose contributed by each microsphere to an area in the tissue can 
be computed. The second condition is almost always satisfied since the 
range of beta radiation in tissue is in the order of a few millimeters. In the 
present situation the maximum penetration of 卯丫 (11 mm) is small compared 
to the size of the liver or the tumours. This condition permits the assumption 
that all energy associated with the beta particles is deposited effectively at the 
site of the isotope emitting it. Under these circumstances, an infinite region 
beta dose, applicable to the entire volume of the tissue (except close to the 
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surface) in which the isotope is uniformly deposited is given by the mean 
energy of the beta particles times the disintegration rate of the isotope. An 
activity of 1 Bq produces one disintegration per second {dps). Thus an 
activity of 0.037 MBq or 1 |j,Ci undergoes 37 x 10 ' dps。 
From the radioactive decay data of 卯丫 (10) the physical half life {V/2) of 卯丫 is 
64 hours. 
Its average life ~ = ^ = 7 ^ ^ = 3,848 days • A ln 2 0.693 
The mean p energy of ®°Y is 0.934 MeV . 
Thus 1 |dCi (0.037 MBq) per g tissue gives an initial dose provided by the 
following : 
1 
0.934 MeV (1.6 x 10 ' ergs / MeV)(— cGy / ^)(37 x 10' dps x 24 x 60 x 60) 
=47.76 cGy / days 
Therefore radiation dose delivered to 1 g tissue over complete radioactive 
decay starting initially with lMBq 
1 
=47.76 {cGy / day) x 3.848 {days) ^ ^ 
=49.67 Gy 
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I 4.3.3 ThG partition model 
It has been established that 卯丫 microspheres are trapped inside the 
microvasculature and decay at the physical half life of 卯丫 to infinity without 
biological degradation (6,7 11-22). Using the MIRD principle (8,9) the 
radiation dose to an organ of mass M (^)with an organ activity uptake of ^ ^ 
GBq of ®°Y is given by the formula :-
49.67(1000)4^(G5^) . . . Dose (Gy) = — which on simplification becomes 
M(g) 
49,610Ao(OBq) Dose (Gy) = ;;77^ W 
M{g) 
For a total activity of A GBq of 卯丫 administered to a patient with lung 
shunting = L% without extrahepatic shunting apart from the shunting into the 
pulmonary system, the lung activity uptake of 卯丫 microspheres 
A = A (盖)GBq m 
By substituting 1000 g as the total mass ( M i ) of both lungs (including 
blood) for a standard man [23] and j { ^ into formula [1] the radiation dose to 
the lungs ( £ ) J can be obtained as 
=49,670 AL(GBg) [3] 
认 一 1000 
The remaining activity of 卯丫 is partitioned between the tumour and the non-
tumourous liver. Let >i^and j [ ^ be activity uptakes of the tumour and non-
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tumourous liver and ^ ^ and ^ ^ be their masses, substituting these 
parameters into formula [1], the radiation doses to the tumour (£)^) and non-
tumourous liver ( D N ) are given as 
n = 49,670 A [4] 
从 Mr 
=49,670 A . [5] 
� M. 
Dividing equation [4] by equation [5] yields the T/N ratio r : 
Ar 
^ = � = M r [6] 
Dn i4iv 
w . 
As stated in section 3.4.1, the sum of the activity uptakes of the lung (⑷， 
tumour (J^^) and non-tumourous liver ( 〜 e q u a l s to the total activity 
administered ( ^ ) : 
A = A + Ar + A^ 
or Ar + AN = A - A 
i.e. Ar + Aiv = A (1- ^ ) [7] 
If masses of the tumour and non-tumourous liver, the percentage of lung 
shunting and the T/N ratio are known, the activity uptakes and hence the 
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radiation dose to the lungs can be readily calculated using equations [2] and 
[3]. 
On the other hand the activity uptakes of the tumour (^ 了）and non-
tumourous liver (AN) can be obtained by solving the simultaneous equations 
[6] and [7]. 
Substituting M i ^ , A r，M w , A v into equations [4] and [5] yield the 
radiation doses received by the tumour and non-tumourous liver. 
Thus estimation of radiation doses with the partition model required : 
1. measurement of the percentage of lung shunting (and the percentage 
of activity shunted to the gastroduodenum if there is a detectable 
amount) 
2. measurement of T/N ratio 
3. determination of the masses of the tumour and the non-tumourous 
liver 
4.3.4 Advantage<： nf using thR Partition Model 
If the partition model can be used to predict the radiation doses to the various 
compartments, it is hoped that it may permit: 
1. prediction of the radiation dose to the lungs and hence the possible 
risk of radiation pneumonitis 
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2. prediction of the radiation dose to the tumour and hence adjustment of 
activity to be given so as to deliver a dose that is regarded as 
tumouricidal (> 120 Gy) 
3. prediction of the radiation to be received by the non-tumourous part of 
the liver and hence adjustment of the activity to be given so as to keep 
the dose below the accepted tolerance limit 
4. pre-determination of an optimal activity of ®°Y microspheres that should 
be given to the patient 
5. With the partition model, the radiation doses to the tumour and non-
tumourous parts of the liver can be documented without the need of a 
laparotomy. ®°Y microspheres can then be administered through a 
percutaneous route. This makes SIR therapy using ®°Y microspheres 
a safe and repeatable treatment. 
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CHAPTER5 
PARAMETERS REQUIRED IN THE PARTITION MODEL 
5.1 MEASUREMENT OF PERCENTAGES OF LUNG SHUNTING 
I Ideally, radioisotopes in the treatment of hepatic cancer should be 
concentrated in the tumours or at least be confined to within the liver. 
Shunting of part of the activity to neighbouring organs such as the lungs and 
gastroduodenum may not only reduce the radiation dose to the tumours but 
may cause damage to these organs。The relatively low radiation tolerance of 
lungs has arouse much caution in treating hepatic cancer with intra-arterial 
infusion of radioactive substances such as 卯丫 microspheres or ^^ 1^ Lipiodo!. 
I 
With the knowledge of arteriovenous shunting in metastatic liver tumours 
(1,2), technetium-99m macroaggregated albumin (®®^Tc-MAA) is widely 
employed to assess the degree of shunting into the pulmonary circulation (3_ 
5) before treatment by radioisotopes. A high percentage of the radioactivity 
shunted into the lungs during treatment may induce radiation pneumonitis. 
The lung shuntings in 125 patients with HCC have been analysed and 
reported from our centre (6). The study has been extended in the present 
study. The percentages of lung shunting in a total of 377 patients with HCC 
and 25 patients with liver metastases from colorectal cancer have been 
assessed. 
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99mTc-MAA is commonly used for detection of abnormal lung perfusion 
patterns. After intravenous injection ®®^Tc-MAA particles are trapped during 
the first pass through the pulmonary capillary bed. Aggregates of albumin 
ranging from 10 - 100 ^m lodge in the capillaries and precapillary arterioles 
and accurately reflect regional difference in pulmonary blood flow. 
99mTc-MAA is the most readily available radiopharmaceutical suitable for 
simulation of selective internal radiation therapy (SIR) by intra-arterial infusion 
of 卯丫 microspheres because of their similar size. Comparison of the 
characteristics of 卯丫 microspheres and ®®^Tc-MAA is shown in Table 5.1. 
Photomicrographs of 卯丫 microspheres and ®®^Tc-MAA are shown in Figure 
5.1 • As can be seen the shapes of the two types of particles are different but 
I they have similar average sizes. The microspheres are spherical while the 
MAA particles have irregular shapes. 
The 377 patients with HCC have either (i) histological proven HCC or (ii) 
evidence of liver tumour on ultrasound with serum alphafetoprotein (AFP) 
level raised above 500 ng/ml. The 25 patients with colorectal cancer had liver 
metastasis only and the primary cancer had been completely resected. 
These patients underwent hepatic angiography as part of an assessment for 
treatment. Hepatic angiography was performed through the Seldinger 
technique. After the angiographic catheter had been selectively placed in the 
hepatic artery, 111 MBq (3mCi) of ®®^Tc-MAA (Amersham Pulmonate II，with 




















































































































































































































































































































































































Figure 5.1 Photomicrographs of^^Y microspheres (a) 
and ^^Tc-MAA particles (b) (magnification 1:40) 
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size 30 M,m) were injected through the catheter into the liver. The catheter 
was then removed. 
After haemostasis of the puncture site, the patient was transported to the 
I gamma camera suite and scintigraphic images of the lungs, liver and 
gastroduodenal regions were taken with an analog/digital gamma camera 
(Philips, Hamburg, Germany)。 Regions of interest (ROIs) were carefully 
i 
I 
drawn around the organs (liver and lungs) on the digitised image and the 
percentage of activities shunted into the pulmonary circulation was calculated 
as the ratio of lung-counts to total-counts。Significant amount of activity in 
any other organs such as the gastroduodenum was also taken into 
,, consideration. 
Tumour sizes were measured either by computerized tomography or 
ultrasound scan。The vascularity of the tumour on hepatic angiography was 
assessed by an interventional radiologist. Grading by a scale from 0 (normal) 
to 4 (extremely hypervascular) was based on the following criteria :-
Grade 1 Presence of mild tumour staining without an increase in the number 
of vessels (Figure 5.2a) 
Grade 2 Moderate tumour staining and increased number of vessels (Figure 
5.2b) 
Grade 3 Intense tumour staining and marked increase number of vessels 
which were also dilated and tortuous (Figure 5.2c) 
Grade 4 Tumours having all the grade 3 characteristics together with 
venous pooling (Figure 5.2d) 
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The degree of lung shunting was correlatedwith the size and vascularity of 
the biggest tumour in the patient. 
Patients with residual or recurrent diseases were reassessed for suitability of 
SIR therapy and the percentages of lung shunting were again measured after 
infusion of ®®^Tc-MAA during hepatic angiography. These values were 
compared with the percentages before the initial treatment. 
Statistical methods for analysis included linear regression and Wilcoxon rank 
test. 
(a) Variation of lung shunting and diffGmnce between HCC and liver 
mGtastases 
\ 
The degree of lung shunting was found to vary between patients. The 
variation among the 377 patients with HCC (mean 士 SD = 12.6% 士 
13.3%) was more remarkable than in the 25 patients with liver 
metastases from colorectal cancer (mean 士 SD = 6.7% 土 5.4%). In the 
HCC patients, the percentage of lung shunting ranged from less than 
1% to 75.4% with a median of 7.6%. The range for the 25 cases of 
丨3 '^-
liver metastases was from less than 1% to 23.9% and the median was 
4.7%. Two representative scintigrams with 5.4% and 75.4% lung 


























































































































































Table 5.2 illustrates the subdivision of the patients according to the 
degree of lung shunting. As can be seen the percentages of lung 
shunting were generally lower in liver metastases with 96% of the 
patients with values equal to or below 15%. On the other hand, 27.9% 







Table 5,2 Lung shunting as determined by ^^^Tc-MAA 
(A) In HCC 
% lung shun t i ng No. of pat ients (%) 
<5.0 126 (33.4) 
5 .0-9.9 103 (27.3) 
10.0- 14.9 43 (11.4) 
15.0- 19.9 26 (6.9) 
20.0 - 24.9 17 (4.5) 
25.0 - 29.9 21 (5.6) 
30.0 - 34.9 14 (3.7) 
35.0 - 39.9 11 (2.9) 
40.0 - 44.9 3 (0.8) 
45.0 - 49.9 3 (0.8) 
>50.0 10 (2.7) 
Total: “ ^ (100) 
(B) In colorecta l l iver metastases 
% lung shun t i ng No, Qf pat ients (%) 
<5.0 13 (52.0) 
5.0 - 9.9 7 (28.0) 
j 10.0-14.9 4 (16.0) 
15.0-19.9 0 (0.0) 
20.0 - 25.0 1 (4-0) 
T o t ^ ^ (100) 
I 
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Figure 5.3 Lung shunting of^^^Tc-MAA 
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(b) Correlation between lung shuntings and .<;i>fi5; of tumour 
Sizes of the biggest tumour from computerized tomography or 
ultrasound scan in the 377 patients with HCC varied from 1.0 to 26.2 
I 
“ cm with a median of 10.0 cm. Plotting of percentages of lung shunting 
against the tumour sizes on log-linear scales is illustrated in figure 5.4. 
•:’:！ 
, I 
丨 Good correlation between percentages of lung shunting and tumour 
size was demonstrated (coefficient of linear regression r = 0.359，p < 
• 
i 0.0001). Such correlation was not observed in our preliminary study 
....ft] 
i 




• 1 ? 
• The patients were stratified into subgroups according the tumour sizes. 
The mean percentages of lung shunting in each subgroup are shown 
in Table 5.3. This analysis is impossible in the preliminary study {6) 





f Table 5.3 Relationship between lung shunting and tumour size 
Subgroup Tumour size (cm) n Lung shunting (%) 
mean range 
A < 1 6 9 " " 5 J 0.0 - 5 2 . 0 ~ " 
B > 5 , < 1 0 W l " " " ^ 0.0-61.1 
C > 10,<15 122 17.7 0.0 - 6 8 . 9 ~ " 
D > 15 ,<20 4 9 " ~ m 2 1 . 8 - 7 5 . 4 ~ " 
E ‘ ^ 2 0 6"""^mO 5.2 - 3 6 . 7 ~ 
p-valves QNWcoxon rank test) 
^ Tumour size ( C m ) “ “ > 5，< 10“ > 10, < 15 > 15, <20 >20 
<^ 0m02 0.0001 0.0001 0.001& 
> 5 ^ < 1 0 0.0001 0.0001 0.0298“ 
‘ > 10 ,<15 0.9170 0.8172“ 
^ > 15 ,<20 — 0.7768 
1 ^ 
There is an increase in the mean lung shunting with increasing tumour 
sizes up to 15 cm, and then the mean lung shunting remained almost 
unchanged up to size > 20 cm. As the distribution of value was non-
Gaussian, Wilcoxon rank test was used to compare the differences 
between subgroups and the p-valves are illustrated as part of Table 
5.3. The differences between subgroups were statistically significant 
except in between the 3 subgroups C, D and E with the largest tumour 
sizes. 
In the 25 patients with liver metastases, the size of the biggest tumour 
ranged from 1.5 to 17.0 cm with a median of 7.6 cm. Similar plot for 
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these patients is shown in Figure 5.5. On excluding one outlier, good 
correlation between the two parameters was shown (linear regression : 
r = 0.686, p < 0.0001). Due to the small number of patients, analysis 































































































































































































































































































































































































































































































































































































































































(c) Relationship between the pGrnentag&s of lung shunting and thG tumour 
vascularity grades 
The relationship between the percentages of lung shunting and the 
tumour vascularity grades as assessed on hepatic angiography for 
HCC and liver metastases are illustrated in Figures 5.6 and 5.7 
respectively. All except two patients with liver metastases had 
vascularity grades of 1 or 2 while the majority of HCC patients had 
vascularity grades of 3 and 4. Thus HCC are generally more vascular 
than liver metastases. 
In our preliminary study patients with HCC having vascularity grades of 
1 and 2 are compared with those having grades of 3 and 4 using 
I Wilcoxon rank test (6). The result (p < 0.0001) suggests that those 
with more vascular lesions had higher lung shunting. With the 
i： extension of this study to indude a total of 377 patient, it is possible to 
analyse the difference between each vascularity grade. The mean 
values of the lung shunting for each vascularity grade are shown in 
Table 5.4. The single patient with grade 0 was excluded from analysis. 
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Table 5.4 Comparison of lung shunting between different vascularity 
grades in patients with HCC 
Vascularity grade n Lung shunting (%) 
mean range 
1 5 ^ ^ 0.0 - 36.7 
2 ^ " " ^ ^ 9 0.0 - 49.9 
3 1 ^ " " " ^ 1.0-66.3 
~ ^ ~ " 2 3 . 8 1.0 - 75.4 
P-valves O^ilcoxon rank test) 
Vascularity grade 2 3 4 
1 0.0148 0.0001 0.0001 
2" 0.0001 0.0001 
3 0 . 0 0 0 1 
The mean lung shunting increases with increasing vascularity grades, with a 
tremendous increase from grade 2 to grade 3 and then to grade 4. The p-
valves from Wi!coxon rank test indicate that statistically significant differences 
exist between any two vascularity grades. 
In comparing the percentages of lung shunting of patients with colorectal liver 
metastases having vascularity grades 1 and 2 with those having grades of 3 
|l and 4 using the same statistical test，a p-value of 0.057 was obtained. 
However this comparison may not be valid because there are only two 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(d) Change in lung shunting after treatment 
Patients with residual or recurrent disease after various types of treatment 
were reassessed with ®®^TC-MAA given through hepatic angiography for 
suitability of SIR therapy. Comparison of the lung shunting before and after 
the initial treatment is shown in Table 5.5. The tremendous increase of lung 
shunting in the first patient made it impossible to treat his recurrent disease 
with SIR therapy. All patients with residual tumours left after SIR therapy 
showed a decrease in lung shunting. On the other hand, patients with 
recurrent disease appearing as new lesions showed both increase and 
decrease in lung shunting. 
Both HCC and colorectal liver metastases are usually more vascular than the 
normal liver parenchyma due to neovascularization (7). ®®^Tc-MAA particles 
f are expected to be caught within the capillaries of the tumour or the normal 
liver because of their size and few particles can leak through if there is no 
arteriovenous shunting. However, arteriovenous shunting is well known in 
HCC (8) and colorectal liver metastases (2). The leaked ®®^Tc-MAA go 
through these abnormal vascular channels and into extrahepatic organs. The 
lungs，being a first-pass organ and having similar capillary structures, hold up 
the leaked ®®^Tc-MAA. Little MAA leak to other organs because the capillary 
bed in the lungs stops any further systemic leak. This theory is consistent 
with our observation that there was no significant extrahepatic spread of 
®®^Tc-MAA except in the lungs. Thus, measuring the degree of lung shunting 
indirectly reflects the degree of arteriovenous shunting in the liver tumours. 
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Hepatic arterial perfusion scintigraphy using ®®^Tc-MAA has been employed 
by others to assess the leakage of regional chemotherapy for liver 
metastases into the pulmonary circulation (2,9). The percentage of lung 
shunting was found to be between 6% and 26% (mean 12.3%) in a series of 
20 patients (2) and between 0.4% and 32% (mean 6.2%) in another series of 
67 patients (9). These ranges are very close to that of our 25 patients with 
liver metastases. A much wider range (< 1% - 67.2%) of pulmonary shunting 
observed in 125 patients with HCC has been reported previously by us. The 
median value for HCC was also higher than that of liver metastases. With 
377 HCC patients in the present study, the range has become even wider (< 
1% to 75.4%). Zeissman et al (9) found that 49% of their patients with 
metastatic tumours had a percentage equal to or greater than 5%. In our 
series of 25 patients with liver metastases, 48% or them had a lung shunting 
of 5% or above. The results of the two studies are therefore very close。 
Significantly higher percentage (66.6%) of HCC patients showed lung 
shunting equal to or greater than 5%. All these suggest HCC to have higher 
lung shunting. Gray et al (10) recommend lung shunting of below 15% as the 
safe limit for SIR therapy. Using lung shunting below 15% as the only entry 
criteria, 27.9% of HCC patients have to be excluded from SIR therapy as 
compared to only 4% of patients with liver metastases. 
Using the MIRD formula employed in establishing the partition model, the 
1 radiation doses to the lungs from a certain activity of 卯丫 microspheres can 
I 
1 actually be predicted : 
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, , n � . ^ � 496.7 X total activity (GBq) x shunting lung (%) Lung dose (j^J (Gy)= — Mass oflungs {g) 
With the mass of lungs taken to be 1,000 g (11)，the radiation dose to the 
lungs is 7.5 Gy per GBq of 卯丫 microspheres administered in a patient with a 
lung shunting of 15%. If 20 Gy is taken as the safety limit based on the 
experience of whole lung irradiation using external beams the maximum 
activity that could be given is 2.66 GBq。For a patient with a lung shunting of 
10%, the estimated lung dose will be 5.0 Gy per GBq of 卯丫 microspheres 
infused through the hepatic artery. Up to 4 GBq could then be safely given. 
It is a more scientific way in setting the entry criteria to SIR therapy using ®°Y 
microspheres to be less than 20 Gy to the lungs，rather than a lung shunting 
below 15% because the activity required to treat the hepatic cancer in 
I different patients may not be the same. 
Our previous study (6) demonstrated that significant differences in lung 
shunting were found between different vascularity grades but not with tumour 
size. The results of the present study showed that the degrees of 
arteriovenous shunting to the lungs were influenced by both the vascularity of 
the tumours as well as the tumour size. The pattern of blood flow through the 
tumour seems to be one of the determining factors of pulmonary shunting. 
This may be due to the fact that tumours which are usually vascular and rich 
inblood supply, have more arteriovenous shunts with a resultant increase in 
[； 丨  
f the percentages of lung shunting. The generally lower percentages of lung 
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shunting observed in colorectal liver metastases is consistent with their lower 
vascularity. The increase in lung shunting with tumour size up to 15 cm is 
probably due to the increase in arteriovenous shunts as the tumour grows. 
As central necrosis occurs when the tumour grows to beyond 15 cm, the 
degree of lung shunting becomes almost constant. 
A strong association between lung shunting and the characteristics of HCC 
present in an individual patient is evident from the comparison between the 
percentages of lung shunting before the initial treatment with that after the 
detection of residual or recurrent disease. A tumour which has been treated 
by SIR should be smaller than the original tumour, !t should also be less 
vascular due to embolization by the 卯丫 microspheres and the necrotic and 
fibrotic effect caused by radiation。The decrease in vascularity explains the 
observed lowering lung shunting associated with residual tumours. On the 
I 
II other hand, recurrence which appeared as new lesions might have 
j completely different size and vascularity. The lung shunting associated with 
the new tumours due to recurrence are usually higher than that before the 
initial treatment unless the new lesion has a size significantly smaller than the 
I original tumour (for examples，in patients 2，4 and 5 in Table 5.5). 
Previous observations of lack of effect of angiotensin II on lung shunting 
(6,12) suggested a neoplastic nature of the blood vessels responsible for the 
shunt. This postulation was further supported by the drastic decrease in lung 




of lung shunting associated with the status of the tumours provides additional 
evidence of the neoplastic nature of the blood vessels involved in the shunt. 
Increased lung shunting found with increasing tumour size poses a great 
challenge to SIR therapy for hepatic cancer using Y-90 microspheres. It is 
large tumours that are more often non-resectable and require palliation by 
SIR therapy. Partial hepatic embolization has been attempted to reduced 
lung shunting but the results were unsatisfactory (13). Active search for 
better methods is required. 
Meanwhile, with the knowledge that lung shunting decreases when a treated 
tumour becomes smaller or less vascular, a possible strategy is to treat 
tumour associated with a high lung shunting using a non-radioactive protocol 
I -
such as cytoreductive surgery (14) or chemoembolization. After surgical 
removal of the main bulk of the tumour or when a response to 
chemoembolization is obtained, the lung shunting can be reassessed using 
99mTc-MAA. If the estimated lung dose from the SIR therapy to be 
contemplated lies within the safety limit, the treatment can then be given. 
I ( 
122 
5,2 MEASUREMENT OF T/N RATIOS 
Gamma scintigraphy using ®®^Tc-MAA has been used to assess the 
vascularity of liver metastases to predict the T/N ratio in SIR therapy (15-17). 
Correlation between T/N ratios and vascularity in 51 patients with HCC has 
been reported by our centre (17). The study has now been extended to 
include another 326 patients with HCC and 25 patients with liver metastases 
from colorectal cancer. 
After the HAG and gamma scintigraphy using ®®^Tc-MAA, technetium-99m, 
two days were allowed for the complete decay of the ®®^Tc-MAA C^^Jc) 
sulphur colloid scans of the liver were then performed for these patients 30 
minutes after intravenous injection of 74 MBq (2 mCi) of the agent. 
丨 Computerized tomographic (CT) images were available in some of them. 
The tumours were outlined as regions of interest (ROIs) on the digitised 
®®^Tc-MAA images with the aids of the ultrasound scan, the HAG the ®®^ Tc-
labelled sulphur colloid scan and CT images in some patients. Similarly the 
liver was outlined. The average count rate per pixel of the tumour over the 
average count rate per pixel of the liver gave the T/N ratio. 
. � , . 
Localization of all the tumours on the ®®^Tc-MAA scan is crucial for accurate 
determination of T/N ratios. Necrotic tumours showing poor uptake of the 
radiopharmaceutical often do not show up on the ®®^Tc-MAA images. 
I Gamma scintigraphic images using ''^Tc-Iabelled sulphur colloid serving as 
the complementary scan may help to identify these tumours with low T/N 
I 
I 
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ratios. In difficult cases, the localization of the tumours needed to be worked 
out in conjunction with other radiological investigations such as ultrasound 
scan and computerized tomography. 
Tumours showing high uptake of ®®^Tc-MAA appeared on the gamma 
scintigraphic images as ‘hot，focal areas in the background of the non-
tumourous liver with generalised low uptake. The T/N ratios for such tumour 
as calculated by dividing the average counts of the tumour over that of the 
non-tumourous liver were high. The image from a patients with a high T/N 
ratio of 12.0 is shown in figure 5.8a. On suppressing the count rates of the 
major tumour, at least 3 satellite lesions were seen in the left lobe making the 
tumour non-resectable (Figure 5.8b). 
! Colloidal particles given intravenously are removed from the body by the cells 
of the recticuloendothelial system (RES) by phagocytosis. In the normal 
individual about 85% of the RES cells are contained in the liver. The 
distribution of RES cells in the liver is relatively homogeneous, and if a 
suspension of ®®^Tc-labelled sulphur colloid is injected it will be become 
uniformly distributed throughout a normal liver. However, a tumour which 
disrupts the normal achitecture of the liver, will displace or damage the RES 
cells in the area and appeared as a cold spot or "hole" in the organ image. 
The 99^Tc-MAA image and the ®®^Tc-labelled sulphur colloid image of another 
patient are illustrated in figures 5.9a and b. 
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Figure 5.8(a) ^^Tc-MAA image of 
a patient with T/N ratio of 12.0 for the 
major tumour in right lobe 
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Figure 5.8(b) At least 3 satellite lesions 
were seen in the left lobe by suppressing 
the countsof the large tumour i] g 
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Figure 5.9(a) ^^Tc-MAA image of a patient 
with good uptake. The major tumour in the left 
lobe appears as ‘hot，focal area 
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Figure 5.9(b) ^^Tc-labelled sulphur colloid 
image. The major tumour appears as a cold area 
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Figure 5.10(a) ^^Tc-MAA image of a 
necrotic tumour showing poor uptake 
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By superimposing figure 5.9a on figure 5.9b it can be seen that for tumours 
with high T/N ratios (theoretically > 1)，the ®®^Tc-MAA scan and the ®^^Tc-
(-
labelled sulphur colloid scan are complementary to each other. However for 
tumours showing poor uptake of ®®^Tc-MAA, the corresponding areas on the 
two scans may both appear ‘colcT An example of this is illustrated in figures 
5.10a and b. A T/N ratio < 1 means higher activity is distributed in the normal 
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The distribution of the different grades of vascularity as assessed by HAG 
and the range and mean of T/N ratios for each grade as determined by ®®^ Tc-
MAA scans are shown in Table 5.6. 
T Table 5.6 
\ A. vascularity grades and mean T/N ratio in HCC 
)| Grade No. of cases Range of T/N ratios Mean T/N ratio (士 SD) 
‘ 0 1 (0.3%) 4^9 
一 1 ^ (14.6%) 0.6-11.4 ^ ~ ± ~ ^ 
娜 2 ^ ” ( 2 8 . 6 % ) ~ ~ 0。3-17。9 4 ^ 9 ~ " ± ~ " ^ 
— 3 t 4 6 ” ( 3 8 . 7 % ) 0.2"19.3 ~ s 7 i ± ~ ^ 
— 4 67 (17.8%) 0.5 - 26.5 4 ^ 9 ~ ± ~ ^ 
<smssi H | ^ 
P'valves QNWcoxon rank test) ^ 
Vascularity grade 2 3 4 
I 
1 0.0072 0 . 0 0 0 9 “ ‘ ~ 0 . 0 2 6 9 ~ 
2 0.4905 0 . 8 4 9 0 ~ 
3 “ 0 . 4 2 3 8 ~ 
e, Vascularity grades and mean T/N ratio in liver metastases 
Grade No. of cases Range of T/N ratio Mean T/N ratio 
1 U (44.0%) 一 ~ 2 . 3 - 7.2 4^3 
2 ?2 (48.0%) 2.4 - 5.8 4.4 
3 2 (8.0%) 3.7 - 3.9 ^ ^ 0 l^ ZIJ^ ^^ ^^ |^[I^ ZZZi!!^ !^ZZI 
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Figure 5.12 shows the distribution of the T/N ratio in relation to the vascularity 
grading. In the previous study on 51 patients (17)，the T/N ratio of grade -0，-
1 and -2 tumours (normal, slight and moderate increase in vascularity) was 
compared with that of grade -3 and -4 tumour (severe, and extreme increase 
in vascularity), but the difference between the two groups is not statistically 
significant (Wilcoxon rank test, p 二 0.057 )• The present extended study 
includes a much greater number of patients. The differences in T/N ratios 
between individual vascularity grade were analysed by the Wilcoxon rank 
test. The p-values in Table 5.6 suggest that the T/N ratio in grade 1 was 
significantly lower than those of higher vascularity grades suggesting T/N 
ratios correlates with vascularity in those patient with grade 1. However, 
there is no significant difference in T/N ratios for higher vascularity grades. 
!• Thus the T/N ratio as measured from ®®^Tc-MAA images cannot be used to 
predict vascularity as assessed by HAG. This finding is consistent with that of 
I , 
j 
I the early report. 
|-
I 
A plot of the T/N ratios against vascularity grades in colorectal liver 
I metastases is shown in figure 5.13. On applying the same statistical 
I 
I 
comparison to the T/N ratios of patients with colorectal liver metastases, there 
is again no significant difference between the group with vascularity grades of 
1 and 2 and the group with vascularity grades of 3 and 4 (p = 0.514). 
1 
I However it must be noted that this comparison may not be valid statistically 





























































































































































































































































































































































































































































































































































































































































Due to the limited number of patients, the relation between T/N ratio and 
tumour size has not been analysed in our previous study (17). When all 377 
patients were taken as one whole group there was no significant correlation 
j between T/N ratios and tumour size in both HCC (linear regression : r = i • 
0.062) and the result was the same in colorectal liver metastases (linear 
regression : r 二 0.12) as shown in figures 5.14 and 5.15 respectively. On 
:丨 
;i 
dividing the patients into subgroups according to the tumour size, the T/N 
ratio for tumours with size > 20 cm was significantly lower than those with 
smaller size as shown in Table 5.7 
ii 
.'.] 
i Table 5.7 Correlation between T/N ratio and tumour size 1. ；； 
!| Tumoursize(cm) n T/N ratio (mean ± SD) 
丨 < 5 ~ " 6 9 ~ 4 . 4 ± 2 . 4 
> 5 , < 1 0 T ^ “ ~ 5.4±4.0 
> 1 0 , < 1 5 122 4,6±2.7 
> 1 5 , < 2 0 49 “ 4 .6±2.6 
" T ^ 6 2 .6±1.0 
j 、 ^ J _ _ _ _ _ _ _ _ _ _ _ _ _ _ ^ ^ _ _ _ _ _ ^ _ _ 
p-values O^ilcoxon rank test) 
Tumour size (cm) | > 5 , < 1 0 | > 1 0 , < 1 5 > 1 5 , < 2 0 >20 
7 ^ 0.0742 0.4238 0.4759 0.0163 
> 5 < 1 0 0.2965 0.4607 0.0072 
^ ^ 0 , < 1 5 0.8845 0.0196 
> 1 5 , < 2 0 0.0277 
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This is probably due to frequent occurrence of necrotic centres in these huge 
tumours. 
I On the other hand, big tumours tend to score higher vascularity grades on 
HAG for both HCC and colorectal metastases (figures 5.16 and 5.17). This 




• size between tumours with vascularity grades of 0，1 and 2 and those with 
I 
I vascularity grades of 3 and 4 is statistically significant by Wilcoxon rank test, 
_:i 
丨 （p < 0.0001). This does not apply to colorectal liver metastases, 
i 
The T/N ratios from ®®^Tc-MAA scans are highly variable. The range of 0.2 to 
N 
[ 26.5 as observed in our HCC patients is much wider than the range of 1。0 to 
I 
'I 10.0 reported by Shepherd et al (18) but is narrower than the range of 0.4 to 
45 reported in colorectal liver metastases (10)。 Previously established 
:i 
anatomic and physiologic aspects of hepatic malignancy indicate that there is 
‘； i I 
a greater arteriolar density in and around the malignant lesion in the liver 
(4，19). It is also known that the usual route by which colorectal cancer 
metastasizing to the liver is via the portal system. Once in the liver, the 
tumour grows and invites the in-growth of branches of the hepatic artery 
which exclusively supplies the growing tumour with its blood supply (20,21). 
However the blood supply varies from different tumours and also at different 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































It has been observed that the best hepatic arterial circulation to hepatic 
metastases is from metastatic carcinoids and from metastases from adrenal 
tumours (1). Metastases from lung primary are relatively avascular (5). 
Metastases from colorectal cancers have a moderate arterial blood supply 
(1,22) during early stages but as the tumour grows, it outgrows its blood 
i a 
! supplies so that the interior of the tumour is largely devoid of arterial blood, 
I 
I 
but a rich plexus of arterioles and capillaries surrounds the outer perimeter. 
r Similar course of changes may also happen to HCC. This explains the very 
i^ , 
I low T/N ratios in some cases of HCC which is generally regarded as a 
|i 
hypervascular tumour (7). 
Our study showed that HAG assessment of tumour vascularity correlated 
poorly with the T/N ratio as estimated by ®®^Tc-MAA scan. The results is 
i 
[ consistent with that of our preliminary analysis of 51 HCC patients (17). This 
agrees with the finding of Gyves et al (16) that ''^Tc-MAA hepatic arterial 
perfusion scan demonstrates the tumour hypervascularity better when 
compared with contrast angiography。 
Grading of vascularity by HAG is a subjective and qualitative estimation. It is 
not uncommon to encounter large tumours having a thin hypervascular shell 
with a large hypovascular centre. Conventional HAG based on the plain two-
dimensional image might give a false impression of a very vascular tumour in 
such cases. The volume of the vascular spaces within this type of tumours is 
relatively small with the resultant poor uptake of the radiopharmaceutical. 
This explains our observation that large HCC appeared to be more vascular 
140 
but generally have low T/N ratios on ®®^Tc-MAA scans. These patients are 
I 
{ not good candidates for intrahepatic arterial treatment. 
I j 
i i 
Blanchard (4) suggested that patients with liver metastases who are not 
, 1 
suitable for hepatic resection should be assessed by angiography for the 
vascularity of the tumour and the hepatic arterial anatomy. If the tumours are 
vascular, the patients am candidates for either continuous intra-arterial 
infusion of multiple chemotherapeutic agents or infusion of a single dose of 
i 




results, the angiography finding alone is unable to predict the actual 
i 
distribution of the radiopharmaceutical within the tumour and the normal liver 
compartments, resulting in sub-optimal treatment for some patients. 
；, 
5.3 nf^tGrminatinn nf magg<q<s nf tumnur and normal liver 
Computed tomography (CT) images of the abdomen were obtained with 1:1 
magnification and 5 mm transaxial thickness. The outlines of tumours and 
normal liver on each section were marked on tracing paper. The areas 
marked as tumours and normal liver were cut out separately and weighed. 
The outline of a phantom of a known area shown on CT image with the same 
magnification was traced, cut and weighed in the same way. Using the 
phantom as a standard, the areas corresponding to the tumour and normal 
liver were calculated. The total area taken over all slices multiplied by the 
section thickness gave the volume. The mass of the tumour ( M r ) and the 
mass of the normal l i v e r ( M J were obtained by multiplying the respective 
141 
volume by the density (1.03 gm/cm®) of soft tissue. Alternatively, the areas 
can be digitised by tracing the outlines by a computer. An example of 
calculation is shown below : 
Area of a phantom of dimensions 20 cmx 20 cm = 400 cnf 
The weight of two of its paper cutting = 0.566 g 
I The total weight of the paper cutting corresponding to the tumour in a patient 
shown on CT slices was 2.236 g while that of the non-tumourous liver was 
I 1.207 g 
t 
i. 
The volume of the tumour is given as : 
(800x |^cm2)(0.5cm) = 1,580 cm' 
: 0,566 
11. 
； The mass of the tumour is therefore 1,580 crn x 1.03 g / crri = 1,627 g 
The mass of the non-tumourous liver equals to 
(800 jc 1.2二：2)(0.5 cm)(1.03 g / cm') = 879 g 
0.566 





PREDICTION OF RADIATION DOSE AND 





6.1 PREDICTION OF RADIATION DOSE USING THE PARTITION MODEL 
The partition model for estimation of radiation doses assumes the distribution 
of 90丫 microspheres during the treatment is identical with the ®®^Tc-MAA 
particles during the diagnostic HAG so the percentage of lung shunting (L) 
and T/N ratio from ®®^Tc-MAA may be substituted into equations [1] to [7] in 
calculations. This was applied on 17 patients who received SIR therapy using 
90丫 microspheres during laparotomy. These included fourteen patients, with 
inoperable HCC (2 were recurrent cases) and three patients with colorectal 
i 
liver metastases but no extrahepatic disease. The whole group consisted of 
I 
3 females and 14 males. The median age was 50 years (range 18-74). 
The patients were subjected to selective hepatic angiography (HAG) and 
99mTc-MAA scan for assessment of the percentage of radioactivity shunted to 
the pulmonary system (L) and the tumour-to-normal ratio (T/N) of uptake of 
99mTc-MAA within the liver as described previously. Masses of the tumour 








！ The patient characteristics, masses of tumour and normal liver, the 
安 .$,•. ？ 
！ percentages of lung shunting, T/N ratios determined from ®®^Tc-MAA images J ‘ ’ 
‘ and the activity of 卯丫 microspheres used in subsequent treatment are shown 
in Table 6.1. The percentages of lung shunting varied between 2.2 and 
15.0% (median 7.3%) and the T/N ratios ranged from 3.0 to 13.6 (median 
4.7). 
The total activity of 卯丫 microspheres administered ranged from 2 to 7 GBq 
with a median of 3 GBq. Using equation [2] the estimated activity of 卯丫 
shunted into the pulmonary system varied between 0.044 and 0.798 GBq with 
a median of 0.219GBq. The corresponding radiation doses to the lungs were 
estimated using equation [3]. The dose varied between 2 and 40 Gy with a 
median of 11 Gy (Table 6.2). 
The activity of 卯丫 microspheres retained in the tumour ( ⑷ and the normal 
liver ( ^ N ) w e r e estimated using the partition model and shown in Table 6.1. 
^ ^ ranged from 0.695 to 5.645 GBq with a median of 2.386 MBq. An 
ranged from 0.237 to 2.190 GBq with a median of 0.766 GBq. The estimated 
radiation doses to the tumour and normal liver obtained by substituting the 
corresponding activity uptake and mass into equations [4] and [5] are listed in 
Table 6.2. The estimated tumour dose ranged from 74 to 395 Gy with a 
median of 147 Gy. The estimated dose to the normal liver ranged from 13 to 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The radiation dose to the whole liver estimated by assuming a homogenous 
distribution of 卯丫 microspheres throughout the entire liver, without distinction 
between tumour and non-tumourous liver were also included in Table 6.2。 
The value range from 39 to 125 Gy with a median of 74 Gy. 
6,2 VERIFICATION OF THE PARTITION MODEL 
a) Calibration of beta-probe 
A solid-state beta eye probe (Figure 6.1) (Radiation Monitoring 
Devices) was calibrated against a rubber phantom containing 
standardized yttrium-90 silicate solution (Amersham) of different 
known radioactive concentrations (MBq/ml) (Figure 6.2). Radiation 
counts per 5 seconds were taken with the probe by starting with the 
highest radioactive concentration, touching the surface of the rubber 
phantom containing the 卯丫 silicate solution. 
The counting was repeated until 5 consistent readings were recorded. 
Serial dilution of 卯丫 silicate solution were performed and the counting 
was repeated for each radioactive concentration. 
A calibration curve of activity concentration (MBq/ml) against the mean 
counts per 5 s was obtained (Figure 6.3). 
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b) Preparation of ^Y microspheres 
Resin-based microspheres 29 - 35 ^im in size with a specific activity of 
approximately 30 Bq per microsphere, 3.3 x 10^ microspheres per GBq 
were supplied by the Australian Nuclear Science and Technology 
Organization (ANSTO), Sydney, Australia. The spheres were radio-
labelled by ion-ion exchange. 
Each batch of microspheres went through the following quality 
assurance tests before being autoclaved and dispensed into aliquots. 
(i) Leach test 
A trace amount of the microspheres was stirred in 50 ml water for 
injection for 30 min. A portion of the suspension was filtered through 
a 0.45 ^im filter. A 500 juJ aliquot of the suspension and the filtrate 
were counted on a liquid scintillation counter (Beckman LS3801) 
(Figure 6.4) after adding EDTA solution (500 \i\), acetic acid and 
appropriate liquid scintillant。The EDTA was added to chelate the 卯丫 
ions and bring them into solution so that the resulting solution has the 
same counting geometry as the filtrate. The acetic acid was for 
adjusting the pH of the resultant solution. The counts of the filtrate 
over the total counts of the filtrate and the suspension gave the 
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Figure 6.4 Liquid scintillation counter 
； 
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A set of typical results is shown below : 
Net counts from 500 [i\ suspension = 2,450,842 cpm 
Net counts from 500 ^1 filtrate = 397 cpm 
397 
...% leaching = ；^；；；^ ^ ^^^ …内 x 100% 
s 397 + 2,450,842 
=0.016% 
(ii) ChRcking of<;pfinifin activity ! 
i 
The number of microspheres in a drop of the diluted suspension used 
in the leach test was counted under a microscope. About 50 - 100 
microspheres were usually counted which were then transferred to a 
scintillation vial and counted against a yttrium-90/strontium-90 
(^Y^Sr ) standard (Amersham). ^Sr decays to 卯丫 with p-emission 
and has a physical half life of 29.12 years. An equilibrium solution 
contains equimolar concentration of ®°Sr and ®°Y. Because of the long 
physical half life of the mother nuclide, the mixture serves as a stable 
standard for liquid scintillation counting of ®°Y. The activity carried by 
each microsphere was then calculated. 
A set of typical results is illustrated below : 
Net counts from ®°Y>^ °Sr standard = 1,324,861 cmp 
Net counts from 108 卯丫 microspheres = 203,952 cmp 
The 9。YA。Sr contains an equimolar of 卯丫 and ®°Sr each with an activity 
of 0.0115 MBq. The equivalent activity of 卯丫 in the standard is 
152 
2 X 0.0115 MBq as both ®°Y and ®°Sr contribute to the liquid scintillation 
counts. 
Therefore the activity carried by each microsphere 
203,952 1 
= 2 . 0 . 0 1 1 5 M B , . ^ ^ ^ x -
=3ABq 
The suspension was then autoclaved and dispensed as aliquots of 
known activity into syringes inside Perspex shields of 1 cm thick in a 
safety cabinet (Figure 6.5) 
！ £ [ 
r 
153 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^K^^^B^^^^^^^m^^<^<yi i^ ^ <*< t 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^|^^^^^H^^^^^^^^^^^^^T<K»:::<:<::X!<:<::K::::XXX::::::::::::::::::K:S::K::::::::“：：.:：：:：：：：：r":,l,.:“““/":.:,.*-*,'‘*.'.,.' 
^ • • ^ ^ ^ ^ ^ l i n . 
M f ^ M l ^ ^ ^ � — � 
I ^ H H ^ ^ ^ H I ^ ^ ^ ^ ^ f t ^ 遍 ^ m i ^ ^ : _ ^ ^ ^ ^ S ^ & : W - ^ H 
M M M M M i ^ ^ " 
^ ^ ^ ^ ^ ^ ^ ^ m u ^ ^ ^ m m ^ i ^ 
Figure 6.5 Dispensing aliquots of^^Y-microspheres 
into syringe inside 1cm thick perspex shield 
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Figure 6.6 Injection of ^ ^Y-microspheres with a 4-way 
valve on a perspex injection bracket 
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c) Administration of ^Y micmspheres and mGasumment of radiation 
d0SGS with beta-pmbe 
Patients were subjected to laparotomy and intra-operative ultrasound 
to document the site and size of the liver tumours. Cholecystectomy 
and ligation of the right gastric artery were performed followed by 
cannulation of the gastroduodenal artery with a Port-A-Catheter 
(Pharmacia Deltec, St Paul, MN USA). Perfusion of both lobes of the . 
liver was checked by infusion of 10 ml of 3% fluorescein (Fluorecite, 
Alcon Laboratories) and inspection of the liver with a Wood's Lamp。 
The catheter was then connected to a four-way valve fixed on an 
injection bracket made with 1 cm - thick Perspex (Figure 6.6) which 
can virtually attenuate all the beta radiation and the operator was 
[ therefore protected. A 20 i^g aliquot of angiotensin 11 (Ciba) was 
pulsed into the Porta-A-Catheter over a period of 10 s. A 
predetermined fraction of ®°Y microspheres as a suspension in water 
for injection was well mixed with the aid of the four-way valve. Thirty-
seconds after the infusion of angiotensin II was completed, the well-
mixed suspension of 卯丫 microspheres was pulsed through the hepatic 
artery into the liver. Allowing lO min for equilibrium, the beta radiation 
emitting from the surface of the tumourous and the non-tumourous 
parts of the liver was counted using the calibrated beta probe (Figure 
6.7). The radiation counts measured by the beta-probe over the 
surface of both the tumour and non-tumourous part were highly 
variable. Usually more than 20 readings were taken over each of 
these areas (Table 6.3). High counts were registered over areas 
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Figure 6.7 Path of the beta-probe on 
the liver surface and sites for biopsy 
V.哼” ^  * " ) ^'^'7 i ^ ) 
[ » 
v / ^ ^ > ^ ^ ^ ^ 一 (”） 
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containing blood vessels. The mean count rate was converted to 
radioactive concentration (MBq/ml) of 卯丫 based on the calibration 
curve obtained with the rubber phantom. The radiation dose was then 
calculated by substituting the radioactivity concentration (MBq/g as the 
density of the 卯丫 silicate solution can be taken as 1 g/ml) into equation 
[1]. 
157 
Table 6.3 Beta-probe counts over tumour and non-tumourous 
liver 
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Mean = 14,297 Mean = 264 
Alternatively，the equation of linear regression for the calibration curve 
of the beta probe can be converted to give a value of the radiation 
dose directly from the count rates as follows : 
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C{cts!5s) = 4,832.9fl(MB^/m/) + 168.49 
= 4 8 3 2 . 9 a ( M B ^ / ^ ) + 168.49 
(c 一 168.49) 
a == 4,832.9 
from equation [1] 
RadiationdoseD (Gy) 二 49.67 Ao (MBq) 
=49.67 (j) = A9£lGy/MBq / g 
••• n(Gy) - 49.67 (Gy / MBq / g) 
… ( C - 168.49) 
= 4 斷 （ 4 832.9 
=0,01 C 一 1.73 
D = 0.01C - 1.73 
Substituting the mean count rates from Table 6.1 
i TumourdoseDr 二 (0.01)(14,297) - 1.73 
=141.24 Gy 
Dose to normal liver 




Figure 6.8(a) Photomicrograph showing distribution 
of 90Y-microspheres in tumour 
圓 
Figure 6.8(b) Photomicrograph showing distribution 
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d) Measurement of radiatinn dose and T/N ratio by liquid 
sc_nt_llat_on of biopsy spec/mgng 
Photomicrographs shown in Figure 6.8a and b illustrate the 
|. distributions of microspheres within the tumour and the normal liver of 
r 
a patient. As can be seen the microspheres concentrated in the 
microvasculatures and were much more dense in the tumour when 
！ »! 
I compared to the normal liver The distributions of microspheres within 
t 
i • 
both the tumour and the normal liver were not uniform and this 
explains why the counts over any region were highly varied and counts 
/ 
on passing over areas containing blood vessels were excessively high. 
It is necessary to take more than 20 readings over any area with the 
beta probe and multiple biopsy specimens taken at different sites are 
desirable for liquid scintillation counting to average out the 
i r 
j. heterogeneity. Of course the risks versus benefit in sampling biopsy 
I ‘ 
from these cirrhotic patients need to be considered seriously. 
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The specimens were cut into small suitable pieces of less than 0.1 g 
each and weighed (Figure 6.9). Each sample was moistened with 50 
HJ of water followed by digestion using 1 ml of tissue solubilizer 
(Protosol from DuPont). The mixture was incubated at 59°C for 16 
hours. Then 500 fjJ of EDTA solution and 1 ml of distilled water were 
added with shaking followed by the addition of 50 ^1 of glacial acetic 
acid and 10 ml of liquid scintillant. The solution was well shaken and 
j 
was counted in a liquid scintillation counter (Beckman LS3801) with a 
yttrium-90/strontium-90 standard (Amersham). The radioactive 
concentrations of the tumour ( A r / M r ) a n d non-tumour parts 
( A w / M w ) o f the liver were calculated from the counts. The 
corresponding radiation doses were computed using equations [4] and 
[5]. 
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Figure 6.9 Cutting ofbiopsy samples for 
liquid scintillation counting 
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An example of calculation is shown below : 
I Mass of tumour biopsy digested = 0.096 g 
j 




1 Net counts from ®°Y/®°Sr standard = 1.35 x 10 cpm 
I Equivalent activity of^°Y in ®°YrSr standard = 2 jc 0.0115 MBq 
\ 
I » • 
3.64 X 10' 丨’、 
Activity of 90Y in biopsy = 2 ^  0.0115 ;c ^ 5 i 7 W 幽 
=0.62 MBq 
Using the equation 
49.67A (MBq) 
Do^ 份 ) = M i g ) 
一 49.67 jc 0.62 
= ~ 0 0 % “ “ 





The tumour dose and normal liver dose determined by direct beta-probing of 
the tumour and normal liver surfaces and those by liquid scintillation counting 
of biopsy samples are listed in Table 6.2. 
The radiation dose to the tumour, as measured by the beta-probe, varied 
between 107 and 305 Gy (median 162 Gy) while that to the n o _ l liver 
ranged from 15 to 77 Gy (median 26 Gy). The values determined by liquid 
scintillation counting of biopsies are close to those measured by the beta 
probe. 
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Correlation between the radiation doses as determined by the partition model 
and the values obtained from intraoperative dosimetry for the tumours and 
the normal liver compartments are illustrated in Figures 6.10 and 6.11. 
Coefficients of correlation for the linear regression performed on the two 
independent sets of data were 0.862 for the tumours and 0.804 for the normal 
liver compartments (p < 0.001). Thus the radiation doses estimated using the 
partition model are close to that measured by intraoperative beta-probing, ,, 
and those from liquid scintillation counting of biopsies (Table 6.2). 
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I Figure 6.10 Correlation Between Estimated & Measured Tumour Doses 
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e) Bremsstrahlung snan 
' Bremsstrahlung radiation is secondary x-rays produced when p 
particles interacting with atoms of heavy elements. The principle of its 
production is illustrated in the schemetic diagrams shown in figure 
I • 
丨 6.12. p-particles striking on the nucleus of the heavy atom or coming 
!: 
across it lose energy which are dissipated as x-rays of different 
i 
wavelength thus forming a continuous spectrum. On the other hand, 
some p-particles knock out electrons in inner orbital. When an 
electron from outer orbital fill the inner orbital, a characteristic x-ray 
I 
with energy equals to the difference in energy levels of the outer and 
inner orbital is emitted。 The continuous spectrum and characteristic x-
rays are shown in Figure 6.13。 The relative distribution of 卯丫 
microspheres in the liver and tumour as shown on the Bremsstrahlung 
i scans performed after treatment was reflected again as a T/N ratio. 
Coefficient of correlation between the T/N ratios determined from the 
Bremsstrahlung images and that from the ®®^Tc-MAA simulation was 
0.884 (p<0.001) (Figure 6.14). 
The Bremsstrahlung image of a patient taken 4 days after the infusion 
of 3.0 GBq of 卯丫 microspheres and the ®®^Tc-MAA image taken before 
the treatment are shown in figure 6.15. As can be seen the areas of 
focal uptake in both images match each other although the image 
quality of the Bremsstrahlung scan is poorer than the ®®^Tc-MAA 
image. The distribution of ®°Y microspheres can be confirmed and the 




figure 6.12 Schematic diagram illustrating the production 
of Bremsstrahlung radiation by 3-particle 
o Q © 
: ^ ^ ^ 
p x ^ ^ • j ^ ^ ^ ^ X-rays forming continuous 
1 ^ ^ ^ ^ 5 ^ " ^ ^ ^ ] f - ^ * ^ ^ ^ spectrum ofBremsstrahlung ^^^ 一 
(a) p-particle bombards on electron in inner orbital of an atom ofheavy element causing its 
removal from the atom, leaving an empty orbital, p-particle bombard on nucleus or 
deflected by it produce x-rays forming the continuous spectrum. 
outer electron 
> 1 = ^ 
/ • ^ • characteristic X-ray component of 
f / ^ ^ ^ \ Bremsstrahlung radiation 
极 
0)) Electrons from an outer orbital fUl the empty orbital in the inner shell and the energy 
difference between the two orbitals is emitted as characteristic X-ray appearing as spike 









































































































































































































































: the Bremsstrahlung scan. Gamma rays from ®®^ Tc produce shaper 
image than the Bremsstrahlung radiation because they are 
monoenergetic while the latter contains energy over a continuous 
spectrum. 
Yttrium-90, being a pure beta particle emitter with a physical half life of 64 hr, 
a mean energy of 0.935 MeV and a maximum penetration depth of about 11 
mm in soft tissue, has been the radioisotope of choice for selective internal 
radiation (SIR) therapy for large liver tumours (1). These physical 
characteristics give the advantages of longer cytotoxic range (penetrating 
through a depth of over 1000 cells), higher dose rate and easier radiation 
protection as the skin and muscles of the abdominal wall are thick enough to 
attenuate the beta radiation. 
The ^Y-Iabelled resin or glass microspheres do not undergo any bio-
degradation. The radioisotope decays with its physical half life and hence the 
radiation dose delivered to any tissue element can be computed easily using 
the MIRD method (2,3) if the radioactivity concentration is known. However, 
the presence of the abdominal wall makes direct measurement of the 
distribution of 卯丫 microspheres impossible. In previous studies, uniform 
distribution of 卯丫 microspheres throughout the entire liver was thus assumed 
in estimating the radiation doses to the liver. 
This assumption was used in most studies (4-11) including a most recent one 
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Figure6.15(a) ^^Tc-MAA image taken 
before SIR treatment 
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Figure 6.15(b) Bremsstrahlung image recorded 
4 days after the infusion of3GBq of ^ ^Y-microspheres. 
The outline of the tumour is less well defined than in 
the 99mTc-MAA image 
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organ, both the threshold tumouricidal dose for eradicating the cancer cells 
and the maximum dose that can be tolerated by adjacent normal tissue need 
to be considered. Radiation doses calculated based on the assumption of a 
homogeneous intrahepatic distribution of 卯丫 microspheres made no 
distinction between the tumour and the normal tissue and therefore did not 
reflect the therapeutic benefit. , 
Ytterbium-169 was the first gamma emitter used to simulate the distribution of 
卯丫 microspheres (13). ®®^Tc-MAA with particle size range close to that of 卯丫 
* 
microspheres become widely used for pre-treatment assessment of 
arteriovenous shunting to the pulmonary system and hepatic perfusion of ®°Y 
microspheres (8-13,14). Assuming the distributions of 卯丫 microspheres 
during subsequent treatment to be identical with that of ®®^Tc-MAA particles 
during the diagnostic HAG, a tumour-to-normai (T/N) ratio or therapeutic gain 
can be calculated by dividing the average count rates of the tumour by the 
average count rates of the norma! liver obtained from the digitised gamma 
scintigraphic images (15). 
With this T/N ratio, the total activity (A^) of ®°V microspheres administered 
and the masses of the tumour (她）and normal liver (y^ fJ from CT，the 
activity of 卯丫 microspheres partitioned between the tumour and the normal 
liver compartment can be computed using the partition model proposed. With 
these activity parameters, the radiation doses delivered to the tumour and the 
normal liver can be estimated readily. Alternatively, with the T/N ratio and the 
masses of tumour and normal liver，the amount of 卯丫 microspheres required 
174 
^w 
to achieve a certain tumouricidal dose or to keep below a safe tolerance limit 
of normal hepatocytes, can be pre-determined. 
The good correlation between the doses estimated using the partition model 
and the intraoperative dosimetry suggests that the model does serve the 
purpose. 
The idea of using a partition model for estimating tumour dose has previously 
been mentioned very briefly by one research group (10,11) but has not been 
explained or adopted in dose estimation. It is surprising to find that with 
readily available T/N ratios from ®®^Tc-MAA scans, the assumption of a 
uniform distribution of 卯丫 microspheres was still used to estimate the 
escalation of whole liver absorbed radiation dose from 5000 cGy to 15,000 
cGy in the most up-to-date work on 卯丫 microspheres (13). These estimated 
values can be very misleading. As the present study illustrated, the real 
tumour doses might be much higher than these values whereas the radiation 
doses actually delivered to the norma! liver tissues might be much lower. 
Despite a new technique that has been developed for activity quantification 
making use of Bremsstrahlung images of pure beta-emitting radioisotopes 
including strontium-89, phosphorus-32 and 卯丫（16-19)，Bremsstrahlung 
scans are still not commonly used for dose calculation in treating hepatic 
tumours with 卯丫 microspheres (13,20). Our reservation on adopting 
Bremsstrahlung images for radiation dose estimation is mainly because the 
卯丫 microspheres therapy dose has to be administered before the 
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Bremsstrahlung scans could be performed. As the therapeutic effect of 
radioisotope is irreversible, our partition model allows planning of the 
radiation doses and hence the amount of radioactivity to be delivered while 
the refined Bremsstrahlung technique might be good for subsequent checking 
of the relative distribution of radioactivity and the radiation doses as estimated 
from the T/N ratios using our partition model. 
The novel strategy of opening up the abdominal wall for direct access to the 
surface of the tumour and the normal liver employed by the team headed by 
Burton and Gray (21-24) has allowed us to obtain intraoperative dosimetry 
data required for verification of our partition model. However, without the 
concept of our partition model, they have reported that the measured 
radiation doses to the normal liver correlated poorly with the total radioactivity 
administered. As has been demonstrated above, the radiation dose received 
by the normal liver depends on the relative masses of the tumour and normal 
liver, the T/N ratio as well as the degree of extrahepatic shunting. These 
parameters vary from patient to patient. 
Ariel and Padula (5) mentioned that the distribution of 卯丫 microspheres 
throughout the normal liver is uniform whereas the radioactivity 
concentrations in the tumour varies according to the underlying blood supply. 
Our photomicographs of biopsies (Fig. 6.8) show heterogenous distribution of 
microsphere in both the tumour and normal tissue. From our experience of 
beta-probing the surfaces of tumour and normal liver during laparotomy, 
count rates over the surfaces of the normal liver and the tumour varied from 
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point to point, indicative of local heterogeneity of 卯丫 distribution. Thus at 
least 20 readings were taken over any region to average out the 
heterogeneity. The inhomogenous distribution of microspheres within normal 
liver was analysed in great detail by Fox et al (25). The location of each 
microspheres was mapped on to a planning computer. The distribution of 
radiation dose around each microsphere being treated as a discret point 
source was computed. From these they deduced that one third of normal 
liver received less than 33.7% of the dose predicted by assuming a 
homogeneous distribution of 卯丫 microspheres and therefore got spared from 
possible radiation damage. Three-dimensional dosimetry calculated from a 
tumour model in the rabbit also demonstrated non-uniform distributions of 
microspheres within a tumour nodule and throughout the normal liver (26). 
Determination of microdosimetry by incorporating stable heavy nuclides such 
as i87Au into the 卯丫 microspheres to make them radiographically detectable 
has been suggested (18) but the feasibility remains to be confirmed. 
Simulation of 卯丫 SIR therapy using ®®^Tc-MAA is the most readily available 
technique for predicting the distribution of 卯丫 microspheres in the tumours 
and the normal liver. The partition of radioactivity between the tumour and 
the normal liver compartments based on the T/N ratio from ®®^Tc-MAA scan 
and masses of the tumour and normal liver allowed a distinction between the 
radiation doses to the tumour and the normal liver to be made. The different 
radiation doses received by the tumour and the normal liver can then be 
estimated with an assumption that the distribution of 卯丫 microspheres within 
either the tumour or the normal liver is uniform and that there is no cross-over 
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of doses at the boundary between the tumour and the normal liver. The 
heterogeneous distribution of ®°Y microspheres has been homogenized by 
averaging serial readings over the surfaces of the tumour and the normal liver 
during intraoperative beta-probing. This averaging process is consistent with 
the calculation of a T/N ratio from the mean count rate of tumour over the 
mean count rate of the normal liver during diagnostic ®®^Tc-MAA scintigraphy. 
With the application of the verified partition model in dose estimation, ®°Y 
microspheres can now be administered percutaneously by hepatic 
angiography or through available arterial port-a-catheters without the need of 
a laparotomy. The optimal doses to the tumour and the normal liver 
compartments and hence the required quantity of 卯丫 microspheres for 
treating a particular patient can easily be pre-determined. The treatment has 
become less traumatic and therefore carried less morbidity. The hospital stay 
is also shortened because the patient does not have a large wound to heal. 
Patients who receive 卯丫 SIR therapy percutaneously can normally be 
discharged home in 4 to 5 days when the radioactivity has decayed to a safe 
level. 
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6.3 ASPECTS OF RADiATION SAFETY 
i As mentioned 卯丫 is a pure beta emitter and its radiation is almost fully 
\ attenuated by 11 mm of soft tissue. Therefore all the beta radiation is 
:《 shielded off by the abdominal wall and only Bremsstrahlung radiation 
I i 
I : (secondary X-rays generated by the p_ray hitting on heavy elements in the I : 
tissue) of approximately 140 KeV is detected outside the body. The radiation-
exposure to personnel from a patient who received SIR therapy using 卯丫 
microspheres is minimal and it has been estimated to be less than 2 mSv per 
hour per GBq administered at a distance of 1 metre from the patient (10,11). 
In our practice the patient is nursed in an isolation room with the abdomen 
shielded by a lead shield. The radiation exposure to personnel is practically 
zero. The level of radiation was recorded when a Bremsstrahlung scan was 
performed 4 days after treatment to confirm the distribution of ®°Y 
microspheres within a patient. For a patient who received 3 GBq of 卯丫 
microspheres, about 10 k counts per second due to the Bremsstrahlung 
radiation were registered by the gamma camera. The count rates from a 
patients who received 111 MBq ®®^Tc-MAA is between 3 to 6 k counts per 
second and that from a patient who received 555 MBq ®®^Tc-MDP for bone 
scan emits about 10 - 15 k counts per second. Thus the patient is ready for 
discharge in terms of radiation safety when the count rate falls below 10 k 
counts per second. 
During the preparation and administration of 卯丫 microspheres, the 
radioisotope is being shielded by a 1 cm thick perspex shield. Perspex has a 




attenuated by the shield. The radiation dose to the fingers of the operator 
was monitored every time by thermoluminescence dosemeter (TLD). The 
doses received during the preparation of 12 GBq of 卯丫 microspheres was 
always below 2 mSv. In administering 3 to 5 GBq of ®°Y microspheres to a 
patient, the finger dose was always less than 1 mSv. A set of typical results 
is shown below: 
Radiation Monitoring Services : Flnger-Tip Dose Measurement 
Date: 9.5.96 
Purpose: Personnels working for SIR therapy for patients with hepatic 
cancer using ^Ymicrospheres through HAG technique 
Finger doses (mSv) 
Patient No. Activity (GBq) Left Right 
1 T s 0 ^ 068 
2 ^ 046 0J5 
3 T^ 025 0?f6 
4 ^ 0.26 o l 2 
Finger doses received by personnel in preparing, sterilizing and dispensing 
12 GBq of 90丫 microspheres were 0.68 mSv (Lt) and 0.35 mSv (Rt) 
respectively. 
According to the regulation of ICRP (International Commission for Radiation 
Protection)(27), the safety limit of radiation exposure to extremities is 16.7 





CLINICAL EVALUATION OF THE PARTITION MODEL 
The validity of radiation doses estimated by the partition model was further 
evaluated in clinical settings 
7.1 ESTIMATION OF RADIATION DOSE TO LUNGS 
Using the partition model, the radiation doses to the lungs in patients who 
received SIR therapy with ®°Y microspheres were estimated using the 
percentage of lung shunting as determined from the pre-treatment ®®^Tc-MAA 
scans and the activity of 卯丫 microspheres administered. 
Two groups of patients were included in the study. The first group consists of 
17 patients with HCC and 3 patients with colorectal liver metastases. SIR 
therapy using 卯丫 microspheres were given to these patients during 
laparotomy. Details of the treatment has been described before. Patients 
with residual or recurrent disease were retreated by infusing the 卯丫 
microspheres through the implanted Port-A-Catheter. The second group 
consists of 75 patients with HCC and 3 patients with colorectal metastases : 
SIR therapy were given by infusing the 卯丫 microspheres through implanted 
Port-A-Catheters in 3 patients and by hepatic angiography in the rest. 
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Repeated treatments were given to patients for residual or recurrent 
diseases. 
Assessment of lung shunting using ®®^Tc-MAA as described previously was 
performed during diagnostic hepatic angiography or immediately before the 
repeated treatment (to save the patient from undergoing two separate hepatic 
angiography). 
The radiation dose to the lungs of every patient in each treatment was 
estimated using equation [2]: 
” . , … \ 496.7 xActivity (GBq) x lung shunting (%) 
Radiation dose (Gy)= — — 
Mass oflungs {g) 
According to Synder et al (1) the total mass of both lungs (including blood) 
was taken to be 1,000 g for a standard man。 
A total of 84 patients with HCC and 6 patients with colorectal liver metastases 
were analysed. The lung shunting as assessed by ®®^Tc-MAA scan before 
the first treatment ranged form less than 1% to 15.9% with a median of 4.9% 
(Tables 7.1 to 7.4). Patients were given 1 to 7 GBq (median 3 GBq) of 卯丫 
microspheres. For patients No. 1 to 90 the estimated radiation dose received 
by the lungs in a single treatment ranged from 0 to 39.6 Gy. The value was 
below 20 Gy in 78 patients. Ten patients received 20.1 to 27.0 Gy and 3 
patient received 31.6, 36.8 and 39.6 Gy of radiation respectively in the initial 
treatment. The 20 patients shown in Table 4.2 and the first patient in Table 
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4.3 and Table 4.4 received multiple treatments. The number of SIR 
treatments ranged from 1 to 5. The cumulative radiation doses to the lungs 
were estimated to be 24.7, 29.1, 38.5，54.1 and 58.9 Gy respectively in 5 of 
these 21 patients while the cumulative doses in the rest remained below 20 
Gy. No evidence of radiation pneumonitis was observed in the first 88 patient 
(No. 1 to 88) while radiation pneumonitis was documented in patients No. 89 
after the second treatment and in patient No. 90 after a single treatment. The 
radiation-induced complications in these two patients, together with 3 other 
cases, have been reported from this centre (2). Patient No. 89 showed no 
signs of pulmonary complication after the first treatment. Figure 7。1 is 
photomicrograph showing a number of microspheres present in the lung 
biopsy from patient No. 90. 
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Figure 7.1 Photomicrograph oflung biopsy showing 




Table 7.1 Estimated radiation doses to the lungs in HCC receiving a single 
treatment (continued) 
「Patient % Lung Activity of Estimated activity Estimated radiation 
No」 Shunting ^Y (GBq) in lungs (GBq) dose to lungs (Gy) 
‘"""^1 4.2 3.0 0.126 6.3 
“ " ~ 2 9^8 ^ 0.196 ^ — 
• j 
“ " “ “3 ^ ^ 0.214 W e 
~ " 4 6 ^ 4.0 0.268 T ^ 
I 5 4!3 3.0 ~ “ 0.129 ^ 
I 6 Ke K6 0.280 T ^ 
f 
f 
~ 7 ~ ‘ ^ ^ ~ ~ 0.480 23.8* ~ 
8 ^ ^ 8 0.054 ^ 
9 T ^ 3 ^ 0.525 2 6 . r 
~ T o 7 ^ 3!0 0.225 TT^ 
~ T ^ 7 2 ^ 0.216 ^ 
~ ^ 2 4?7 3^0 “ 0.141 7 ^ 
~ ~ ^ 3 7 ^ 4^0 0.304 ^ 1 
~ U ^ 4^0 0.240 TT9 
~~"?5 ^ 4!0 — 0.324 ^ 1 
~~?6 7 ^ 4!0 0.316 ^ 
~~?7 ^ ~ " ~ 3 ^ 0.063 3?i 
~ ? 8 ^ 4.0 0.112 “ Ke 
~ ? 9 ^ ^ 4!o 0.480 — 2 3 . 8 * ~ 
~~20 ^ 3^0 0.201 ^ 
~ 2 l ~1 3^0 0 0 ~ ~ 
~ " 2 2 ~ ~ ^ ^ 0.124 ~ " ^ 2 
~ " ^ 7 2 5 ^ 0.360 ^7^9 
~ ~ 2 4 ？ ^ 4 ^ 0 0 . 4 3 2 2 1 . 5 * 
~ ^ T!S 4!0 0.052 “ ^ 
*Dose > 20 Gy 
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Table 7.1 Estimated radiation doses to the lungs in HCC receiving a single 
treatment (continued) 
patient % Lung Activity of Estimated activity Estimated radiation 
2 ^ Shunting 卯丫 (GBq) in lungs (GBq) dose to lungs (Gy) 
“-""^^~ 1.9 4.0 0.076 3.8 
""27 <1 ^5 0 � 
“"""28 ^8 4^ 0 0.072 3^ 6 
" " "^ ^ T^ 0.048 ^ ~ 
"~"30 ^ K 6 “ 0.405 20.1* 
"~3^ 6^ 4 K6 0.320 ^ 
~""32 < 1 T^ 0 0 
~"33 7A Z5 0.185 ^ 
~ ^ T^7 ^ 0.441 ~ ~21.9* 
~ ^ 3^ 8 4^ 0.152 7^ 
“ ^ 4^ 6 T^ 0.069 3!4 
~ 3 7 ^ K6 0.450 22.4* 
~~38 <1 3!0 0 0 
~ 3 ^ ^ ^ — ~ 0 0 3 T!s 
” 4 0 ^8 T^ 0.027 T1 
~ 4 ^ 5 ^ 3!0 0.174 ^ 
~ 4 2 <1 4 ^ ~ ~ 0 0 
~ 4 3 ？ ^ 3 ^ 0 . 3 7 8 1 ^ 
~ 4 4 7^ T!o 0 ~ ~ ~ 0 
~ " 4 5 < 1 T^ ~ ~ ~ 0 ~ 0 
~ 4 6 8^7 ~ "4 jO ' ~ 0.348 T7s 
~ 4 7 ^ 4^0 0.272 ^ 
~~^48 ~ ^ 3^0 0.114 ^ 
~ 4 9 K ] r ^ 0.094 4^7 
~~"50 4!6 3^0 0.138 ^ 




Table 7.1 Estimated radiation doses to the lungs in HCC receiving a single 
treatment (continued) 
「Patient % Lung Activity of Estimated activity Estimated radiation 
j j g Shunting ^Y (GBq) in lungs (GBq) dose to lungs (Gy) 
^ T i 1.2 3.0 0.036 1.8 
“""""K ^ T ^ 0.033 T!e" 
“"“^M 4?i ^ 0.123 ^ 
" ~ 5 4 4^7 ^ 5 0.071 3 ^ 
i “ “ 5 5 T ? 4^0 0.068 3 ^ 4 ~ 
" ~ ^ KQ ~ ~ 4 ^ 0.232 TTs 
“ ^ W r 4!9 3!0 0.147 v J 
~ 5 8 4 y 0 8 0.038 ^ 
~ " ^ ^ ^ 0.282 ~ u ! 0 
~ 6 0 ^ 4!0 0.108 ^ 
~ 6 l ~ 4!0 ^ 5 0.055 3 ^ 
~ ^ 7 1 r i 0 0 
~ 6 3 ^ ^ 0.120 ^ 
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Table 7.1 Estimated radiation doses to the lungs in HCC receiving a single 
treatment (continued) 
「patient Treatment % Lung Activity of Estimated activity Estimated radiation Cumulative radiation 
No. _NO; Shunting ^Y (GBq) in lungs (GBq) dose to lungs (Gy) dose to lungs (Gy) 
‘"""^ 64 1 11.4 7.0 0.798 39.6* 
2 7.3 4.0 0.292 14.5 54.1* 
“-""^ 65 1 TTs 4 ^ 0.472 2 3 ^ “ 
2 3.8 3.0 0.114 5.7 29.1* 
• " " i i 1 a6 s!o 0.198 a s “ 
2 < 1 4.0 0 0 9.8 
" “ ^ ^ 1 5^2 3.0 0.156 77 
2 < 1 4.0 0 0 7.7 
“ ^ 1 ~ “ 2^2 ZO 0.044 2!2 
2 1.5 3.0 0.045 2.2 4.4 
“ 6 9 1 7J 3!0 0.231 TT i 
2 18.1 3.0 0.543 27.0* 38.5* 
~ ^ 5 1 4 ^ 3^0 0.147 7^3 
2 <1 1.5 0 0 7.3 
~ 7 1 1 ^ i !0 0.200 9.9 “ 
2 2.2 3.0 0.066 3.3 13.2 
"““72 1 ^ 4Z 0.248 T2!3 
2 <1 3.0 0 0 12.3 
~ 7 3 1 a2 4!0 ~ 0 . 2 4 8 TZ3 
2 2.0 3.0 0.060 3.0 15.3 
“ 7 4 1 Z3 aO 0.069 3^4 
2 2.5 1.5 0.038 1.9 5.3 
“ 7 5 1 2 ^ s!0 0.115 57 
2 < 1 4.0 0 0 5.7 
~ 7 6 1 T7 40 0.308 15^ 
2 1.7 3.0 0.051 2.5 17.8 
~ 7 7 1 a4 4!0 0.256 ^ 
2 <1 3.0 0 0 12.7 
~ 7 8 1 3 ^ 4 ^ 0.152 7^ 5 
2 5.6 3.0 0.168 8.3 15.8 
*Dose > 20 Gy 
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I ―；Table 7.2 Estimated radiation doses to the !ungs in HCC receiving multiple treatments I • (continued) 
m 
fpatient Treatment % Lung Activity of Estimated activity Estimated radiation Cumulative radiation 
No. No. Shunting '°Y (GBq) in lungs (GBq) dose to lungs (Gy) dose to lungs (Gy) 
"^"75 1 2.8 1.5 0.042 2.1 
2 1.8 2.0 0.036 1.8 
3 3.2 1.0 0.032 1.6 5.5 
‘""S5 1 <1 i!o 0 0 
2 2.2 4.0 0.088 4.4 
I 3 1.9 4.0 0.076 3.8 8.2 
！ " “^8l 1 2^ ^ 0.063 3?i 
2 2.3 3.0 0.069 3.4 
3 6.9 3.5 0.242 12.0 18.5 
~ 8 2 1 37 4 ! 0 ~ 0.148 7A 
2 4.0 3.0 0.120 6.0 
3 9.1 2.5 0.228 11.3 24.7* 
~ ^ 1 ^ T I 0.054 27 
2 2.0 2.0 0.04 2.0 
3 2.2 2.4 0.053 2.6 
i 4 3.1 1.5 0.047 2.3 
5 3.4 2.0 0.068 3.4 13.0 
*Dose > 20 Gy 
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Table 7.3 Estimated radiation doses to the lungs in colorectal !iver metastases receiving 
SIR therapy 
patient Treatment % Lung Dose of »°Y (GBq) Estimated activity Estimated radiation Cumulative radiation 
Na No； Shunting in lungs (GBq) dose to lungs (Gy) dose to lungs (Gy) 
^ " ^ ^ 1 3.3 4.0 25/6/92 0.132 6.6 
2 <1 2.5 2/10/92 0 6.6 
" ^ 1 7^3 3^0~~16/7/92 0.219 ^ 9 
" ^ 1 i O "To~"11 /8 /94 0 2 ^ ^ 
‘"""87 1 5^3 s!o~~16/3/95 0.159 7 ^ 
i ‘•""88 1 ^ s!0~~6/4/95 0.126 6^3 
Table 7.4 Estimated radiation doses to the lungs in patients who developed radiation 
pneumonitis 
Patient Sex/Age Dtagnosta Treatment %Lung Doee of Estimated acSvlty fn Estimated radiatton Cumulating radiation doee 
No. No^ Shunting ^Y(GBq) lungs (GBq) dose to lungs (Gy) to lunge (Gy) 
~"~89 M ^ liver metastases from i 14.8 5.0 0.740 36.8* 
CA colon 2 13.1 3.4 0.445 22.V 58.9 
" ~ 9 0 ^ ^ inoperable HCC i ^5^9 J T " 0.636 3 ^ 
Result in ( ) were obtained post partial hepatic embolization using lvalon particles to reduce lung shunting 
*Dose > 20 Gy 
Table 7.5 Estimated radiation doses to the lungs in patients who received partial 
embolization 
Patient Sex/Age Diagnosis % Lung Dose of ®。Y Estimated activity Estimated radiation dose 
No. Shunting (GBq) in lungs (GBq) to lungs (Gy) 
~ 9 3 W ^ inoperable HCC 32.8 4.0 1.312 65.2* 
(< 1) W W 
~ 9 2 FBA inoperable HCC 3 ^ 1 4^0 1.368 & 7 ^ 
(5.8) (0.232) (11.5) 
~ " 9 U ^ ^ inoperable HCC 23J ~ ~ ~ 4 ^ 0 0.948 47.1* 
(5.3) (0.212) (10.5) 
~ ~ 9 ^ W ^ inoperable HCC 36^ “ ^ T M 72.5* 
(12.8) (0.512) (25.4) 
~~5i5 TJS2 inoperable HCC ^ i !o 2^8 113.2* 
(10.1) (0.505) (25.1) 
Results in ( ) were obtained post partial hepatic embolization using lvalon particles to reduce lung shunting 
*Dose > 20 Gy 
#Patients developed radiation pneumonitis 
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The results of these 90 patients suggest that the development of radiation 
j pneumonitis is unlikely if the estimated radiation dose received by the lungs is 
I 
i 
below 30 Gy from a single SIR treatment using 卯丫 microspheres. Eight-
seven patients with their lung dose estimated to be below 30 Gy from a single 
treatment showed no evidence of radiation pneumonitis. On the other hand, 
radiation pneumonitis was detected in 1 of 3 patients who received a lung 
dose above 30 Gy giving a percentage of 33.3%. A dose of 25 Gy is still 
being accepted as the limiting dose in whole lung irradiation with external 
beam (3). Our results suggested that 30 Gy from a single treatment could be 
the upper limit below which radiation pneumonitis caused by radiation 
delivered internally from 卯丫 microspheres is unlikely. The lungs seemed to 
have slightly higher tolerance towards radiation delivered by 卯丫 microspheres 
-
as discrete point sources. As mentioned before the actual distribution of 卯丫 
microspheres is not uniform. Some part of the lungs may receive less doses 
than estimated and therefore get spared. 
The results of the patient with liver metastasis from colon cancer (No. 89) 
who showed no sign of radiation pneumonitis after receiving 36.8 Gy to his 
lungs from the first treatment but didso when another 22.1 Gy was delivered 
in the second treatment 6 months later suggested that the damaging effect 
may be accumulative. Comparison with the estimated cumulative radiation 
doses to the lungs in the other 20 patients who received multiple treatments 
and did not develop radiation pneumonitis suggests that the risk is low for 





to the lungs below 50 Gy developed the complication whereas one among the 
2 patients received a cumulative dose > 50 Gy did so. 
It is also interesting to note that the tolerance of the lungs towards radiation 
varied from patient to patient. A patient (No. 64) who received 39.6 Gy to his 
lungs from a single treatment and an accumulative dose of 54.1 Gy from 2 
treatments did not develop radiation pneumonitis. 
With the partition model the radiation dose to the lungs from SIR therapy 
using a required activity of 卯丫 microspheres can actually be predicted. 
Instead of setting a limiting value for the percentage of lung shunting, 30 Gy 
to the lungs from one single treatment may be regarded as the safety limit 
based on the results of the present study. This will allow opportunity for 
future retreatment of residual or recurrent disease as far as the accumulative 
dose to the lungs is kept below 50 Gy. 
Simulation of SIR therapy using 卯丫 microspheres with ®®^Tc-MAA scan to 
assess the degree of pulmonary shunting is an important step in patient 
selection. It allows exclusion of patients who are at high risk of developing 
radiation pneumonitis. 
7.2 PREDICTION OF THE RISK OF COMPLICATION 
Five patients (Nos.91 - 95) had lung shunting > 20% as assessed by ®®^ Tc-




the activity of 卯丫 microspheres administered and the percentage of lung 
shunting. The results are shown in Table 7.5. The estimated dose ranged 
from 47.1 to 113.2 Gy. Based on our clinical experience, all these 5 patients 
were very likely to develop radiation pneumonitis as their lungs received more 
than 30 Gy in a single treatment. 
In fact the possible risk was realized as the percentage of lung shunting of 
these patients were well above our original safety limit (15%). Partial hepatic 
embolization to reduce lung shunting in these 5 patients were attempted 
using lvalon particles (Nycomed lngenor, France) of size 150 - 300 ^im. The 
percentage of lung shunting after partial embolization was reassessed using 
99,Tc-MAA before SIR therapy was contemplated. The results and the 
expected radiation doses to the lungs estimated based on the new 
percentages of lung shunting were shown in brackets in Table 7.5. This 
technique and the results in 3 of the patients (Nos. 93-95) have been 
reported (2). 
In fact partial hepatic embolization with lvalon particles of size 150 - 300 p.m 
was first attempted in a young man (patient No. 91) who had an AFP level of 
1,154 ng/ml). The intention was to reduce his lung shunting so that he might 
benefit from SIR therapy using 卯丫 microspheres. Subsequent ®®^Tc-MAA 
scan documented that his lung shunting was reduced to < 1%. He was then 
given 4 GBq of 卯丫 microspheres through an hepatic angiographic catheter. 
The patient responded very well with normalization of AFP level and there 




Encouraged by the results in this patient, partial hepatic embolization with 
lvalon particles were further attempted in 4 other patients. The technique 
seemed to be feasible in patient No. 92 with her lung shunting being reduced 
from 34.2% to 5.8%. She responded very well to the treatment with 4 GBq of 
卯丫 microspheres and showed no sign of radiation pneumonitis. She died of 
bone metastases 5 months later. The partial hepatic embolization appeared 
to have failed in the remaining 3 patients who developed radiation 
pneumonitis after treatment. Details of the complications in these 3 patients 
and the other 2 (No. 89 and 90) formed the first clinical report of radiation 
pneumonitis which resulted from internal radiation therapy (2). 
Human lung tissue is quite susceptible to radiation damage. From the 
experience of external beam therapy, radiation-induced pneumonitis seldom 
occur with whole lung irradiation with doses less than 20 Gy but is highly 
probably when doses exceed 60 Gy (4). Both the volume of lung tissue 
irradiated and the radiation dose delivered were found to be critical. 
Therefore 20 Gy has been generally accepted as the tolerance limit of the 
pulmonary system towards whole lung irradiation with external beam. 
Most cases of radiation pneumonitis reported in the literature were results of 
treatment of lung and breast cancer with external beam irradiation (5,6). 
Apparently internal radiation therapy of hepatic cancer by selectively targeting 
the tumours with radioisotopes reduces the risk of radiation pneumonitis. 
However arteriovenous shunting of a high percentage of microspheres to the 
lungs may result in radiation pneumonitis. 
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The partition model estimated that all these five patients who received > 30 
Gy in a single treatment were at high risk of developing radiation pneumonitis. 
The result turned out that 3 (60%) out of five suffered from radiation 
pneumonitis after the SIR therapy despite partial embolization was carried out 
to cut down on the lung shunting. In the 3 patients who had partial hepatic 
embolization with lvalon, ®®^Tc-MAA scan performed immediately after 
embolization showed the lung shunting were reduced to below 15%. The 
radiation doses to the lungs estimated from the percentage of reduced lung 
shunting were 10.5, 25.4 and 25.1 Gy respectively. 
Thus if the partial hepatic embolization really worked well, radiation 
pneumonitis should not have occured in the last 3 patients (No. 93 - 95) as 
the radiation doses estimated from the percentages of lung shunting 
determined after embolization were below 30 Gy. 
It seems that the lvalon particle were only able to stop the ®®^Tc-MAA 
particles from passing through the arteriovenous shunts, but not the 卯丫 
microspheres in 3 out of the 5 patients who underwent partial hepatic 
embolization. A number of possible explanations can be put forward : 
(i) The ®®^Tc-MAA particles might stick to the lvalon particles due to their 
albumin nature while the ®°Y microspheres do not. 
(ii) The higher density and greater number of 卯丫 microspheres open up 
some of the blocked arteriovenous shunts. 
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r (iii) New collaterals and arteriovenous shunts open up before the SIR 
therapy using 卯丫 microspheres. 
j-: 
r. 
f As partial hepatic embolization succeeded in reducing the lung shunting and 
prevented radiation pneumonitis in 2 out of 5 patients, explanation (iii) 
seemed to be the most reasonable cause of failure as the rate of opening up 
['. 
！ .-
of new collaterals and arteriovenous shunts may vary from patient to patient. 
It must be pointed out here that the data based on which the deduction in 
section 7.1 and the prediction in section 7.2 were made have their 
weaknesses. Firstly the criteria for diagnosis of radiation pneumonitis are 
never clearly defined. Subclinical radiation pneumonitis might have occured 
in some of the patients. Secondly both the deduction of limiting radiation 
doses and the prediction of complication were based on relatively small 
number of patients (one out of three and three out of five respectively). 
Knowing the approximate doses that may lead to complication, the treatment 
is now put under very cautious control. Thus the chance of seeing more 
cases of radiation pneumonitis is extremely low. These weaknesses have to 
be addressed in an animal model. 
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Z3 ESTIMATION OF RADIATION DOSES TO TUMOUR AND NON-
TUMOUROUS LIVER 
In the present study, the total radiation doses received by the tumour and the 
non-tumourous liver from single or multiple treatments were estimated using 
the partition model. 
The aim of the study is to find out: 
i 
j (i) what range of radiation dose given in single and multiple treatments is 
tumouricidal for HCC? 
(ii) what is the maximum tolerance of non-tumourous liver, majority of 
which is cirrhotic, towards this form of treatment? 
(iii) do response rate and survival correlate with the level of radiation dose 
to the tumour as predicted by the partition model? 
Seventy-one patients with inoperable HCC entered the study. This inciuded 
62 males and 9 females. The median age was 55 years (range 24 to 85 
years). 
Fifty one patients were treated at initial diagnosis, 20 were post operative 
recurrences. Sixty five (91.5%) patients were carriers of hepatitis B antigen 
(HB3Ag) and 41 (57.7%) had cirrhosis. The size of the biggest tumour nodule 
ranged from 1.0 to 22.6 cm with a median of 8.5 cm. In 37 patients, the HCC 




The other 34 patients had ultrasound scans, computerized tomography and 
hepatic angiography which were consistent with a diagnosis of HCC. The 
serum AFP level at presentation was raised above 500 ng/ml (range : 619 -
809,700 ng/ml, median 8,667 ng/ml) in 24 of these 34 patients (70.6%). 
These evidences, in combination with the high percentages of positive HBgAg 
and cirrhosis supported a clinical diagnosis of HCC. Percentage lung 
shunting and T/N ratios were obtained from ®®^Tc-MAA images and masses 
of tumour and non-tumourous liver were calculated from CT slices as 
described before. 
Patients with lung shunting < 15% and T/N ratios > 2 and no obvious poor 
uptake area within the tumour were given SIR therapy using 卯丫 
microspheres. 
After quality assurance tests which included checking of specific activity and 
percentage of leaching followed by sterilization,卯丫 microspheres in aliquots 
of 1.0 and 1.5 GBq were suspended in a mixture of equal volumes of water 
for injection and Omnipaque 300 (Nycomed, Oslo, Norway) to a final volume 
of 5 ml. The Omnipaque was added to make the suspension radio-opaque 
so that the flow of radioactive microspheres could be closely monitored under 
fluoroscopy during infusion either through an implanted Port-A-Catheter or 
hepatic angiographic catheter. 
For patients with an implanted Port-A-Catheter, infusion was done by 
connecting a Hubber needle punctured on the port and connected to the four-
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way valve of an injection bracket made of 1 cm-thick perspex. In patients 
I without an arterial port, the treatment started with repeating the selective 
HAG which had been performed for ®®^Tc-MAA simulation. The angiographic 
catheter was linked to the four-way valve of the injection bracket. Pre-
determined fractions of 卯丫 microspheres were mixed by means of the 4-way 
valves before they were pulsed slowly through the catheter under 
fluoroscopy. The total activity administered to each patient was decided 
empirically based on the size of the tumour. After treatment, the patients 
were nursed in an isolation room for 4 to 5 days. A Bremsstrahlung scan of 
the liver and lungs was performed to record the level and distribution of 
radioactivity before the patients were discharged home. The distribution of 
卯丫 microspheres as documented by the Bremsstrahlung image was matched 
with that predicted by the ®®^Tc-MAA scan。 
The radiation doses to the tumour and the non-tumourous liver in each 
treatment were estimated by the partition model as described before. The 
response to treatment was monitored by the change in levels of tumour 
markers (AFP or ferritin) and also by serial CT scans after treatment. For 
patients with pre-treatment AFP levels above 500 ng/ml, a drop in the level by 
more than 50% was regarded as a partial response and normalization of the 
marker (< 10 ng/ml) was considered as a complete remission in terms of 
AFP. The criteria for response based on reduction in tumour volume shown 
on CT scan are : 
i) Complete response (CR) is the complete disappearance of all known 




m . ；!. 
ii). Partial response (PR) is a decrease of 50% or more in tumour volume. 
There should be no appearance of new lesions or progression of 
lesions. 
iii) Static disease (SD) is a decrease in tumour volume of less than 50% 
or an increase in tumour volume of less than 25%. 
iv) Progressive disease (PD) is an increase in tumour volume of more 
than 25% or the appearance of new lesions. 
a) The treatment 
The percentages of arteriovenous shunting as assessed by ®®^Tc-MAA 
scan ranged from < 1 to 14.7 with a median of 4.6 in these 71 patients 
at the initial treatment。The T/N ratios from ®®^Tc-MAA before the first 
treatment ranged from 2.06 to 18。7 with a median of 4.11。 
Patients received an initial activity of 0.8 to 5.0 GBq (median 3.0 GBq) 
of 90丫 microspheres. In 3 patients the microspheres were administered 
through implanted Port-A-Catheter while for the rest the doses were 
infused through an hepatic angiographic catheter. 
Repeated treatments with an activity of 1.0 to 4.0 GBq (median 3.0 
GBq) were given to 15 patients with residual or recurrent disease. Ten 




received a total of five treatments. The intervals between treatments 
ranged from 2.5 to 25.4 months with a median of 5.2 months. The 
total activities received by the 10 patients who were treated twice 
I 
ranged from 4.5 to 9.0 GBq with a median of 7 GBq. The 4 patients 
who were treated three times received a total of 4.5, 9.5，9.5 and 13.0 
i 
i 
GBq of 卯丫 microspheres respectively. The remaining patient received 
I , 
a total activity of 9.7 GBq of ®°Y microspheres from the five treatments. 
]• 
b) Estimation of radiation doses 
The radiation doses to tumour and non-tumourous liver were estimated 
by the partition model. 
The radiation doses to the tumour and non-tumourous liver in 56 
patients who received a single treatment are shown in Table 7.6. The 
patients were arranged in the ascending order of tumour dose which 
ranged from 83 to 748 Gy (median 224.5 Gy). With the exception of 
the first 3 patients, the estimated doses to tumour were all greater than 
120 Gy. The doses to the non-tumourous liver was between 25 and 
136 Gy with a median of 52 Gy. 
The radiation doses for each treatment and cumulative doses in the 15 
patients who were being treated more than once are shown in Table 





Gy (median 538 Gy). The cumulative doses to the non-tumourous 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fifty nine patients tolerated the treatment very well. Twelve of them 
had abdominal distending discomfort and nausea/vomiting shortly after 
the infusion probably as a result of the embolizing effect. Low grade 
fever occurred in ten patients. However, these side-effects were 
transient and subsided in a few days. No bone marrow toxicity was 
observed. No signs and symptoms of radiation pneumonitis and 
radiation-induced hepatitis was observed among these 71 patients. 
The patients were discharged home within 5 days after the treatment. 
d) Monitoring of response 
AFP was used as the tumour marker for monitoring the response of 39 
patients who had a pre-treatment level above 500 ng/ml and an 
additional 7 patients who had pre-treatment levels between 131 and 
346 ng/ml. The AFP showed a drop in all these patients (Figure 7.2). 
In patients who had pre-treatment AFP levels of 500 ng/ml or above, 
the trough value after the first treatment represented a fall between 20 
to > 99% (median 88%). The time taken to reach the trough value lay 
between 2 to 295 days with a median of 50 days. Thirty-five (90%) 
patients had more than 50% drop in their AFP levels and 6 out of these 
I 
i 
I had normalization (< 10 ng/ml) of their AFP after the first treatment. 
Thus, there were 29 (74%) patients who had objective partial 
remission and 6 (15%) patients who had complete remission in terms 





.,pjgyre 7.2 Percentage change of AFP level after intraaterial ®°Y therapy 
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level, the marker dropped by 36 to > 99% (median > 99%) in 8 to 230 
days (median 55 days) after treatment. The values dropped by more 
than 50% in 6 patients and was normalized in 4 patients. 
Serum ferritin was used as a tumour marker in the 25 patients whose 
pre-treatment AFP was not elevated (7,8). The ferritin level showed a 
spike during the first few days after treatment and then fell steadily. 
The maximum drop in ferritin level was between 34 and 99% with a 
median of 62% (Figure 7.3). 
Based on the criteria for response in terms of reduction in tumour 
•••-ma>.-
volume shown on CT scans, there was no complete remission. Partial 
f remission representing 51 to 87% reduction in tumour volume was 
1 observed in 19 patients (26.7%) after the first treatment.. Figures 7.4 
； illustrates the significant reduction in tumour size on serial CT scans in 
； a patient at 3，5 and 9 months after treatment The rest had static or 
progressive disease after the first treatment. Classification as 
progressive disease was either due to appearance of new intrahepatic 
lesion or distant metastases. As shown in table 7.6 10 out of 22 
(45.5%) patients who received > 300 Gy to their tumours achieved 
partial remission as compared with only 4 out of 34 (11.8%) patients 
with lower tumour doses (< 300 Gy). The difference is statistically 
significant (Chi Square test : p < 0.05). Thus the response rate 
showed a dependence on the level of the tumour dose as estimated by 
the partition model. 
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I pigure 7.3 Change of serum ferritin level after intraarterial ®°Y therapy 
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I •e； Survival and cau.QgQ of death 
1^ The median survival from the date of diagnosis of these 71 patients 
- was 9.4 months (range 1.8 to 31.0 months) (Figure 7.5). There was 
. . • : , . . 
If no difference between the median survivals of the 20 patients with 
； post-operative recurrence and the 51 patients who received initial 
treatment (Figure 7.6). This suggests that SIR may be a useful 
treatment option even in recurrent HCC. However the median survival 
of 36 patients who received > 300 Gy of radiation, as estimated by the 
partition model was 11.0 months。This is better than the 6.8 months in 
35 patients who received estimated tumour doses < 300 Gy (Figure 
7.7) but the difference is not statistically significant (log-rank test : p = 
也 , 
0.3502). Thus this needs to be verified by increasing the number of 
patients. Fifty of the patients had died at the time of analysis. The 
commonest cause of death was disease complication from residual or 
recurrent tumours with 32 who died of intrahepatic residual or recurrent 
disease, 4 who died of bone metastases and 4 who died of lung 
metastases. Other causes of death included hepatic failure (3 
patients), bleeding oesophageal varies (4 patients), uncontrolled 
sepsis from acute cholecystitis which may be induced by the 
radioactive microspheres (1 patient) and unrelated cause (1 patient). 
The remaining patient died of hepatic failure after hepatic resection 
carried out to remove the residual tumour. No malignant cells was 
found in the resected "tumour" nodule and this represented a 
histologically-proven case of complete remission after two infusions 
with activities of 4 and 3 GBq respectively of ®°Y microspheres 
M^^  
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K administered by hepatic angiography. The patient received a total of 
攀 279 Gy to his tumour and 64 Gy to his non-tumourous liver. 
‘mm 
1 . ^ 
H 
I f His AFP level was 2,972 ng/ml at the time of diagnosis which dropped 
to < 10 ng/ml after the second 卯丫 treatment. A great number of 
microspheres were found inside the resected specimen but viable HCC 
cells could not be detected. It was unfortunate that this patient did not 

























































































































































































































































































































































































































































































































































































































































































Among the 21 patients who are still surviving, 3 patients had their 
tumours being converted to be operable after SIR therapy and the 
residual tumours were resected by surgery. The first patient had a 
histologically proven tumour of 11 cm at initial diagnosis. The tumour 
extended from the right lobe of the liver into the left lobe making it not 
resectable in the presence of cirrhosis. The tumour shrunk to 6.0 cm 
with hypertrophy of the left lateral segment of the liver 10 months after 
receiving 4 GBq of 卯丫 microspheres。 The residual tumour was 
resected. Viable HCC cells were detected within the necrotic centre of 
the nodule where only a small number of microspheres were found 
(Figure 7.8). In the periphery of the tumour, only necrosis and fibrosis 
were detected adjacent to dense clusters of microspheres (Figure 7.9). 
In the second patient, a right lobe HCC of 16 cm was diagnosed 
histologically and a satellite tumour was found in the left lobe。 He 
received two treatment of ®°Y microspheres. Each time 4 GBq were 
given and the total radiation received by the tumour and non-
tumourous liver were 426 Gy and 103 Gy respectively. When the 
tumour was reduced to 8 cm in size and the left sided lesion 
disappeared, right hepatectomy was performed. A small tumour 
nodule containing viable HCC cells was found at the peripheral of the 
main bulk of tumour which consisted of fibrosis and necrosis, and lots 
of microspheres. The specimen resected from the left lobe which 
contained a scar contained no HCC cells. The third patient had a 
small tumour of 2 cm in his right lobe. However hepatic resection was 






Figure 7.8 Necrotic centre of tumour containing small 
number of microspheres. Area away from the microspheres 
demonstrated viable HCC cells 
^ » 
M Figure 7.9 Necrosis and fibrosis in the periphery of a 




Cirrhosis). A dose of 1 GBq of 卯丫 microspheres was given by HAG. 
The estimated radiation dose to his tumour was 189 Gy. His serum 
AFP level normalized after treatment. Surprisingly the liver function of 
the patient improved as follow-up CT scans revealed hypertrophy of 
the left lobe of his liver. His residual tumour had subsequently been 
resected. No viable HCC cell was found in the resected tumour. It 
contained only fibrotic and necrotic cells and microspheres. This 
patient represents the second histologically proven case of complete 
remission after SIR therapy. All these 3 patients recovered well from 
减 
参1 
' the surgery. 
The results obtained from these 71 patients are encouraging. The rapid fall 
in tumour markers post treatment in most patients is not commonly observed 
I 
i ' 
with other palliative treatment modalities. The response rates based on 
changes in tumour volumes from digitised CT images are much lower than 
that determined by tumour markers. Previous workers have pointed out that 
CT is of limited use in monitoring response to radiotherapy (9,10). Barone et 
al (9) found in a number of patients with hepatic metastases, no change or 
even increase in the liver defects were detected on CT scans yet on 
exploration, no tumour was found in the liver. The discrepancy was attributed 
to fibrosis produced by radiation therapy and that decreases in CEA level was 
felt to be a more reliable indicator of response. This experience is very 
similar to our two patients, each having a residual ‘tumour nodule，on CT scan 
which contained no viable HCC cells in the resected specimen. The 
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images. Nauta et al (10) suggested that the nodule size measurements on 
CT after treatment are dependent not only on the limited ability of the imaging 
modality to define the tumour nodule but also on the rate of tumour cell death, 
the rapidity with which the reparative and re-organization processes proceed, 
and the extent to which the repair is visualized on CT scans. These probably 
explain that despite tumours of significant size were still seen on CT, the 
resected specimens from the other two patients in our series only contained a 
small number of viable HCC cells。 Nauta et al (10) actually suggested that 
the main use of CT in the post-treatment period is not to measure the treated 
!• I 
nodule size, but to examine the remaining liver for signs of progression of the 
disease. Positron emission tomography (PET) which is capable of quantifying 
metabolic rates over different regions of an organ through dynamic imaging 
/ 
utilizing radio-labelled glucose or amino acid may be the radiological imaging 
I 
modality of choice in differentiating viable tumours from defects due to 
necrosis and fibrosis (11,12). 
The commonly reported median survival of patients with inoperable HCC in 
areas of high incidence is 2 months (13,14), although longer survivals have 
been reported in the literature (15-17). A median survival of 9.4 months was 
achieved in this group of patients. As a selected group of patients were being 
treatment, it cannot be concluded at this stage that the treatment has a 
beneficial impact on survival. A randomised trial is required to prove this 





More importantly the treatment carries very little morbidity and the quality of 
life after treatment is good. Symptoms of alopecia, persistent nausea and 
vomiting which commonly associate with cytotoxic chemotherapy were not 
seen in these patients. The majority of patients enjoyed normal life until very 
near to the terminal stages of their disease. 
The estimated radiation dose received by the non-tumourous liver of the 71 
patients at the initial treatment were generally much higher than 30 Gy which 
is the commonly accepted tolerance limit for whole liver irradiation by external 
beam (18,19). Yet there were no signs or symptoms of radiation hepatitis in 
these patients. 
The much higher tolerance of the liver towards internal radiation from 卯丫 
microspheres has been explained by the inhomogeneous distribution of 
radioactive microspheres (20). The tolerance of normal liver towards 
radiation delivered by 卯丫 microspheres in animal models have been well 
studied. Wollner et al recorded a dose of 127 Gy to 355 Gy in dogs (21) 
while a much higher dose of 114.1 - 845.2 Gy was found to be well tolerated 
by rabbits (22). The first vague due to the tolerance limit of the human liver 
towards radiation delivered internally by ®°Y microspheres came from the 
case of radiation pneumonitis reported by Grady (23). The total radiation 
dose received by the liver as a whole was estimated to be 60 Gy from two 
separate treatments of 50 mCi each. It is logical to assume that the T/N ratio 
was > 1 otherwise the treatment should not be given. Thus it can be deduced 
that the radioactivity concentration of ®°Y in the tumour should be higher than 
I 223 
1 
in the normal liver and the dose of the normal liver should then be less than 
60 Gy. If the T/N ratio is 1，then 60 Gy represented a possible limit of 
tolerance for the normal liver. The tolerance limit of the normal liver in human 
was proposed to be 80 Gy by Fox et al (20). In all the other studies, although 
some values of tumour and normal liver doses have been mentioned 
(20,24,25), the radiation doses estimated were referred to the liver as a whole 
with no distinction between tumour and non-tumourous liver and so do not 
i 
really provide any clue to the tolerance limit of the non-tumourous liver. 
1 
i 1 
It is even more interesting to note that the non-tumourous parts of the livers, 
which were cirrhotic in most of the patients who received multiple treatments 





developing radiation hepatitis. The cumulative dose even exceeded the 
threshold limit of 80 Gy which is proposed for non-cirrhotic liver (20). 
Probably the time gap between treatments had allowed for repair of sub-lethal 
damages to the hepatocytes. 
However, similar to the situation with radiation pneumonitis, the criteria for 
differential diagnosis of radiation hepatitis are never clearly defined. 
Subclinical radiation hepatitis might have occured in some of the patients. 
The works on animal models (21.22) needs to be carried further to find out 
what radiation level will induce radiation hepatitis, both clinically and sub-
clinically. 
A radiation dose of 120 Gy is commonly accepted as tumouricidal for HCC 
(26). But what level of radiation is required to eradicate completely the 
tumour (s) in a particular patient is a question without an answer. Although 
histologically-proven complete remission has been documented in two of our 
patients, one received a cumulative radiation dose of 279 Gy to his tumours 
from 2 treatments, and the other received 189 Gy to his tumour from a single 
treatment, such a dose may not be able to eradicate all the tumours in 
another patient because of difference in radiosensitivity. Even within the 
same tumour in a patient, different clones of cells may show different 
radiosensitivity. While some clones of cells are killed by radiation at a certain 
dose level, others may survive. As can be seen in our 71 patients, residual or 
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Figure 7.10(a) Enlarged view of a tumour on 
99mic-MAA scan. Average T/N ratio = 4.35 
but there are two obvious necrotic areas within 
the tumour 
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Figure 7.10(b) Computation from the counts over the 
digitised image indicated that the two necrotic area 
represent 9.4% of the whole tumour and have T/N 




the estimated average doses to the tumour were well above 120 Gy in most 
cases. 
Figure 7.10a showed an enlarged view of the distribution of ®®^Tc-MAA in a 
tumour which is non-uniform. The T/N ratios are calculated by dividing the 
average radiation counts per pixel of the tumour by that of the non-tumourous 
liver. For a T/N ratio of 2 or above, the tumour receives an average dose of > 
120 Gy when the radiation dose to the cirrhotic non-tumourous liver is 60 Gy. 
The tumour shown in Figure 7。10a has an average T/N ratio of 4.35. 
However detailed analysis of the tumour revealed that 2 necrotic areas 
representing 9.4% of the tumour having T/N ratio of less than 2 (Figure 
7.10b). Thus the radiation dose received by this part of the tumour may be 
suboptimal which may remain as residual disease while the rest of the tumour 
i regresses. This phenomenon is commonly seen in large tumours with a 
necrotic centre. This observation is consistent with our finding of viable HCC 
cells at the centres of the resected nodules which consisted mainly of necrotic 




Even if the initial treatment resulted in good control of the original tumour, a 
new lesion may appear in the same or a different lobe of the liver. 
Microscopic seedling of these new lesions might have already existed before 
the initial treatment but they were not vascular enough to take up a 
tumouricidal dose of ®°Y microspheres. Figure 7.11 illustrates a patient with a 
large tumour in the right lobe which showed good uptake of ®®^Tc-MAA. 
Several small satellite lesions in the left lobe are virtually invisible. However, 
on suppressing the high counts of the major tumour, the satellite lesions 
become visible. Figure 7.12 shows that new lesions developed in the left lobe 
of a patient as the major tumour in his right lobe regressed after SIR therapy. 
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Figure 7.12(b) However, new lesion started to grow into 
the left lobe and thus re-treatment is required 
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Our experience has also shown that for patients who have raised serum AFP 
before treatment, the levels usually drop to a trough value rapidly and then it 
starts to rise, with or without passing through a plateau, as the residual or 
recurrent disease starts to grow. Thus the survival gained is approximately 
r 
equal to the time taken for the AFP to reach the trough value and then returns 
to the starting point (Figure 7.13). 
As long as the disease is still confined to the liver, further treatment with ®°Y 
microspheres can offer an additional period of control of the disease (Figure 
7.14). The results of those patients who received multiple treatments indicate 
that repeated treatments are feasible and well tolerated. The time for 
repeating the treatment is crucial. It should be considered early once the 
residual or recurrent disease is confirmed, either by rise in tumour marker 
level (Rgure 7.15) or by radiological evidence, and before the tumour 
becomes metastatic or the general condition of the patient has deteriorated. 
The results of the two patients who underwent liver resection after 卯丫 therapy 
with histological complete remission suggest that this form of treatment can 
be curative provided the tumour is adequately treated. The other 2 patients 
open the possibility of converting inoperable tumours by 卯丫 SIR therapy to 
operable ones. Likewise, satellite lesions may be eradicated by SIR therapy 
leaving a single tumour nodule that can be removed by surgery. 
The efficacy of SIR therapy for hepatic cancer using ®°Y microspheres can be 
evaluated in more scientific ways with the partition model for estimating 
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Figure 7.13 Change of AFP levels 
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radiation doses to the various compartments. An estimated doses of < 30 Gy 
to the lungs from a single treatment and an estimated cumulative dose of < 
50 Gy from multiple treatments is the most important criteria for preventing 
radiation pneumonitis. The total activity of 卯丫 microspheres to be 
administered in each treatment can be determined in two alternate ways : 
1. The estimated radiation dose to the non-tumourous liver is kept at 70 
Gy which is considered to be the tolerance limit for cirrhotic liver. This 
will result in patients who receive different tumour doses. Analysis of 
the response rate and actuarial survival in relation to the different 
tumour doses may provide information about the optimal radiation 
i 
[ doses for treating hepatic cancer. 
2. The estimated radiation dose to the tumour is kept at a fixed value, for 
j 
i example 300 Gy. Then the non-tumourous livers will receive different 
radiation doses in different patients. This will ultimately yield 
information about the actual tolerance of the non-tumourous liver 




7 . 4 . EXPLAINING WHY SIR THERAPY IS MAINLY PALLIATIVE RATHER 
THAN CURATIVE 
Apart from the two patients who achieved histological complete remission 
after treatment with ®°Y microspheres, no other complete response has been 
documented in our patients who received SIR therapy. Even the first patient 
who achieved CR needed repeated treatment for the residual tumour left after 
the first treatment. These suggest that SIR therapy in its present setting is 
I 
largely a palliative rather than a curative treatment for inoperable hepatic 
cancer. As postulated in the last section that this could be due to the fact that 
the radiosensitivity of tumour cells in different patients or even within the 
same patient is not identical. There is also evidence that there is a non-
uniform distribution of ®°Y microspheres within the tumour and viable tumour 
cells can be left in areas containing a low concentration of microspheres. The 
existence of necrotic areas within the tumour with T/N ratio < 2 on ®®^Tc-MAA 
scan means that these areas receive sub-optimal radiation doses even 
though the average dose to the whole tumour is tumouricidal (> 120 Gy). 
This may explain why residual disease which required repeated treatment 
was so common. 
To prove this point, the ®®^Tc-MAA images of all the 71 patients who received 
9。Y microspheres through a percutaneous route (via Port-A-Catheter or 
hepatic angiographic catheter) were reviewed to document the percentages 
of the areas within the tumour which received < 120 Gy in SIR therapy. 
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The expected radiation dose received by the non-tumourous compartment 
(Z)w) in each treatment was estimated using the partition model. For areas 
of the tumour which received > 120 Gy, these areas must have a T/N ratio(r) 
equal or greater than 120/£)^ . The maximum count rate per pixel i C n ) '^ 
the gamma image was given by the computer. The average count rate per 
pixel over the tumour { C r ) and non-tumourous liver (C*N) were obtained as 
before by localizing the tumour and the liver as regions of interest. 
r 
Q^ was expressed as a percentage of〔M ‘ Pi^ = y f ~ ^ 100% 
UM 
For a region of the tumour to received > 120 Gy, G should be > r p 『 T h e 
computer was instructed to calculate and to show the portion of the tumour 
with count rates per pixel between vp^ (%) and 100%. The portion of the 
tumour left was circumscribed as ROI and its area was calculated by the 
computer. The difference between the area of the whole tumour and this part 
of tumour which received > 120 Gy divided by the area of the whole tumour 
gave the percentage of the tumour which received less than 120 Gy of 
radiation. 
The percentages of tumours which received less than 120 Gy in each 





Table 7.8 Percentage of tumour received < 120 Gy from single SIR therapy in HCC 
L ^ ^ ^ _ _ ^ ^ ^ ^ ^ ^ _ 
Patient Average Activity o1 Estimated radiation dose (Gy) Minimum T/N %oftumour 
™ ratio ，。Y(GBq) tumour non-tumours liver ratio for> 120 Gy received < 120 Gy 
1 2 . 0 6 ~ 0.8 83 41 2.93 48.2 
2 Z23 Ts 99 ^ 2 ^ 609 
3 3 ^ 3!0 To^  28 ^ 30l 
4 ^ 4!0 ^ 36 3 ! ^ ^ 
5 3^60 TZ ^23 34 3^53 56^2 
6 3.16 T ^ ?29 4^ Z93 67^9 
7 2!^ r i ^30 52 2Ji 3^ 
8 4^68 3!0 ^33 29 i T u 715 
9 4!04 ^ 3^3 ^ ^ ^ 
To 3!33 T^  ?33 5^ i3o 7ii 
vi 4T7 4!0 ?34 32 3.75 53^ 8 
?2 3!33 ^ ?52 ^ 2 i i i ^ 
?3 2^7 ？^ ^54 52 2Ji ^ i i 
U Z95 5!0 ^54 52 i J i 58^7 
^5 2!O6 n “ “ “ ? 5 8 77 T ^ ^ 
Ti aOO ？^ l69 56 2?M 17^ 2 
^7 248 3!0 176 7l Ti9 3 ^ 
?8 3isl 5!0 ^ Tf Z55 62!3 
^ 3!24 i !o ^82 56 ^ 6 2 i i 
20 a85 3!0 ?84 “ ^ 4 ^ 50.6 
^ 5^2 T^ ?89 ~ 3 3 ^ 2M 
22 5 ! i i 5!0 200 52 2!3l ^ 
23 2!90 T i 206 ~^ ?j69 55!5 
24 3^0 3!0 2^8 73 ^64 ^ 
25 5 ! ^ 4!0 2TI ^ 2 i 3 307 
26 4Ti 3!0 22l 54 2!22 5 ^ 
27 Z96 Z0 224 元 1.58 ^ 
28 3^92 T 1 224 57 2T i ^ 
29 Z9 l ^ 0 225 77 ？ ^ 23J 
30 Z76 3!0 225 ^ T ^ 502 
*Residual tumour nodule resected 
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Table 7.8 Percentage of tumour received < 120 Gy from single SIR therapy in HCC 
(continued) 
Patient Average Activity of Estimated radiation dose (Gy) Minimum T/N %oftumour 
T/N ratio ^Y(GBq) tumour non-tumours liver ratio for> 120 Gy received < 120 Gy 
31 2 M ^ 555 ^05 ~ 902 
32 5!9O TZ 265 ^ Z67 308 
• 33 3 ! ^ 3!0 268 79 ? l 2 ^ 
34 523 Z6 272 52 ZSl 76^ 
^ 3 ! ^ SZ 302 79 r 5 2 577 
36 3 ! ^ ^ W l 9 0 “ T!S3 3 T l 
37 330 ^ 3 ^ 90 ^33 W o 
38 3 ^ 4Z 3?3 5^ Tl3 2I7 
^ ^ i 5 ^ 323 52 2 J i 5 ^ 
^5 2^60 4Z 330 T27 0 i 4 r7!5 
Ti 6^3 r i ^ 52 2 J i 3 T l 
^ 5^80 3 ^ 334 58 Z07 57^9 
^ 3^5 4Z 3^ ^F" 2 ^ T9!4 
^ 12.14 T!s 352 29 4Tfs ^ 
^ i T ^ 3!0 354 25 4^80 3?^ 
^ ^!55 aO 383 96 ^25 s!o 
^ s7io 3!0 ^ ^ T^ ^ 
:• 
^ ^ ^ ^ 3^6 088 Ti!o 
I 
j ^ ^ 4 ^ 474 52 2 J i 5^8 
50 486 T^ ^ 3^5 T^ i5 ^ 
51 572 3!0 5 ^ 90 T ^ 237 
i ^^^^^_^_^^_ ^^^_^^^_<^^_ ^__^^^__^_^_^_ _^^^^^^^^^^_^_^^^^^^___^ >^><_<_--^^^^^_-^-_ ^^^_^^^^^_^^^^^_^__ 
5 2 ^ 3!0 5 3 5 ？ ^ 0 ^ 2 ^ 
53 11.34 ^ 556 49 ^ 2a2 
54 ^8J 4!0 567 30 ^!55 ^ 
55 670 3 ^ 663 99 TTl i 0 3 
56 r7!9 ^ 748 ^ Z86 37^2 L _ _ L _ J 







Table 7.9 Percentage of tumour received < 120 Gy in each SIR therapy in HCC 
Patient Rx T/N Activity of Estimated radiation dose (Gy) Minimum T/N %oftumour 
No ratio ^Y(GBq) tumour non-tumours Uver for> 120Gy received < 120 Gy 
“ ^ 1 4^80 4^0 T ^ S T u 604 
2 4.01 3.0 : m 35 3.43 36.6 
(279) (64) 
58 n 5^87 4^0 ^96 ~ M 3^64 33?! 
2 3.00 3.0 m 5Q 2.03 21.7 
(372) (92) 
59 1 4 ^ 4^0 m ^ 2J9 35?i 
2 2.33 3.0 2 1 2 9 1 1.32 41.3 
(385) (134) 
60 1 5^30 s!o i^5 22 i ! ^ 6 ^ 
2 4.37 4.0 101 23 5.22 52.9 
3 2.67 4.0 lBB. TL 1.69 47.4 
(409) (116) 
F^ 1 3^60 4!0 ^75 47 Z55 364 
1 
2 2.80 3.0 24a aa 1.36 29.4 
(418) (135) 
j ^ 1 a i o 4!0 ?83 28 ^ 21.6 
l< 
;. 2 3.24 3.0 242 Z5 1.60 24.8 
i 
(426) (103) 
63 1 sTi “ “ T i ^ ~?6 7^50 7^ 
2 3.82 2.0 188 48 2.50 57.5 
3 6.26 1.0 i3D. 21 5.71 73.7 
(445) (85) 
64 i 5!9O 5!0 257 “ ^ 2^73 ^ 
2 3.19 3.0 2S1 aa 1.36 34.1 
(538) (132) 
65 1 ^ i !0 274 72 ^67 ^ 
2 9.06 4.0 312 35 3.43 31.3 
(591) (107) 
*Residual tumour nodule resected 
()cumulative doses 




Table 7.9 Percentage of tumour received < 120 Gy in each SIR therapy in HCC 
(continued) 
Patient Rx T/N Activity of Estimated radiation dose (Gy) Minimum T/N %oftumour 
No ratio ^Y(GBq) tumour non-tumours liver for> 120Gy received < 120 Gy 
^ 1 4 ^ 3.0 ^ 62 T!94 35!5 
2 5.10 3.0 351 ea 1.76 24.5 
(607) (130) 
67 1 10.70 ^ 3 ^ 36 3^3 T ^ 
2 7.90 1.5 265 M 3.53 11.7 
i (648) (70) 
68 1 11.35 3!0 ?85 ?6 7^0 78^ 
2 15.56 3.0 317 20 6.00 35.2 
3 2.6 3.5 20a aQ 1.50 43.6 
(710) (116) 
55 1 842 4!0 ^ 35 3 ^ 2T!3 
2 5.01 3.0 244 49 2.45 25.0 
3 7.99 2.5 248 31 3.87 36.2 
I (788) (115) 
j , 7 0 1 5 ^ 8 9 3 ! 0 5 ^ 3 ^ T ! 3 8 i T i 
2 5.20 1.5 2Sa 5£ 2.14 40.2 
(801) (143) 
7l 1 We r8 200 ^ 10.00 308 
2 3.00 2.0 310 104 1.15 21.7 
3 5.00 2.4 462 92 1.30 27.2 
4 3.42 1.5 211 62 1.88 18.9 
5 7.30 2.0 39Z 54 2.22 32.5 
(593) (318) 
*Residual tumour nodule resected 
()cumulative doses 





Figure 7.16(a) Tumour with an average T/N ratio 
of3.37 and a necrotic centre 
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Two examples for illustration are given below : 
Patient No. 4 
The 99mTc-MAA images of this patient is shown in figures 7.16a. By the 
partition model, the dose to the non-tumourous liver was estimated to be 36 
Gy. Thus for a region of the tumour to received > 120 Gy, it should have a 
T/N ratio r > 120/36 二 3.33. The maximum count rate per pixel (C%) 
recorded on the image is 148 whereas the average counts rate per pixel of 
the non-tumourous liver (Cw) '^ 18.2. 
Therefore (^^ expressed as a percentage of G ^ is given as 
18 2 
P , = J ^ X100% = 12.3% 
For a region of the tumour to have a T/N ratio r > 3.33，the count rate per 
pixel C i should be > r x P n 
when expressed as a percentage of〔M。 
r P ^ = (333)(12.3%) = 41% 
Then the computer was instructed to show the portion of the tumour having a 
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Figure 7.17(a) Tumour with an average T>TSf ratio 
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Figure 7.17(b) The portion oftumour (30.8%) 




The portion of the tumour satisfying this condition was as shown in figure 






^^. , ,^  , 1,289 — 678 
This meant that ~ j ^ — — j c 100% = 474% of the tumour, corresponding 
to the necrotic centre and the periphery, actually received less than 120 Gy in 
the SIR therapy. This probably explains why the AFP in this patient dropped 
from 207,200 to 95,230 ng/ml and then started to rise again as the residual 
tumour continued to grow although the average dose to the tumour in this 
patient was estimated to be 123 Gy by the partition model. 
Patient No. 60 
Figures 7.17a and 7A7b illustrate the situation in the first SIR treatment given 
to this patient. The average dose to the tumour was estimated to be 120 Gy 
but from analysis, 69.2% of the tumour actually received less than 120 Gy of 
radiation. Figure 7.17b showed that instead of a necrotic centre, the right half 
of the tumour was under dose. There were persistent disease in this patient 
after two further treatments. The cumulative tumour dose was up to 408 Gy. 
The patient died after new lesions were detected in his left lobe. 
The results in Tables 7.8 and 7,9 show that there is inevitably certain 
percentage of the tumour which received less than the tumouricidal radiation 
dose although the average dose was > 120 Gy. The percentage is between 
3.6 and 90.2%. This explains logically the persistence of residual disease 




By mapping the position of all the 卯丫 microspheres in a 1 cm cube of normal 
liver taken after SIR therapy to a planning computer, Fox et al (20) deduced 
that one third of the normal liver received less than 33.7% of the radiation 
dose predicted by assuming a uniform distribution of 卯丫 microspheres 
throughout the entire liver and therefore got spared. Making use of the 
partition model and ®®^Tc-MAA simulation a much simpler method is available 
for estimating the percentage of a tumour which receive less than the 
tumouricidal dose and is likely to remain as residual disease. 
Thus the radiation doses estimated by the partition model can explain the 





CONCLUSIONS AND FUTURE DEVELOPMENT 
8.1 CONCLUSIONS 
The prognosis of inoperable HCC or colorectal liver metastases has been 
grave. Not much can be offered by the conventional palliative procedures. 
SIR therapy using 卯丫 microspheres seems to give some light in the dark. 
The simulation with ®®^Tc-MAA for assessing the extrahepatic shunting and 
T/N ratio has made it a safe treatment. The partition model has proved to be 
able to predict the radiation doses to the lungs，the tumour and the non-
tumourous liver. It can be used clinically to predict complications such as 
radiation pneumonitis and to predict recurrence or residual disease by 
determining the percentage of tumour which receive inadequate dose. A 
better understanding of the physical aspects of the SIR therapy permits the 
delivery of optimal doses to the tumours, either in a single treatment or 
through well-controlled repeated treatments without the need of a laparotomy. 
It is hoped that our randomised trial will confirm a beneficial impact of SIR 




8.2 FUTURE DEVELOPMENT 
The maximum tolerance of non-tumourous liver towards radiation delivered 
by SIR therapy using 卯丫 microspheres will be documented ultimately when 
experience accumulates in repeated SIR therapy for residual or recurrent 
diseases. The optimal tumouricidal dose for hepatic cancer remains 
uncertain。Probably there is no definite answer as radiosensitivity varies from 
patient to patient and from tumour to tumour even within the same patient. It 
is however logical to conclude that a higher radiation dose to the tumour 
should give better control. 
The results of the present study indicate that the level of radiation dose that 
can be delivered to the tumour is limited by the T/N ratio, the tolerance of the 
non-tumourous liver to radiation as well as the degree of lung shunting. A 
patient with a high T/N ratio and low lung shunting is an ideal patient for SIR 
treatment. If 70 Gy is still being accepted as the tolerance limit of cirrhotic 
liver for a patient with T/N = 2，the highest dose that can be delivered to the 
tumour is 140 Gy in order to avoid radiation damage to the non-tumourous 
liver. The use of radiosensitisers such as iododeoxyuridine to enhance the 
sensitivity of the tumour towards radiation may be helpful. Synergistic effect 
from concurrent application of internal radiation and cytotoxic chemotherapy 
may also increase the number of tumour cells being killed. Giving a booster 
dose to the necrotic area within the tumour using MeV X-rays from 
intraoperative linear accelerator is an alternative method to increase tumour 




microspheres for SIR therapy has been proven to be an effective single agent 
in our randomised trial. 
Sometimes an activity of 卯丫 microspheres for an optimal dose to the tumour 
cannot be administered even though the radiation dose to the non-tumourous 
liver is within safety limit because of high lung shunting. Methods better than 
the partial hepatic embolization using lvalon particles in reducing lung 
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